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1.1    PROTEIN KINASES 
1.1.1 Protein phosphorylation 
Proteins are in a constant state of flux, with their activity, sub-cellular localization, 
molecular interactions and stability being modified in response to external and internal 
signals. Many cellular processes, e.g. those involved in intracellular communication and 
coordination of complex functions, are controlled by protein phosphorylation. The 
phenomenon of protein phosphorylation is known for over 100 years by now: in 1906 the 
presence of a phosphate in the protein Vitellin was described (1) and in 1933 a 
phosphate group was found to be attached to a serine residue in Vitellin (2). 
Interestingly, it took another 20 years before the first enzymatic phosphorylation of 
proteins was reported (3).  
 
1.1.2 Protein kinases 
Eukaryotic protein phosphorylation is conducted mainly by a single superfamily of 
eukaryotic protein kinases, one of the largest of protein families, being encoded by 1.5-
2.5% of all eukaryotic genes (4). 518 protein kinases have been identified. Interestingly, 
48 of these proteins are called pseudokinases and lack one or more of the conserved 
amino acids in the kinase domain that are required for catalytic activity. Pseudokinases 
are therefore predicted to be enzymatically inactive. However, five pseudokinases in 
addition to their pseudokinase domains contain a fully functional kinase fold making 
them catalytically active (5). Furthermore, several pseudokinases were shown to interact 
with other kinases leading to their activation. For example, HER3 upon binding to its 
ligand forms a complex with the kinase HER2 stimulating its autophosphorylation and 
activation (6).  
Protein kinases add the γ-phosphate group of ATP to specific amino acid residues on 
protein substrates. Within a protein, phosphorylation can occur on several amino acids 
such as serine, threonine, tyrosine or histidine. Phosphorylation on serine residues is the 
most common, followed by threonine residues. Tyrosine phosphorylation is relatively 
rare and was discovered by Hunter and colleagues in 1979 (7). Depending on the 
specificity of the substrate amino acids, protein kinases are known as serine/threonine 
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(Ser/Thr) kinases, tyrosine (Tyr) kinases, histidine kinases (8) or as dual specificity 
(Ser/Thr and Tyr) kinases (9).  
 
Figure 1 
A timeline of key events in the development of protein kinase inhibitors. 
 
Kinase activity is subjected to spatial and temporal regulation, often by more than one 
regulatory mechanism. Mutations and deregulations of protein kinases are often 
associated with cellular transformation and cancer and as a matter of fact the first 
discovered oncogene was the protein kinase v-Src (7, 10). Since the importance of 
kinase activities in many physiological processes was recognized, extensive efforts have 
been undertaken to develop kinase inhibitors (Fig. 1) for the treatment of a wide range of 
cancers. 
 
Table 1 
Drugs approved for clinical use in human cancer therapy. 
DRUG TRADEMARK PRODUCER TARGET 
IMATINIB GLEEVEC Novartis ABL, KIT, PDGFR 
ERLOTINIB TARCEVA Roche EGFR 
GEFITINIB IRESSA AstraZeneca EGFR 
SORAFENIB NEXAVAR Bayer KIT, VEGFR, PDGFR, FLT3, RAF 
SUNITINIB SUTENT Pfizer KIT, FLT3, PDGFR 
DASATINIB SPRYCEL Bristol-Myers Squibb ABL 
LAPATINIB TYKERB GlaxoSmithKline HER2, EGFR 
NILOTINIB TASIGNA Novartis ABL 
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Up to date, there are 8 kinase inhibitors that received a FDA approval for the clinical use 
in human cancer (Table 1). Many more are currently in the clinical trials. Interestingly, a 
first protein kinase inhibitor (Fusadil) was approved for clinical use in Japan to treat 
cerebral vasospasm. 
 
1.1.3 Tyrosine protein kinases 
The human genome contains 90 tyrosine kinase genes and 9 presumed tyrosine kinase 
pseudogenes (6).  
 
 
Figure 2 
Dendrogram representing the tyrosine kinase family comprising 90 proteins (adapted from 
www.cellsignal.com). 58 of them are classified as receptor tyrosine kinases (magenta) and 32 as 
cytoplasmic tyrosine kinases (blue). Kinases that are classified as pseudokinases are marked by 
a red dot and those that contain in addition to the pseudokinase domain a kinase domain are 
marked with a white star.    
 
There are two classes of tyrosine kinases (Fig. 2). Receptor tyrosine kinases (RTKs) are 
type I transmembrane proteins possessing an N-terminal extracellular domain, which 
can bind activating ligands, a single transmembrane domain and a C-terminal 
cytoplasmic domain that includes the catalytic domain. Cytoplasmic tyrosine kinases 
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lack the transmembrane domain and they act as the catalytic subunits for cytokine 
receptors that lack their own catalytic domain. Based on kinase domain sequences, the
family of RTKs and cytoplasmic kinases can be grouped into 20 and 10 subfamilies, 
respectively (11).  
Tyrosine kinases contain highly conserved catalytic domains similar to those in protein 
serine/threonine and dual specificity kinases but with unique sub-domain motifs clearly 
identifying the members as tyrosine kinases (12).  
 
1.1.4 Activation mechanism of kinases 
To date, numerous protein kinase structures have been solved in both active and 
inactive states (13, 14). Comparative studies of structures yielded insights in the 
mechanism of kinase activation, substrate recognition and ATP/inhibitor binding (15, 16).  
Modulation of kinase activity is vitally important and its malfunction leads to many 
diseases. Most kinases are multi-domain proteins and the regulation occurs at multiple 
levels to keep these enzymes in the non-active state. Thus, the activation mechanisms 
tend to be very different from one another on the level of the activation of whole protein. 
Kinase activity can be regulated by different mechanisms such as protein-protein 
interactions, alteration in subcellular localization within the cell, 
phosphorylation/dephosphorylation and many more competitive, non-competitive or 
allosteric mechanisms (17-20).   
 
1.1.4.1 Regulation of the kinase domain 
Phospho-transfer activity relies on the kinase domain, which consists of two lobes: a 
smaller N-terminal lobe and a larger C-terminal lobe (Fig. 3). The space between these 
two lobes is the catalytic cleft, which serves as docking site for ATP and the substrate. 
The kinase domain of protein kinases can adopt two fundamentally different states: the 
inactive “OFF” and active “ON” state. Upon activation all serine/threonine kinases and 
tyrosine kinases catalyze the same reaction of the transfer of the γ-phosphate from ATP 
to hydroxyl groups of serine, threonine or tyrosine. Therefore, the catalytically active 
conformation they adopt shows high structural similarity (19).  
Transition from the inactive to the active state requires changes in the conformation of 
the kinase domain (Fig. 3). 
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Figure 3 
Schematized structures of the insulin receptor kinase (IRK) depicting the conformational 
transitions involved in the regulation of kinase activity. Key structural elements within the kinase 
domain are colored as follows: αC helix (purple) and activation loop (red). The red arrow 
indicates the direction of N-lobe rotation upon kinase activation. In the inactive state the IRK does 
not accommodate ATP. Upon binding of insulin to the IRK the conformational change is induced. 
Phosphorylation of the activation loop at tyrosine residues stabilizes the kinase in an active 
conformation what enables binding of ATP and substrate (yellow). Adapted from (17). 
 
In the inactive state the kinase domain displays a closed conformation. Upon 
phosphorylation the activation loop moves away from the catalytic center and adopts a 
conformation that allows substrate binding and further catalysis. Additionally, the N-lobe 
undergoes a certain twist leading to the formation of an ion pair between the highly 
conserved glutamate residue localized in αC helix and the conserved lysine residue 
which binds the α and β phosphates of ATP. Then, the active kinase toggles between 
the open and closed conformation as it goes through the catalytic cycle (see also Fig. 
5B).  
                                
1.1.4.2 Structural similarities in the activation mechanism of protein 
kinase domains 
The first crystal structure to be solved was the one of cyclic AMP-dependent kinase PKA 
(protein kinase A) (21). The structure of PKA in complex with ATP and substrate was 
visualized by X-ray crystallography capturing the protein kinase in a conformation that is 
primed and ready for the phosphotransfer (21, 22). The comparison of the inactive and 
active status of many solved kinase structures has shown that the activated state of 
kinase domains is very conserved. In the following these common traits are presented 
using PKA as an example.  
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The N-terminal lobe of the protein kinase fold is composed of five β sheets and one α 
helix, which is called αC helix (Fig. 4A). The C-terminal lobe is predominantly helical. 
The transition from the “OFF” to “ON” state leads to the formation of the so-called 
hydrophobic spine that links together the N- and C-lobes of the kinase domain (Fig. 4A).  
 
Figure 4 
A: Model structure of the serine/threonine kinase PKA where the hydrophobic interior of the 
catalytic core of the N-lobe (blue) and the C-lobe (yellow) is indicated. Upon kinase activation the 
hydrophobic spine is formed (red) that links the cores of two lobes. Adapted from (18). B: The 
ribbon representation of the crystal structure of the kinase domain of PKA. Key functional 
elements within the kinase domain are highlighted. A PKI inhibitor colored in yellow mimics the 
PKA substrate. Adapted from (17).  
 
The spine is formed only when the activation segment and the αC helix have 
reorganized. Under such conditions several residues building the spine become aligned 
what supports the active conformation of the kinase domain. Another proposed role for 
the spine is to provide a flexible hinge for the open/closed transition required for binding 
ATP and releasing ADP (23). There are several residues and loops important for 
interactions with ATP and substrate that are conserved among protein kinase families 
(Fig 4B). The ATP-binding pocket is deeply buried between these two lobes right 
beneath a highly conserved glycine-rich loop connecting the β1 and β2 strands. This 
loop contains a conserved glycine-rich sequence (GXGXφG) where φ stands usually for 
a tyrosine or phenylalanine residue. The glycine residues make the loop very flexible in 
the absence of bound ATP. Upon kinase activation, the loop gets into close proximity of 
ATP and modulates the phosphoryl transfer step.  
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Figure 5 
A: Diagram of known interactions between the protein kinase catalytic core, ATP and the 
substrate peptide (PKA numbering is used). Hydrophobic interactions between the HRD motif, the 
DFG motif and the αC helix leading to the formation of the hydrophobic spine are shown by black 
arrows, while important polar interactions between the kinase residues and ATP or substrate are 
highlighted by dashed lines. The red arrow indicates catalyzed transfer of the γ phosphate of ATP 
to the hydroxyl group of a protein substrate. Adapted from (19) B: Schematic representation of 
protein kinase activation on the example of PKA. In the inactive state the hydrophobic spine is not 
stabilized and the αC helix with E91 has not undergone rearrangement. Upon activation the 
threonine 197 residue in the A-loop becomes phosphorylated. The A-loop is translocated as to 
interact with R165 and is stabilized in this position. The N-lobe of the kinase domain is twisted 
bringing the αC helix into close proximity of the ATP-binding pocket what results in formation of a 
polar contact between Lys 72 and Glu 91. Furthermore, the hydrophobic spine is formed (blue 
disks) which stabilizes the kinase domain in the active state. During the catalytic cycle the kinase 
performs motions going through open (left) and closed (right) conformations. Adapted from (19). 
 
One of the most important residues for the transition from the inactive state to the active 
state is the lysine residue (Lys72) positioned in the β3 strand of the N-terminal part of 
the kinase domain. Lys72 directly interacts with ATP by binding to its α and β 
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phosphates and positioning ATP properly for the catalysis. Moreover, in the active state 
Lys72 makes a polar contact with the conserved glutamic acid residue Glu91, which is 
localized in the αC helix (Fig. 5A and 5B). The altering of the conformation of the αC 
helix is an important step in the modulation of the kinase activity. The Lys72-Glu91 
interaction couples the conformation of the αC helix to nucleotide binding. 
One of the most important motifs for catalysis is the universally conserved Asp-Phe-Gly 
(DFG) motif, where an aspartate (Asp184) residue contacts the phosphates of ATP. 
Asp184 together with another residue Asn171 positioned in the catalytic loop are 
required for the binding of two divalent cations involved in coordinating ATP. The most 
conserved motif throughout the protein kinase family is composed of the histidine, 
arginine and aspartate residues (His-Arg-Asp, HRD). The Asp166 residue of HRD triad 
is responsible for the correct orientation of the hydroxyl group of the peptide substrate 
that becomes phosphorylated. Furthermore, most protein kinases require 
phosphorylation of the activation loop and the role of HRD Arg165 is to support the 
proper configuration of the activation segment by coordinating the phosphate of the 
phosphorylated residue in the A-loop (Thr197 in PKA). This stabilizes the PKA kinase 
domain in the active conformation. Interestingly, this arginine is conserved only in the 
eukaryotes, and usually kinases lacking the HRD arginine are not phosphorylated in the 
activation loop (13).  
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1.2    KINASES AS INHIBITOR TARGETS 
Since protein kinases are directly involved in many diseases, including cancer and 
inflammation, they have become one of the most important classes for drug 
development (24, 25). The approval of imatinib (Gleevec) for chronic myeloid leukemia 
(CML), gefitinib (Iressa) and erlotinib (Tarceva) for non-small lung cancer (NSCLC) has 
provided proof-of-principle that small molecule kinase inhibitors can be effective drugs. 
Since the vast majority of these compounds target the kinase ATP site, which is highly 
conserved within the protein kinase family, they might target more than only one single 
kinase. However, even though they target many signaling pathways, multikinase 
inhibitors have been approved for the use in patients with cancer (see Table 1) and they 
are well tolerated with minor side effects (26). In contrast to clinical utility, the specificity 
of an inhibitor is of critical importance for its utility in research. 
 
1.2.1    The chemical genetics approach 
The common mechanism of action of the majority of kinase inhibitors relies on the 
competition of the inhibitor and ATP for binding to the catalytic cleft of a target kinase. 
The importance of a given kinase can be assessed by inhibitor-based suppression of its 
activity and monitoring the response of the biologic system. However, due to possible 
unspecific actions of an inhibitor on kinase-mediated signaling cascades, it is not 
possible to directly attribute the biological effects of the inhibitor to its effects on the 
investigated kinase. To circumvent the specificity problem associated with conventional 
small-molecule inhibitors of kinases, a chemical genetics approach has been developed 
(27-29). The approach exploits a conserved, large hydrophobic residue in the kinase 
active site (termed the “gatekeeper”), which makes direct contact with the N6 group of 
ATP. In the case of Janus kinases the gatekeeper corresponds to a methionine residue 
localized within the β5-sheet (Fig. 6). When this residue is mutated from the naturally 
occurring bulky residue to glycine or alanine, a pocket not found in any wild-type kinase 
is created within the kinase’s active site (27). 
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Figure 6 
A: View of the catalytic cleft of the Jak2 kinase domain where the space occupied by the atoms 
constituting Met929 is represented as dotted spheres and the region from the β5-sheet to the αD 
helix (also shown in the sequence alignment in B) is highlighted by a colored backbone. B: 
Sequence alignments of the four Jaks with the methionine at the gatekeeper position highlighted 
in blue.    
 
The re-engineered kinase becomes analogue-sensitive and can be potently and 
uniquely targeted by inhibitors that contain a bulky substituent that can occupy this 
enlarged ATP-binding pocket (30). Likewise, this enlarged ATP-binding pocket allows 
such mutants to use unnatural N6-modified ATP analogues that are not accepted by any 
wild-type kinases, what enables the labeling of specific kinase substrates (Fig. 7) (31, 
32). So far two different substrate identification methods have been reported. The first 
one relies on the radioactive labeling of the direct substrates by the γ-phosphate group 
(γ-32P) of an ATP analogue that can be used only by the analogue-sensitive kinase (33). 
Very recently, a non-radioactive method for substrate identification has been proposed. 
In this case, the analogue-sensitive kinase uses an N6-alkylated ATPγS analogue what 
leads to thiophosphorylation of its substrates. All other kinases will instead transfer 
phosphate groups to their substrates. Thiophosphorylated substrates can be enriched by 
a thio-phosphate ester-specific antibody (31) or by a thiopropyl Sepharose (34) and 
identified by mass spectrometry.   
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Figure 7 
(Upper part) View of the catalytic cleft of the Jak2 kinase domain with the bulky N6-benzyl-ADP 
molecule highlighted in orange. (Lower part) Ribbon and surface representation of the Jak2 
kinase domain with the bulky ADP molecule. Mutation of methionine at the gatekeeper position in 
the Jak2 kinase domain to the smaller residue glycine creates a new pocket that can be uniquely 
accessed by the “bulky” analogue molecule. The presence of the benzyl group in the analogue 
molecule precludes the binding to the pocket of the wild-type kinase. The sterical clash between 
the methionine gatekeeper residue of wild-type Jak2 and the analogue molecule are highlighted 
in red in the left panels. In the case of the analogue-sensitive mutant no sterical clash occurs 
(right panels). The space occupied by the gatekeeper residue is represented as dotted spheres.   
 
1.2.2 Possible intolerance of a kinase to the gatekeeper residue 
mutation 
Since all protein kinases contain the conserved gatekeeper residue, the chemical 
genetics approach is in principle applicable to the whole kinome. Bcr-Abl, PI3-K, Erk2, 
Src, Jnk2 and Zap70 represent only few examples of kinases that were subjected to this 
approach and rendered analogue-sensitive (32, 35-38, 45). Despite the broad 
applicability, a considerable number of kinases does not tolerate the mutation of the 
gatekeeper residue to glycine or alanine, and is thus not amenable to the chemical 
genetics approach (36, 39, 40). These intolerant kinases have a severe loss in catalytic 
activity and/or cellular function upon introduction of the space-creating gatekeeper 
mutation. To solve the problem of severe loss in activity by some analogue-sensitive 
mutants, a structure-guided mutational approach has been developed (41). It has been 
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suggested that the space-creating gatekeeper mutation can destabilize the N-terminal 
lobe of the kinase domain which contains numerous residues important for ATP binding 
and catalysis. To minimize the perturbation of the structure and function of the analogue-
sensitive kinase, conservative suppressor mutations have been designed (such as 
C→V, S→T, and L→I). This mutational strategy should stabilize the upper lobe of the 
kinase domain, and thus rescue the loss of activity due to the gatekeeper mutations. 
Noteworthy, in addition to constituting a minimal perturbation, second-site suppressor 
mutations should not negatively affect the ability of the engineered kinase to accept 
unnatural ATP analogues or inhibitors.  
However, even in cases in which the gatekeeper mutation resulted in an inactive kinase, 
valuable results could be obtained, e.g. for IRE1. Binding of the inhibitor analogue 1NM-
PP1 by this transmembrane kinase which is involved in the unfolded protein response 
(UPR) resulted in an activated conformation of the kinase domain, which in turn 
activated the RNase domain adjacent to the kinase domain resulting in activation of the 
XBP1-dependent ER-stress response (42).  
 
1.2.3 Elucidation of kinase-mediated effects 
The function of a given enzyme in cells can be probed by two dominant approaches: 
genetics and pharmacology. In many cases, a small molecule and a genetic mutation 
can perturb a protein’s activity in different ways, leading to different conclusions about 
the protein’s biological function. There are many examples where different phenotypes 
emerge depending on whether a protein is targeted by a small molecule inhibitor or a 
knockout of the gene (43). Gene knockout approaches have provided important insights 
into the roles of specific proteins. However, some knockout mice may not be viable at all, 
or “secondary” adaptations such as cellular compensation may occur: e.g. the Jnk2 
knockout caused a compensatory increase in Jnk1 activity and c-Jun expression. On the 
other hand, suppression of Jnk2 activity by a small molecule inhibitor resulted in 
blockade of c-Jun phosphorylation and suppression of cellular proliferation (44).  
Kinase inhibitors are all too often unspecific and even the few potent compounds may 
have more than one target. Only 5% of the human kinome is currently targeted by potent 
inhibitors and there is no way to comprehensively identify the cellular targets of a small 
molecule inhibitor.   
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Chemical genetics represents a good alternative approach for investigation of specific 
kinase-mediated effects. A clear advantage of chemical genetics is the fact that the 
analogue-sensitive kinase can be reversibly inhibited, and more importantly, this specific 
inhibition can be controlled over time, which is not possible if the whole protein 
expression is regulated or if kinase-inactive mutants are used (46). Since the importance 
of protein kinases as a major class of drug targets has been recognized, generation of 
“fingerprints” of transcriptional changes associated with selective kinase inhibition would 
be of great use. A comparison of the effects of a drug candidate inhibitor with data 
obtained with a corresponding analogue-sensitive variant, thereby providing the 
“fingerprint”, would identify off-targets effects elicited by the tested compound (47). What 
makes the chemical genetics approach even more valuable with respect to 
pharmacologic target validation is the fact that the mutated alleles of analogue-sensitive 
kinases have been successfully introduced into mouse models (48).  
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1.3    JANUS KINASES 
1.3.1 Discovery 
In the early 1990s four members of the family of Janus kinases were identified (49-52). 
This family comprises Jak1, Jak2, Jak3 and Tyk2. While Jak1, Jak2 and Tyk2 are 
ubiquitously expressed, Jak3 is confined mainly to cells of the hematopoietic system (53, 
54).  
 
1.3.2 Structure and function of Jaks 
Out of the 518 protein kinases encoded by the human genome, 48 family members 
contain pseudokinase domains (5). Combination of a pseudokinase domain and a 
kinase domain directly adjacent in the same protein was found only in five 
pseudokinases. These are the four members of Janus kinase family and the 
serine/threonine kinase GCN2. This unique feature clearly distinguishes these five 
kinases from other members of the protein kinase family. This is, however, the only 
similarity between the Jaks and GCN2. As for the Jaks, the pseudokinase domain in 
GCN2 is thought to keep the kinase domain inactive in the absence of stimulus (6). In 
addition to the pseudokinase and kinase domain Jaks contain two more structural 
domains, namely the SH2 and FERM domain (Fig. 8).  
 
Figure 8 
Structural organization of the Janus kinases and known functions of the different domains. Model 
structures of the FERM, SH2 and pseudokinase domains of Jak1 as well as the solved crystal 
structure of the kinase domain of Jak2 (PDB entry code: 2B7A) are represented. Adapted from 
(55). 
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Sequence similarities between Jak family members had led after their discovery to the 
description of seven Jak homology (JH) domains (50). The JH3 to JH7 regions are better 
described as FERM and SH2 domain, while the JH1 and JH2 domains represent the 
kinase and pseudokinase domains, respectively (50, 56). 
 
1.3.2.1 The FERM domain: receptor binding and localization 
The N-terminal part of the Janus kinases contains a FERM domain (FERM stands for: 
band four point one (4.1) protein, ezrin, radixin, and moesin) (56). The FERM domain is 
mainly involved in constitutive binding of Jaks to the cytokine receptors (57-60), which 
lack an own kinase domain. The association of Jak with the cytokine receptor results in a 
tight complex that mimics (in many aspects) the RTKs. Published X-ray structures of 
FERM domains show that these domains consist of three separate subdomains 
arranged in a clover shape. The N-terminal F1 subdomain has a ubiquitin-like β-grasp 
fold, the F2 subdomain contains many α-helices and shows structural similarity to the 
acetyl-CoA-binding protein and the F3 subdomain has a PH-domain (pleckstrin 
homology) fold (61-65). 
Jaks associate with cytokine receptors at the membrane-proximal region containing the 
so-called box1/2 region. Due to the constitutive binding of Jaks to cytokine receptors, 
these tyrosine kinases are mostly localized to the plasma membrane (Fig. 9), although it 
has been reported that e.g. Tyk2 can be found also in the nucleus, if it is expressed to 
higher level (66). The significance of nuclear Jaks is not clear, given that all functional 
features of Jak proteins point to their involvement in events occurring at the cell surface. 
Recently, however, Jak2 was reported to directly phosphorylate histone H3 in the 
nucleus (67). Further studies involving e.g. the preparation of highly purified membrane-
free nuclear fractions will have to verify a potential presence of Jak2 in the nucleus. It will 
be also interesting to address the possible involvement of other kinases mediating 
histone tyrosine phosphorylation.  
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Figure 9 
U4C cells (Jak1-deficient) were transfected with Jak1-YFP (Yellow Fluorescent Protein) and γ2A 
cells (Jak2-deficient) with Jak2-YFP or YFP. The YFP-associated fluorescence was monitored in 
living cells by confocal microscopy showing exclusive membrane localization of Jaks. Adapted 
from (68).  
 
1.3.2.2 The unconventional SH2 domain 
The FERM domain is followed by a predicted SH2 domain, which does not seem to fulfill 
a classical SH2 domain function, i.e. the binding to specific motifs containing 
phosphorylated tyrosine residues (69). SH2 domains contain about 100 amino acids and 
consist of two α-helices and a central antiparallel β-sheet. A conserved arginine residue 
at position βB5 in SH2 domains contacts the phosphate group of a binding 
phosphotyrosine motif. Accordingly, this residue was found to be present in 99.8% of 
SH2 domain sequences, emphasizing the strict requirement for this amino acid at this 
position. Interestingly, this arginine is not equally well conserved in Jaks and it is found 
only in 80% of all Jak SH2 sequences. A functional study of Jak1 SH2 domain revealed 
that mutation of arginine (R466) to lysine had no effect on neither the sub-cellular 
localization of Jak1 nor its binding to the cytokine receptor or signaling capacity (70). 
Noteworthy, mutation of the corresponding arginine in human Jak2 (R426) had no effect 
on STAT1 activation upon IFN treatment (71). However, in truncation mutants and SH2 
domain swapping mutants, the SH2 domain of Jak1 was shown to be structurally 
important for binding to OSMR and consequently for efficient OSMR surface expression 
(70). In contrast, the SH2 domain of Jak1 was not necessary to bind the gp130 receptor 
chain (72). Binding of Jak2 and Tyk2 mutants to EpoR and interferon-α receptor 
(IFNαR1), respectively, was also not affected by the lack of SH2 domain, although the 
SH2 domain was required for the upregulation of receptor surface expression (73, 74). 
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1.3.2.3 The pseudokinase domain  
The Jak pseudokinase domain is localized between the SH2 domain and the kinase 
domain. Pseudokinase domains of Jaks lack conserved residues critical for kinase 
activity (6) what renders them inactive (50, 75). The loss of function of the pseudokinase 
domain is thought to be mainly due to the lack of the aspartate residue within the HRD 
motif necessary for correct ATP orientation. Moreover, two tyrosine residues in the 
activation loop whose phosphorylation stabilizes the activation loop of a kinase in the 
active conformation are missing in pseudokinase domains. The Jaks’ pseudokinase 
domain interacts with the kinase domain and it is assumed to prevent basal activity of 
the kinase domain (76-78). The assumption of an inhibitory role of the pseudokinase 
domain is largely supported by the identification of many mutations in this domain that 
render the Jaks hyperactive (79). However, structural data would be necessary to reveal 
how exactly the pseudokinase domain interacts with the kinase domain. 
1.3.2.4 The kinase domain 
The kinase activity is exerted by the C-terminal kinase domain comprising approximately 
300 amino acids. All protein kinases share the bilobal kinase fold (Figs. 4, 10) and Jaks 
contain all the critical functional regions of kinases which have been described above 
(see Fig. 5A). 
 
Figure 10 
The solved crystal structure of the kinase domain of Jak2 (PDB entry code: 2B7A) where the 
following regions are highlighted: αC helix (blue), glycine-rich region (yellow), catalytic cleft 
(cyan), the HRD motif (red), the DFG motif (magenta) and the activation loop (green) where the 
phosphotyrosine residues are represented as dotted spheres. The N-terminal and C-terminal 
lobes are indicated. Pymol was used for molecular modeling and graphical representation (The 
PyMOL Molecular Graphics System, DeLano Scientific, San Carlos, CA, USA).   
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The two tyrosine residues in the activation loop that become phosphorylated upon 
kinase activation have been investigated by a mutational analysis of Jaks. It has been 
shown that the first tyrosine residue from the double tyrosine motif (Y1007 in Jak2, 
Y1033 in Jak1) (80, 81) if mutated to phenylalanine renders the kinase inactive (Table 
2). Additionally, substitution of the aspartates in the extremely conserved HRD motif by 
asparagine leads to inactive Jaks (Table 2). Jak1 and Jak2 mutants bearing a lysine 
residue substitution at position 908 and 882, respectively, showed a similar phenotype 
(82).  
Interestingly, according to sequences of murine Jak1 (reference number NP_666257) 
and human Jak1 (reference number NP_002218) that are available in the database of 
NCBI, the double tyrosine motif is located at position 1033/1034 and 1034/1035, 
respectively. This is not consistent with the numbering which is currently in use by e.g. 
biotech companies producing antibodies against phosphorylated tyrosines of Jak1, here 
these two tyrosine residues are supposedly placed at position 1022/1023.     
 
Table 2 
Amino acids sequences of selected loops and motifs important for the catalytic activity of the 
kinase domain of human and murine Jak1 as well as Jak2 are shown. The glycine-rich loop 
(GxGxxG), the ATP-binding loop (AVKxL), the HRD, DFG and double tyrosine motifs are shown. 
Positions of highlighted residues and functional consequences of their substitutions are indicated.  
 
 
* “Jak1 and Jak2 in IFN signaling: a chemical genetics approach to dissect their relative 
contributions” – see Results section page 47  
MOTIF JAK1 SEQUENCE MURINE HUMAN MUTATION PHENOTYPE REFERENCE 
GxGxxG GEGHFG G881 G882 - - - 
AVKxL AVKSL K907 K908 K-E Kinase-inactive 82 
HRD HRD D1002 D1003 D-N Kinase-inactive Kaczor et al. * 
DFG DFG D1020 D1021 D-S Kinase-inactive 82 
YY YY Y1033/1034 Y1034/1035 Y1033-F Kinase-inactive 81 
    Y1034-F Kinase-active 81 
MOTIF JAK2 SEQUENCE MURINE HUMAN MUTATION PHENOTYPE REFERENCE 
GxGxxG GKGNFG G856 G856 - - - 
AVKxL AVKKL K882 K882 K-E Kinase-inactive 82 
HRD HRD D976 D976 D-N Kinase-inactive Kaczor et al. * 
DFG DFG D994 D994 - - - 
YY YY Y1007/1008 Y1007/1008 Y1007-F Kinase-inactive 80 
    Y1008-F Kinase-active 80 
INTRODUCTION	   21	  
 
JANUS	  KINASES	   21	  
 
1.3.3 Activation mechanism of Jaks 
Under normal conditions, Jaks are kept in their inactive state until receptor activation 
occurs leading to conformational changes of the receptor and receptor-bound Jaks. 
Janus kinases associate with the membrane-proximal region of cytokine receptors but 
due to the lack of crystallographic data, the mechanism leading to the initiation of the 
activation of Jaks remains unclear.  
 
1.3.3.1 The cytokine receptor/FERM domain interaction 
Janus kinases are constitutively bound to cytokine receptors and localized to the plasma 
membrane by receptor binding. Among receptors, there is little sequence homology 
except short stretches called box1 and box2, which serve as docking sites for Jaks. 
Within the relatively long stretches of the membrane-proximal region, quite a number of 
residues were shown to be essential for Jak/receptor interaction (55). Interestingly, for 
several cytokine receptors (gp130, EpoR), residues were identified, which do not impair 
binding but which affect Jak activation (83, 84). This shows that the Jak/receptor 
contacts determine a conformation, which is crucial for normal cytokine-dependent Jak 
activation.  
Proper cytokine receptor function must depend on communication between the 
extracellular and intracellular domains that are connected by a rigid α-helical 
transmembrane domain. Upon stimulation, conformational changes of the extracellular 
domains of the receptor are transmitted to the cytosolic domain activating Jaks. There is 
growing evidence that the helical structure of the transmembrane regions can extend 
into the intracellular as well as extracellular region as became evident by mutagenesis 
studies involving insertions, deletions of amino acids of the transmembrane helix and by 
cysteine-scanning mutagenesis (83, 86, 87). The Jak/receptor interaction interface in the 
extension of the transmembrane helix plays a role in correct positioning of Jaks so that 
ligand-induced receptor conformational change can lead to their mutual activation.  
Jaks bind to cytokine receptors via the FERM domain (60, 72). In addition to receptor 
binding, however, it has been proposed that the FERM domain also plays a role in the 
overall organization of the kinase structure and its subsequent activation. By a 
mutagenesis study it was shown that the integrity of the F1 and F2 subdomains is crucial 
for Jaks receptor binding (60, 88). Furthermore, the FERM mutations in Jak1 can 
influence the phosphorylation status of the kinase and its ability to become properly 
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activated to promote downstream signaling events upon cytokine stimulation. Moreover, 
naturally occurring mutations in the FERM domain of Jak3 have been identified in 
patients suffering from SCID (89). These mutants were characterized by reduced but not 
complete lack of receptor association. Regardless of that residual receptor binding, 
neither kinase activity nor downstream STAT5 activity was observed.  
 
1.3.3.2 The pseudokinase/kinase domain interaction 
Another level of regulation of Jak activity involves the pseudokinase domain, which 
according to the accepted theory negatively regulates activity of the kinase domain. 
Theoretical models of the Jak2 structure suggested that the kinase domain and the 
pseudokinase domain are facing each other and the activation loop is buried in this 
interface (90, 91). Phosphorylation of the activation loop is thought to prevent this 
pseudokinase/kinase interaction and therefore releases inhibition. The well-known 
V617F mutation, which renders Jak2 constitutively active, was shown to be transferable 
to Jak1 and Tyk2 (92), i.e. the homologous mutations in Jak1 (V658F) and Tyk2 (V678F) 
also lead to hyperactive kinases. Interestingly, the conserved valine residue in Jak1, 
Jak2 and Tyk2 is replaced by methionine in Jak3 and the mutation of this residue to 
phenylalanine does not activate the enzyme and that indicates a different regulatory 
mechanism occurring for Jak3.  
The enzymatic activity of Jaks relies on the kinase domain. Similarly to the other tyrosine 
kinases, maximal stimulation of Jak activity is attained upon the phosphorylation of 
tyrosine residues positioned in the activation loop. The double tyrosine motif is found in 
all members of the Jak family and its phosphorylation has been well documented. The 
role of these residues has been assessed through the study of mutants bearing 
phenylalanine substitutions. Maximal Jak activity relies on the phosphorylation of the first 
tyrosine, while the role of the second tyrosine residue seems to be different among Jaks, 
e.g. the Y1008 residue in Jak2 does not seem to be important for its activity while Y981 
in Jak3 acts as a negative regulatory site (80, 93).  
 
1.3.3.3 Model of activation of Jaks 
The FERM, pseudokinase and kinase domains represent interdependent modules, 
which in fact need to interact with each other to ensure the proper regulation of the 
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protein. The interaction of the FERM domain with the receptor additionally contributes to 
the regulation of the catalytic activity of Jaks.  
Constitutively associated with the intracellular region of cytokine receptors Jaks are kept 
in an inactive state. After the receptor binds its respective ligand (a cytokine or a growth 
factor), it undergoes a conformational change reorganizing the position of its 
extracellular and intracellular domains (Fig. 11). Rearrangement of the receptor 
transforms the two Jaks into an active state, at which they can bind ATP. Additionally, 
they are brought close enough to phosphorylate each other leading to stabilization of the 
kinase domain in its active conformation enabling further transduction of the intracellular 
signal. 
 
 
Figure 11 
Model of activation of Jaks. Cytokine binding (1a) triggers a conformational change of the 
receptor, which is transduced to the intracellular domains (1b). The rearrangement of the receptor 
leads to the juxtaposition of the two Jak molecules and induces a conformational change of the 
Jaks (1c). Changes in the conformation of the receptor activate Jaks so that they can 
phosphorylate each other (2), leading to full activation. In the presence of cellular phosphatases 
dephosphorylating Jaks, fully activated Jaks are sustained by continuous phosphorylation of their 
tyrosine residues (3).   
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1.4    CYTOKINE-MEDIATED ACTIVATION OF JANUS KINASES 
1.4.1 Jak-dependent cytokine signal transduction 
Shortly after the discovery of Jaks, their essential function in cytokine signaling was 
established in a series of experiments using mutagenized cell lines that were resistant to 
the effects of interferons (IFNs). By transfecting the cells with expression vectors 
encoding different Jaks that were initially not expressed in those cells, the signaling 
could be fully reconstituted. Specifically, IFNα/β signaling was found to require Jak1 and 
Tyk2, whereas IFNγ needed Jak1 and Jak2 (85, 94, 95). To date, knockout mice of all 
four Jaks exist and their phenotypic analysis yielded valuable information for the 
understanding of their physiological role. These mice all show phenotypes that are linked 
to cytokine signaling deficiencies (Table 3) (54). 
 
Table 3 
Phenotype of Janus kinase gene-targeted mice. 
 
 
Nowadays, it is clear that a wide array of cytokines and growth factors activate Jaks 
thereby stimulating cell proliferation, differentiation, cell migration and survival. Cytokines 
first bind to their respective receptors to initiate the signaling cascade. With respect to 
Jaks, these cytokine receptor systems are restrictive concerning the usage of one Jak or 
Jak combinations, thereby, together with the differential activation of the various 
signaling proteins, determining the signaling characteristics. For instance, receptors 
required for hematopoietic cell development (EpoR, TpoR) use only Jak2, common γ-
chain receptors transducing signals of e.g. IL-2, IL-4 or IL-7 use Jak1 and Jak3, while 
type II cytokine receptors use only combinations of Jak1 and Tyk2 (IFN α/β receptor) or 
Jak1 and Jak2 (IFNγ receptor) (79).  
According to the accepted model, upon cytokine-induced receptor aggregation Jaks 
auto-activate and transphosphorylate themselves. Subsequently, the cytoplasmic tail of 
GENE PHENOTYPE 
JAK1 Perinatal lethality caused by failure of cytokine signaling in neurogenesis 
JAK2 Embryonically lethal due to failure in erythropoiesis 
JAK3 SCID caused by failure of cytokine signaling from γc-containing receptors 
TYK2 Increased susceptibility to pathogens caused by impaired responses to IFN α/β and IL-12  
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the receptor containing several tyrosine residues becomes phosphorylated by Jaks and 
that provides docking sites for SH2 domain-containing signaling molecules (Fig. 12).  
One class of SH2 domain-containing proteins, the STATs, latent cytoplasmic 
transcription factors, is particularly important for Jak-mediated signal transduction. Once 
recruited to the receptor complex, they can be phosphorylated by Jaks what further 
propagates the signal. Additionally, adaptor proteins such as Shc or the p85 subunit of 
PI3K can associate with certain phosphorylated tyrosines of the receptor leading to the 
activation of MAP kinase and PI3-K/Akt pathways (96). 
 
 
 
Figure 12 
Activation of the Jak/STAT pathway by cytokine binding to its receptor. Cytokine-induced receptor 
aggregation brings Jaks into close proximity what results in their phosphorylation and activation. 
Tyrosine residues of the receptor become phosphorylated by Jaks, providing docking sites for 
STATs and other adaptor proteins.  
 
The STAT proteins are thought to be recruited from a cytoplasmic pool and have been 
shown to interact with specific phosphotyrosine motifs within the activated receptors (97, 
98). The receptor-bound STATs are then phosphorylated by Jaks on a conserved 
tyrosine residue and the SH2 domains mediate the dimerization through reciprocal 
phosphotyrosine/SH2 domain interactions. STAT dimers are then translocated to the 
nucleus where they bind to specific sequences in the genome and activate gene 
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expression. Seven mammalian STATs have been identified: STAT1, STAT2, STAT3, 
STAT4, STAT5a, STAT5b and STAT6. Through generation of gene-targeted mice, the 
biological functions of STAT family proteins could be revealed. Knockout mice of each 
STAT displayed impaired cytokine-mediated functions (Table 4) (54, 99).  
 
Table 4 
Phenotype of STAT gene-targeted mice. 
 
 
1.4.2    IFNγ-mediated signal transduction 
In the year 1957 Isaacs and Lindenmann discovered a substance called interferon (IFN) 
that had protective properties on cells against viral infections (100, 101). IFNs represent 
proteins that are associated with host defense and homeostasis. They are secreted from 
cells in response to a variety of stimuli and can be organized into three classes: type I 
(α, β, ω and τ), type II (γ) and type III (λ). This chapter will focus on IFNγ.  
IFNγ is secreted by activated immune cells (mainly T and NK cells) (102). Conventional 
IFNγ signaling follows the binding of IFNγ to its cell surface receptors IFNγR1 and 
IFNγR2 thereby leading to oligomerization of the receptor and activation of Jak1 and 
Jak2 (103). Jak-mediated phosphorylation of tyrosine Y440 of human IFNγR1 (104) 
provides a binding site for STAT1, which is phosphorylated by Jaks on tyrosine Y701. 
Interestingly, cells bearing the IFNγR1 mutant where Y440 was mutated to F still sustain 
a substantial IFNγ response (105).  
In addition to Y701, STAT1 becomes phosphorylated in response to IFNγ on serine 
S727, which has been reported to have role in regulation of transcriptional activity (106). 
GENE PHENOTYPE 
STAT1 Viable and fertile, defective IFNα/β and IFNγ signaling, increased tumorigenicity 
STAT2 Viable and fertile, defective IFNα/β signaling 
STAT3 Embryonically lethal 
STAT4 Viable and fertile, defective IL-12-driven Th1 differentiation, increased susceptibility to intracellular pathogens 
STAT5a Viable and fertile, defective in prolactin functions and mammary gland development 
STAT5b Viable and fertile, defective in sexually dimorphic growth 
STAT5a/b Viable, female infertility, defective mammary gland development, reduced body mass, defective T cell proliferation 
STAT6 Viable and fertile, defective IL-4-driven Th2 differentiation, increased susceptibility to helminthic infestation 
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The molecular mechanism underlying the IFNγ-mediated S727 phosphorylation is not 
completely understood. The reported candidate kinases and mechanisms responsible 
for S727 phosphorylation are very diverse (107-112). Nevertheless, in vivo studies 
clearly showed the importance of the S727 modification; mice expressing the STAT1 
S727A mutant exhibit a strong reduction in IFNγ-mediated target gene expression (113). 
The phosphorylated STAT1 forms a homodimer and translocates to the nucleus in an 
importin-α5-dependent manner (114, 115) where it initiates transcription of genes 
containing a gamma activated sequence (GAS) (116) in their promotor region. Most 
STAT1-mediated transcription is entirely dependent on STAT1 tyrosine phosphorylation. 
However, there is some evidence that STAT1 can initiate transcription of a subset of 
genes independently of tyrosine phosphorylation (117, 118). Activated and 
phosphorylated STAT1 has been described to interact with other transcription cofactors. 
Among others, CREB-binding protein (CBP/p300), mini-chromosome maintenance 
protein 5 (MCM5) and breast cancer susceptibility gene 1 (BRCA1) have been identified 
as STAT1 interacting proteins modulating its transcriptional activity (119-121). CBP/p300 
has histone acetyl transferase (HAT) activity and functions as co-activator, while MCM5 
and BRCA1 associate with serine-phosphorylated STAT1 enhancing its transactivation. 
The physiological relevance of IFNγ-dependent signaling through the Jak/STAT pathway 
has been further established by generating and characterizing mice with a targeted 
disruption of the STAT1 gene (122, 123). STAT1-null mice revealed no defects in 
development; however, they lacked many classical responses to IFNs (α, β, γ) and thus 
were very susceptible to microbial and viral infections.    
In addition to the Jak/STAT pathway, IFNγ was shown to activate several other signal 
transducing proteins, including kinases like proline-rich tyrosine kinase Pyk2, the Src-
family kinase Fyn or MAP kinases. Except tyrosine and serine/threonine kinases, the 
adaptor proteins c-Cbl, CrkL and CrkII were reported to participate in generation of 
growth inhibitory effects of IFNs on primary hematopoietic progenitors (124).  
Experiments with STAT1-null cells confirmed the existence of STAT1-independent 
pathways activated in response to IFNγ. Surprisingly, IFNγ exerts suppressive effects on 
the growth of wild-type cells but it enhances the proliferation of STAT1-null cells (125, 
126). Genes, whose expression is not induced by IFNγ in wild-type cells, were transiently 
activated in STAT1-null cells (126). Furthermore, although STAT1 is crucial for efficient 
antiviral responses, STAT1-null mice were more resistant to some viruses like murine 
cytomegalovirus (MCMV) and Sindbis virus than mice lacking IFN receptors (125). Most 
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cytokines are known to activate multiple STATs. In wild type cells, IFNγ dominantly 
activates STAT1, but a residual STAT3 phosphorylation is also observed. In absence of 
STAT1 though, STAT3 activation is strongly enhanced compared to wild type cells (127), 
what has a stimulatory effect on the expression of genes that have a STAT3-binding site 
in their promotor sequences (SOCS3, GADD45 or CEBPB) (128, 129). A similar 
example is the switch of IL-6 signaling, which occurs mainly via STAT3, to a dominant 
STAT1 activation in STAT3-deficient cells (130). It causes the downstream induction of 
genes, whose expression would be normally induced by IFNγ.  
It would therefore be of interest to compare STAT1-knockout with STAT1 dominant-
negative systems e.g. STAT1-Y701F, to discriminate between effects dependent on 
DNA binding of phosphorylated STAT1 from effects maybe mediated by opportunistic 
modules taking advantage of the absence of STAT1.  
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1.4.3    Negative regulation of Jak-mediated cytokine signaling 
Sustained and/or excessive action of cytokines can be harmful to organisms. 
Accordingly, several mechanisms have been reported to modulate cytokine signaling to 
prevent this overreaction to cytokine.  
Proteolytic shedding of some cytokine receptors is known to control the action of 
cytokines (131). Proteosomal and lysosomal degradation have been shown to regulate a 
large set of signaling molecules and cytokine receptors (132-136). However, the key 
regulators of Jak/STAT signaling include suppressor of cytokine signaling (SOCS) 
proteins, protein inhibitors of activated STAT (PIAS) and protein tyrosine phosphatases 
(PTP).  
 
1.4.3.1 SOCS proteins 
The SOCS family comprising 8 members (CIS, SOCS1-SOCS7) is the most thoroughly 
studied family of regulatory proteins. Some of the SOCS proteins inhibit cytokine 
signaling through distinct mechanisms: SOCS1 mainly binds directly to tyrosine 
phosphorylated Jaks (137). SOCS3 binds to activated cytokine receptors and also 
directly to Jaks (138) while CIS competes with STATs for binding to the receptor docking 
sites (139). Noteworthy, only SOCS1 and SOCS3 can inhibit Jak tyrosine kinase activity 
because they both have the kinase inhibitory region (KIR) in their N-terminal domain. 
Moreover, all SOCS proteins contain a SOCS box that binds components of an ubiquitin 
E3 ligase complex which targets signaling proteins for degradation (140, 141). The 
importance of SOCS proteins in modulating cytokine responses was shown e.g. by the 
generation of several knockout mouse models (Table 5) (54). 
 
Table 5 
Phenotype of SOCS gene-targeted mice.  
 
 
GENE PHENOTYPE 
SOCS1 Viable but perinatal lethality due to severe IFNγ-dependent inflammatory diseases 
SOCS2 Viable, gigantism owing to unopposed signaling to GH and IGF-1 
SOCS3 Embryonically lethal due to placental defects and hematopoietic defects 
SOCS5 No phenotype 
CIS No phenotype 
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1.4.3.2 Phosphatases 
Tyrosine dephosphorylation of cytokine receptors and associated kinases is carried out 
by protein tyrosine phosphatases. SHP1 and SHP2 are SH2-domain-containing 
phosphatases (142) that can bind directly to phosphorylated tyrosine motifs of the 
activated cytokine receptors and negatively affect Jak activity (143-145). Moreover, the 
SHP2 phosphatase can act as a scaffolding protein, leading to the recruitment of other 
adaptor proteins such as Grb2 and Sos and thereby contributing to the cytokine 
signaling (146). Three other members of the PTP family, CD45, PTP1B and TCPTP 
have also been reported to directly dephosphorylate Jaks (147-149) and STATs (150, 
151).  
 
1.4.3.3 PIAS 
DNA binding of activated STATs in the nucleus can be negatively regulated by PIAS. 
The PIAS family consists of PIAS1, PIAS3, PIASx and PIASy. It has been proposed that 
PIAS1 and PIAS3 function by blocking the DNA-binding activity of STAT1 and STAT3, 
respectively (152, 153). In contrast, PIASx and PIASy repress the transcriptional activity 
of STAT1 and STAT4 by recruiting corepressor molecules such histone deacetylases 
(HDACs) (154, 155). Interestingly, functions of the PIAS proteins are not restricted only 
to STATs. They can also function as SUMO (small ubiquitin-related modifier) ligases 
targeting transcription factors to nuclear bodies where they become transcriptionally 
active or inactive (156).  
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1.5    CYTOKINE-INDEPENDENT ACTIVATION OF JANUS KINASES 
 
Due to the fact that Jak-dependent pathways such involving e.g. STATs, Erks, and AKT 
regulate cell growth, it is very likely that any kind of deregulation may lead to disease. 
Indeed, a number of diseases including cancer are linked to a dysfunctional Jak/STAT 
pathway activation.  
 
1.5.1 Jak fusion proteins 
It is well established that recombination of genes encoding members of the Jak family 
can result in their intrinsic activation. The Jak2 gene has been shown to be recombined 
with parts of several other genes leading to the formation of a fused oncogenic allele and 
the expression of hyperactive Jak2 fusion proteins. These have been associated with 
lymphoid and myeloid leukemia or with unclassified myeloproliferative neoplasms (MPN-
U). Several fusion genes that involve the kinase domain alone or together with the 
pseudokinase domain of Jak2 have been described: ETV6-Jak2 (157), TEL-Jak2 (158, 
159), BCR-Jak2 (160, 161), SSBP2-Jak2 (162) and PCM1-Jak2 (163-166). In all cases it 
is believed that the kinase domain contributed by the Jak2 gene drives the oncogenic 
transformation of these cells. So far Jak2 is the only member of the Jak family shown to 
be involved in such translocations with its oncogenic consequences. However, fusion 
genes constructed in vitro with other Jak family members are also constitutively active 
and transform BAF cells to factor-independent growth (167). 
 
1.5.2 Jak2-V617F as an example of a gain-of-function mutant 
Jak2 has been also described to be constitutively active in the myeloproliferative 
neoplasms polycythemia vera (PV), essential thrombocythemia (ET) and primary 
myelofibrosis (PMF). Within weeks in 2005, 4 different research groups from Cambridge 
(168), Boston (169), Paris (170) and Basel (171) published reports describing a novel 
Jak2 mutation affecting the pseudokinase domain. By sequencing DNA templates from 
PV patients, a guanosine (G) to thymidine (T) alteration at position 2343 could be 
identified. This results in a valine (V) to phenylalanine (F) substitution at the conserved 
residue V617 generating a constitutively active kinase that leads to cytokine-
independent activation of various signaling proteins, like STATs, MAP kinases and 
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PI3K/AKT (170, 172). In bone marrow transplantation assays, introduction of the Jak2-
V617F mutant into mouse was sufficient to induce a PV phenotype (173-176). 
Noteworthy, Jak2 harboring the V617F mutation was found in MPN patients with a high 
incidence: in 99% of PV patients, in 50% of ET patients and in 50% of PMF patients. 
However, another study by Scott and collegues has shown that Jak2-V617F expression 
is rather uncommon in cancers and myeloid malignancies other than classic BCR-ABL-
negative myeloproliferative neoplasms (177). The transforming potency of Jak2-V617F 
mutant depends on binding to cytokine receptors (172) and, as very recently shown, on 
STAT5 activation (178). A study on the Jak2-V617F mutant-expressing erythroid 
leukemic cell line HEL has shown that specific inhibition of Jak2-V617F activity with a 
small molecule inhibitor leads to G1 cell cycle arrest (179). This inhibition correlated with 
decreased expression of cyclin D2 and increased expression of p27; both proteins are 
involved in cell cycle regulation. Moreover, the Jak2-V617F mutant induces homologous 
recombination (HR) activity what results in genetic instability (180). It is hypothesized 
that the constitutively active Jak2 mutant deregulates the HR mechanism what initiates 
development of MPNs. The induction of genetic instability may also explain the evolution 
of MPN to acute myeloid leukemia. The Jak2-V617F mutation is not the only one 
identified in Jaks. A number of other mutations of Jak2 (Fig. 13), but also of Jak1 and 
Jak3 were found in patients suffering from different leukemias (acute lymphoblastic 
leukemia (ALL), acute megakaryoblastic leukemia (AMKL), and acute myeloid leukemia 
(AML)) (79). In addition to hematologic diseases, somatic Jak1 and Jak3 mutations were 
also found in solid tumors: Jak1 in lung and breast carcinoma, Jak3 in breast and gastric 
carcinoma (181). Interestingly these are tissues in which Jak3 is normally not expressed. 
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Figure 13 
Domain structure of Jak2 and model structure of the Jak2 pseudokinase domain. Residues for 
which mutations were reported in patients resulting in constitutively active kinases are indicated. 
The point mutations are represented as green stick models with spheres indicating the Van-der-
Waals radii of atoms. Regions carrying insertions (ins) and/or deletions are highlighted by a 
colored backbone. Adapted from (79). 
 
1.5.3 Non-canonical Jak/STAT signaling caused by gain-of-function 
mutants 
It is known that massive remodeling of the chromatin precedes Jak/STAT-mediated 
transcriptional activation (182, 183). It is also widely assumed that the effects of STAT 
activation are mediated by direct transcriptional induction of STAT target genes. 
Chromatin and higher order chromosome structures play a central role in a number of 
aspects of DNA biology in eukaryotes. Processes ranging from gene expression to 
chromosome dynamics during cell division are regulated by the folding of DNA into 
chromosomes. Heterochromatin and euchromatin are two types of chromatin found in 
chromosomes. Heterochromatic domains are in general inaccessible to DNA-binding 
factors and are transcriptionally silent. Euchromatin in contrast, defines more accessible 
and transcriptionally active portions of the genome. Very interestingly, using the 
Drosophila hopTum-l hematopoietic tumor model, signaling via Jaks and STATs has been 
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reported to directly affect the stability of heterochromatin (184, 185). The Drosophila 
genome contains only one Jak, called Hopscotch (Hop) and a single STAT protein 
(STAT92E). These two proteins are most homologous to Jak2 and STAT5, respectively 
(186, 187). The hopTum-l gene encodes an allele of Hop that is hyperactive due to a 
G341E mutation located presumably in a regulatory region of the protein (188-190). In 
this hematopoietic tumor model based on the hyperactive Jak mutant, HopTum-l globally 
disrupts heterochromatic gene silencing, which enables expression of genes that are not 
necessarily under direct STAT transcriptional regulation. It has been hypothesized, that 
Jak-mediated constitutive activation of STATs enables STAT-binding partners like 
p300/CBP, which possess HAT activity, to acetylate surrounding histones resulting in 
chromatin decondensation and expression of other than the canonical STAT-responsive 
genes (191).  
Very interestingly, similarly to human leukemias, HopTum-l causes overproduction and 
clonal expansion of particular blood cell types what deregulates the Drosophila blood cell 
development (189) and results in a high incidence of hematopoietic tumors. The 
tumorigenicity of HopTum-l strongly depends on the disruption of heterochromatic gene 
silencing (184). Given the evolutionary conservation of the canonical Jak/STAT pathway 
among different species, the non-canonical pathway affecting heterochromatin might 
also operate in vertebrates. To date, a number of constitutively active gain-of-function 
Jak mutants and Jak fusion proteins were found in human leukemias (79), so it would be 
of great interest to investigate this issue in mammalian cells.  
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My objectives were the following:  
 
1) Elucidation of the relative contribution of Jak1 and Jak2 in the signal transduction 
process of IFNγ 
a) Establishment of a cellular system suitable to study analogue-sensitive Janus 
kinases 
i) Generation of the analogue-sensitive mutants of Jak1 and Jak2 and their 
stable expression in Jak1- or Jak2-deficient cells  
ii) Biochemical characterization of the analogue-sensitive kinases 
b) Studying the outcome of specific pharmacologic inhibition of Jak1 and Jak2 in the 
context of IFNγ-mediated signal transduction 
2) Contribution to a better understanding of the mechanisms underlying signal 
transduction mediated by the Jak2-V617F mutant 
a) Studying the effects of inhibition of the constitutively active Jak2 and Jak3 
mutants in leukemic cells 
b) Studying negative feedback mechanisms counteracting signaling through 
hyperactive Jak2 mutants 
3) Characterization of protein kinase inhibitors designed to inhibit Jak kinase activity or 
reported to have suppressive properties against cells expressing Jak mutants 
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Material and methods: 
 
a) In vitro experiments were performed with the following cell lines or primary cells: 
i) Leukemic cell lines 
(1) HEL – human erythroleukemia (Jak2-V617F) 
(2) UKE-1 – cell line derived from a patient with transformed myelodysplastic   
               syndrome (Jak2-V617F) 
(3) SET-2 – human essential thrombocythemia (Jak2-V617F)  
(4) CMK – human acute megakaryocytic leukemia (Jak3-A572V) 
(5) CMY – human acute megakaryoblastic leukemia (Jak3-A573V) 
ii) Human fibrosarcoma cell lines 
(1) 2C4 (parental cell line for U4C and γ2A) 
(2) U4C (Jak1-deficient) 
(a) U4C-FRT-Jak1-WT 
(b) U4C-FRT-Jak1-M955A and M955G (analogue-sensitive) 
(c) U4C-FRT-Jak1-D1002N (kinase-inactive) 
(3) γ2A (Jak2-deficient) 
(a) γ2A-FRT-Jak2-WT 
(b) γ2A-FRT-Jak2-M929A and M929G (analogue-sensitive) 
(c) γ2A-FRT-Jak2-D976N (kinase-inactive) 
iii) Human embryonic kidney cell lines 
(1) HEK-Flp-In-293-EpoR 
(a) HEK-Flp-In-293-EpoR-Jak2-WT 
(b) HEK-Flp-In-293-EpoR-Jak2-K539L, -V617F and -T875N 
(2) HEK-Flp-In-YFP 
(a) HEK-Flp-In-YFP-Jak2-WT, -V617Fand -T875N 
iv) Other cancer cell lines 
(1) A431 – human epidermoid carcinoma (EGFR overexpressing cell line) 
(2) HepG2 – human hepatocellular carcinoma 
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v)     Primary CD14+ monocytes
b) Expression and phosphorylation of proteins were assessed by: 
i) Immunoprecipitation (page 132) 
ii) Western blot (page 132) 
c) Gene expression assessed by: 
i) Whole-genome DNA microarray (pages 46 and 63) 
ii) Immunology DNA microarray (page 64) 
iii) Quantitative PCR (pages 46 and 62) 
iv) Semi-quantitative PCR (page 86)  
d) Cloning of Jak1 or Jak2 mutant expression constructs:  
i) Mutations introduced by site-directed mutagenesis (page 62) 
ii) Constructs cloned into the pcDNA5/FRT/TO expression vector (page 62) 
e) Cellular growth was monitored by: 
i) WST-1 assay (page 86) 
f) Cellular apoptosis was monitored by: 
i) FACS Annexin-V assay (page 87) 
g) Protein localization was followed by: 
i) Confocal cell live microscopy (page 129) 
 
Detailed information about each method can be found in the results section on the 
indicated pages.  
 
Growth condition for the above-mentioned cells can be found on the following pages: 
• Human leukemic cell lines – page 106 
• Human fibrosarcoma cell lines – page 62 
• Human embryonic kidney cell lines – page 132 
• Human epidermoid carcinoma A431 – page 106 
• Human hepatocellular carcinoma HepG2 – page 168 
• Primary CD14+ cells – page 87 
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4.1  “JAK1 AND JAK2 IN IFNγ  SIGNALING: A CHEMICAL GENETIC 
APPROACH TO DISSECT THEIR RELATIVE CONTRIBUTIONS”  
 
4.1.1 Preamble  
 
Although it is well documented that Jak1 and Jak2 are the key components of IFNγ 
signal transduction, the respective contribution of Jak1 and Jak2 to initiate and sustain 
the IFNγ response remains to be fully understood.  
 
 
Figure 14 
Diagram representing the principle of the chemical genetics approach used to dissect the relative 
roles of Jak1 and Jak2 in the IFNγ-mediated signaling response. The chemically modified inhibitor 
1NM-PP1 contains a bulky substituent (highlighted by a red circle) that precludes binding of the 
inhibitor to the wild-type Jak. 1NM-PP1 can inhibit only kinases with the extra space inside the 
ATP-binding pocket generated by mutation of the gatekeeper residue, what means that in U4C 
cells only Jak1AS would be suppressed and only Jak2AS in γ2A cells. JI1 targets both analogue-
sensitive and wild-type kinases. This approach enables the generation of signaling and gene 
expression profiles characteristic for the inhibition of either Jak1 (U4C) or Jak2 (γ2A). 
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In the following work we have addressed the question concerning the requirements of 
Jak1 and of Jak2 activity for an efficient IFNγ response using a chemical genetics 
approach. The analogue-sensitive mutants of Jak1 and Jak2 were stably expressed in 
U4C and γ2A cells that are deficient in Jak1 and Jak2, respectively (Fig. 14).  
 
Both analogue-sensitive mutants of Jak1 and Jak2, in contrast to wild-type Jaks, were 
inhibitable by the inhibitor analogue 1NM-PP1, what gave us the possibility to tightly 
control the activity of either Jak1 (in U4C cells) or Jak2 (in γ2A cells) and monitor the 
response to IFNγ in early as well as late phases. Specific inhibition of Jak1 or Jak2 by 
1NM-PP1 was compared with the effects of the pan-Jak inhibitor JI1.  
 
We could demonstrate that inhibition of either Jak1AS or Jak2AS potently reduces 
STAT1 tyrosine phosphorylation what had a strong repercussion on IFNγ-mediated 
target gene expression. The suppression of STAT1 phosphorylation was consistently 
stronger upon inhibition of Jak2AS compared to the inhibition of Jak1AS. Interestingly, 
expression of STAT1 and IRF1 only seemed to depend on Jak2 activity; Jak1 activity 
was not necessary to induce STAT1 and IRF1 protein up-regulation. Importantly, U4C 
and γ2A cells expressing kinase-inactive mutants of Jak1 and Jak2, respectively, 
showed a similar regulation of STAT1 and IRF1, thereby supporting the results obtained 
by the chemical genetics approach.   
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Abstract 
 
Interferon γ (IFNγ) is involved in many biological processes including antiviral responses and 
immune surveillance. IFNg signals though the receptor-associated Janus kinases Jak1 and Jak2. 
Using a chemical genetics approach we investigated the relative contribution of Jak1 and Jak2 in 
IFNγ signal transduction. We constructed analogue-sensitive mutants of Jak1 and Jak2. They 
have normal activity in IFNγ-mediated signaling and can be specifically inhibited by kinase 
inhibitor analogues. Single inhibition of either Jak1 or Jak2 activity by an inhibitor analogue 
showed differential effects on IFNγ-mediated STAT1 phosphorylation, Jak2 inhibition having a 
stronger suppressive effect. Analysis of the transcriptome of IFNγ-stimulated fibrosarcoma cells 
revealed that both active Jak1 and Jak2 are required for full expression of many genes, e. g. 
those involved in antiviral responses and antigen presentation. Furthermore, we identified STAT1 
and IRF1 as genes, whose increased expression upon IFNγ stimulation strongly depends on 
active Jak2 but not Jak1. Exploiting the quick and reversible pharmacological inhibition of 
analogue-sensitive kinases we address the temporal requirement of Jak2 activity and the 
importance of different phases of the IFNγ response. 
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Introduction 
 
IFNγ is involved in many biological processes including antiviral responses or immune 
surveillance. IFNγ signaling involves phosphorylation of the protein tyrosine kinases Jak1 and 
Jak2 associated with IFNγR1 and IFNγR2, respectively. Upon IFNγ stimulation, STAT1 is 
recruited to tyrosine-phosphorylated Y440 of (human) IFNγR1. STAT1 is then phosphorylated on 
Y701, and dimers of Y-phosphorylated STAT1 molecules translocate to the nucleus where they 
bind to GAS (gamma activated sequences) elements in promoter regions of IFNγ target genes (1-
4). The relative role of the two Jaks for signal transduction is not entirely clear yet. Cellular and 
animal knockout models (5-11) have shown that lack of Jak1 or Jak2 expression prevents IFNγ 
signaling. However, the requirement of the expression of a Janus kinase in a certain cytokine 
signaling pathway does not automatically prove that its kinase activity is essential. Studies with 
kinase-inactive Jaks have yielded valuable data but in similar cellular systems differences have 
been reported (12, 13). 
During the last years a number of inhibitors targeting the Jak family of kinases have entered 
clinical trials for different indications (14). A minority of these inhibitors has good specificity within 
the Jak family. This raises the question whether inhibitors affecting more than one Jak might have 
significant side effects due to inhibition of other cytokine signaling pathways: e. g., inhibition of 
IFNγ signal transduction is likely to enhance the risk of viral infections and to reduce cancer 
immune clearance.  
To address the relative importance of Jak1 and Jak2 in IFNγ signal transduction we used a 
recently described chemical genetic approach (15, 16). This involves a genetic re-engineering of 
the kinase of interest, which is specifically rendered sensitive to a chemically modified ATP or 
inhibitor. To achieve this, the gatekeeper residue in the ATP binding pocket of the kinase is 
mutated to a smaller residue (e.g. glycine). Thereby, the space of the ATP-binding pocket is 
increased and is now accessible to a bulky derivative of a kinase inhibitor (or of ATP), which does 
not fit into the ATP-binding pocket of the wild-type kinase of interest, nor into the one of other 
kinases present in the cell. The possibility to specifically regulate the activity of a kinase by an 
ATP-competitive inhibitor has obvious advantages over e. g. the regulation of the expression of 
the whole protein or the use of kinase-inactive mutants (17, 18). The quick and reversible 
pharmacological inhibition of analogue-sensitive kinases by bulky inhibitors prevents the possible 
occurrence of compensatory processes often observed in “knock out studies” (19).    
Using a chemical genetics approach we investigated the relative contribution of Jak1 and Jak2 in 
IFNγ signal transduction. We demonstrate that single inhibition of either Jak1 or Jak2 activity by a 
bulky inhibitor has a strong though not complete suppressive effect on IFNγ-mediated STAT1 
phosphorylation. Analysis of the transcriptome of IFNγ-stimulated cells revealed that both active 
Jak1 and Jak2 are required for full expression of many genes, e. g. involved in antiviral responses 
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and antigen presentation. Furthermore, we have identified STAT1 and IRF1 as genes, whose 
expression upon IFNγ stimulation strongly depend on active Jak2 but not Jak1 and address the 
temporal requirement of Jak2 activity for their expression.  
 
Material and Methods 
 
Inhibitors 
Jak Inhibitor 1, 1Na-PP1 and 1NM-PP1 were obtained from Calbiochem.   
 
Cell lysis and Western blot analysis 
Cell lysis was performed as described before (20). Proteins were separated by SDS-PAGE, 
followed by electroblotting onto a PVDF (Roth) or Nitrocellulose membrane (GE Healthcare). Anti-
STAT1, anti-phospho-STAT1, anti-Jak1 and anti-Fin13 antibodies were from Transduction 
Laboratories. Anti-IRF1 and anti-α-Tubulin was from Santa Cruz and anti-actin from Millipore. 
Anti-Jak2 and the HRP-conjugated secondary antibodies were purchased from Cell Signaling. 
The fluorescently labelled secondary antibodies (IRDye®680 and IRDye®800CW) were from Li-
COR® Biosciences. Signals were detected using an ECL solution containing 2.5 mM luminol, 2.6 
mM hydrogen peroxide, 100 mM Tris/HCl pH8.8 and 0.2 mM para-coumaric acid (21) and a CCD 
camera system (Intas) or an Odyssey Infrared Imaging System (Li-COR® Biosciences). 
Quantitation was performed on single channels with the analysis software provided by the 
manufactor (Li-COR® Biosciences). Briefly, the signals to be quantitated were normalized with 
respect to the loading control for each lane and the signal intensity was then represented as fold 
induction or as % of the strongest signal. 
 
Quantitative PCR 
Total RNA was extracted using the NucleoSpin RNA II (Macherey-Nagel) and 1 µg of total RNA 
was reversely transcribed with the ThermoScript RT-PCR System (Invitrogen) in a volume of 20 
µL, using 50 mM oligo(dT)20 according to the manufacturer’s instructions. The real-time PCR was 
carried out on a CFX96 Detection System (BioRad) using a total volume of 20 µL containing 
cDNA corresponding to 50 ng RNA template, 10 pmol of each forward and reverse primer and 10 
µL of 2x Absolute QPCR SYBR Green Fluorescein Mix (ThermoScientific). For further information 
please consult the supplemental information section. 
 
Whole genome microarray analysis 
U4C-Flp-In-Jak1AS and γ2A-Flp-In-Jak2AS cells were left untreated or stimulated with IFNγ or 
IFNγ + inhibitors (1NM-PP1 or JI1) for 24h. Total RNA was extracted using the miRNeasy kit 
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(Qiagen) and subjected to whole human genome microarray analysis (Agilent Biotechnologies). 
Detailed methodologies and bioinformatic analyses are described in the supplemental material.   
 
Results 
 
Characterization of the gatekeeper mutants of Jak1 and Jak2. 
The gatekeeper residue in the catalytic cleft of Jak1 and Jak2 was genetically modified by site-
directed mutagenesis. Jak1M955 and Jak2M929 were mutated to either glycine or to alanine. 
Expression constructs encoding wild-type Jak1 and Jak2 as well as the potential analogue-
sensitive mutants were stably inserted into the FRT (Flp-In system, Invitrogen) site of human 
fibrosarcoma cell lines deficient in Jak1 (U4C-Flp-In cells) or deficient in Jak2 (γ2A-Flp-In cells). 
The use of the FRT site allows the isogenic expression of WT and mutated Jaks from the same 
site in the genome. To test the functionality of the different gatekeeper mutants of Jak1 and Jak2, 
U4C-Flp-In cells expressing either Jak1WT or Jak1 mutants and γ2A-Flp-In cells expressing 
either Jak2WT or Jak2 mutants were monitored for IFNγ-mediated target gene expression upon 
IFNγ stimulation. Quantitation of STAT1 and IRF1 protein expression upon IFNγ treatment 
revealed no major differences between U4C-Jak1WT and U4C-Jak1M955G (Jak1AS) or γ2A-
Jak2WT and γ2A-Jak2M929A (Jak2AS) (Figure 1A) expressing cells. Furthermore, quantitative 
analysis of LMP2 and TAP2 mRNA expression by real-time PCR confirmed the functionality of 
the mutated Jaks (Figure 1B). Moreover, the functionality of Jak1AS was further verified by a 
focused microarray containing 243 immunology-related genes showing a similar response of 
Jak1M955G (Jak1AS) and Jak1WT cells to IFNγ (Supplemental figure 2).  
To verify if bulky inhibitors can indeed explore the extra space generated by mutation of the 
gatekeeper residue and inhibit these Jak1 and Jak2 mutants, the tyrosine phosphorylation of 
STAT1 upon IFNγ treatment with or without inhibitors was monitored in U4C and γ2A cells stably 
expressing WT or mutant Jaks. STAT1 phosphorylation in all cell lines was effectively abrogated 
by Jak Inhibitor 1 (JI1), a pan-Jak inhibitor (22) targeting the wild-type forms of Jak1 and Jak2 as 
well as the analogue-sensitive mutants. Of the two inhibitor analogues that were tested, 1NM-
PP1 (23) was able to inhibit the Jak1M955G (Jak1AS) and Jak2M929A (Jak2AS)-dependent 
IFNγ-mediated signal transduction (Figure 2, supplemental figure 1). Pre-treatment with the bulky 
inhibitor 1NM-PP1 led to a dose-dependent down-regulation of IFNγ-mediated STAT1 
phosphorylation only in cells expressing analogue-sensitive Jaks (data not shown). Moreover, 
1NM-PP1 only suppressed the phosphorylation of the analogue-sensitive Jaks, in contrast to 
wild-type Jaks (data not shown). The characterization of the mutants Jak1M955A, Jak2M929G, 
which were not further used in this study and experiments using a second inhibitor analogue, 
1Na-PP1, are shown in supplemental figure 1 and supplementary table I. 
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Thus, in response to IFNγ treatment, U4C-Jak1WT and -Jak1M955G (Jak1AS) or γ2A-Jak2WT 
and -Jak2M929A (Jak2AS) cells showed a similar pattern of target gene expression, indicating 
that the introduced gatekeeper residue mutation does not compromise protein function. Both 
analogue-sensitive Jak mutants were also inhibitable by the 1NM-PP1 compound while the 
corresponding WT Jaks were not inhibited. Therefore, these mutants hereafter called Jak1AS and 
Jak2AS were selected for further study. 
 
Jak2 and Jak1 are essential for full phosphorylation of STAT1 but Jak2 plays the more important 
role. 
In the chemical genetic approach the activity of an analogue-sensitive kinase can be inhibited 
quickly in a time-dependent manner. To address the issue of temporal requirements of both Jaks 
for STAT1 phosphorylation, cells expressing either Jak1AS or Jak2AS were stimulated with IFNγ 
for 20 min or left untreated. To inhibit only the analogue-sensitive kinase, 1NM-PP1 was used 
and administrated 30 min prior to, simultaneously with or 10 min after cytokine stimulation (Figure 
3A). Regardless of the time of the 1NM-PP1 treatments, STAT1 phosphorylation was efficiently, 
though not completely down regulated. Very interestingly, only 10 min of inhibitor treatment (+10) 
was as effective to reduce the phospho-STAT1 signal as longer treatments (-30: pre-treatment; 0: 
co-stimulation), which is indicative of a quick dephosphorylation of phospho-STAT1 (24). 
Quantitation of the STAT1 phosphorylation revealed that inhibition of Jak2AS resulted in a 
stronger suppression of STAT1 activity compared to Jak1AS (down-regulation to below 20 % for 
selective Jak2 inhibition compared to 40 % for selective Jak1 inhibition) 
The enzymatic activity of a kinase can be perturbed in two different ways: by small molecule 
inhibitors, which have to compete with cellular ATP for binding to the catalytic cleft or by the 
introduction of kinase-inactivating mutation. We compared the analogue-sensitive kinases that 
could be selectively inhibited by 1NM-PP1 with the kinase-inactive mutants Jak1DN 
(Jak1D1002N) and Jak2DN (Jak2D976N) in the context of STAT1 activation upon IFNγ 
 treatment.  As shown before (Figure 2), 1NM-PP1 inhibition of Jak1AS and Jak2AS resulted in 
significant, though not complete suppression of STAT1 phosphorylation upon IFNγ treatment 
(Figure 3A) and Jak2 inhibiton was again more efficient in mediating this down-regulation. Cells 
expressing the kinase-inactive Jak1 mutant (Jak1DN) showed also residual STAT1 
phosphorylation upon IFNγ  stimulation, in contrast to Jak2DN expressing cells where STAT1 
activation was not observed (Figure 3B). Expectedly, pharmacological inhibition of the analogue-
sensitive Jaks was slightly less effective than mutation-based inactivation of kinase activity. 
However, the qualitative comparison shows that the specifically inhibited state reflects the kinase-
inactive state. Taken together the data indicate that Jak2 is more important in IFNγ-mediated 
STAT1 activation than Jak1. 
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Full regulation of the vast majority of IFNγ-regulated genes requires both active Jak1 and Jak2. 
To investigate the general impact of Jak1 and Jak2 inhibition on IFNγ-mediated target gene 
expression, a whole genome microarray analysis was carried out. U4C-Jak1AS and γ2A-Jak2AS 
cells were stimulated with IFNγ and treated with either 1NM-PP1 (to inhibit the activity only of the 
analogue-sensitive mutant) or JI1 (to suppress both wild-type and analogue-sensitive Jaks) for 
24h. IFNγ stimulation resulted in the differential expression of 345 genes that were common for 
both U4C-Jak1AS and γ2A-Jak2AS cell lines of which 305 were up-regulated and 40 were down-
regulated compared to the untreated control. Selective inhibition of either Jak1 or Jak2 resulted in 
down-regulation of the expression of the majority of genes regulated by IFNγ (Supplemental 
figure 3 (blue dots highlight a few well known examples) and Supplemental table VI); among 
others those involved in the antiviral response (OAS, PML, IRF1) (25-28), antigen presentation 
(HLA-A, -B and -C), and negative regulation of IFNγ signaling (SOCS1) (29). We confirmed this 
partial down-regulation of IFN-responsive genes by qPCR (Figure 4). Suppression of both Jaks 
by Jak inhibitor 1 (JI1) completely abrogated the inducible expression of these genes (Figure 4) 
while specific inhibition of Jak1 or Jak2 resulted in significant but not complete down-regulation. 
Taken together, the microarray and qPCR data suggest that both active Jak1 and Jak2 are 
indispensable for full expression of the vast majority of IFNγ -regulated genes. Supplemental 
tables II-VII provide an overview of the statistically relevant differentially regulated genes in the 
setting of the microarray study. 
 
IFNγ-mediated STAT1 and IRF1 gene expression depends on active JAK2 but not JAK1. 
Microarray analysis revealed that some genes might be regulated by Jak1 or Jak2 only 
(Supplemental Figure 3 (red dot highlights STAT1) and Supplemental tables II-V). Interestingly, 
STAT1 was among the genes depending on Jak2 activity only. To investigate this, we treated 
cells expressing Jak1AS and Jak2AS with 1NM-PP1 30’ prior to, simultaneously with or 1 h, 3 h 
and 6 h after cytokine stimulation. Phospho-STAT1, IRF1 and STAT1 were analyzed at 24 h post 
IFNγ stimulation. Jak1AS-expressing cells show persistent phospho-STAT1 signals after 24 h 
even if Jak1AS is inhibited by 1NM-PP1. This is in contrast to Jak2AS-expressing cells treated in 
the same way. Only inhibition of Jak2AS blocked the protein up-regulation of STAT1 and IRF1 
(which is dependent on PY-STAT1) regardless of the time of the inhibitor treatment (Figure 5A), 
whilst inhibition of Jak1AS did not reduce STAT1 and influenced IRF1 expression only slightly. As 
a control, the same experiment was performed for Jak1WT and Jak2WT expressing cells 
showing no influence of 1NM-PP1 on the IFNγ-mediated STAT1 and IRF1 response 
(Supplemental Figure 4). Cells expressing the kinase-inactive Jak1DN or Jak2DN mutants show 
the same Jak2-dependence of STAT1 upregulation as the specifically inhibited analogue-
sensitive Jaks (Figure 5B).  
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Reversible inhibition of Jak2 reveals differences in the regulation of IFNγ-mediated STAT1 and 
IRF1 protein expression. 
In contrast to experiments involving dominant negative kinases, experiments with analogue 
sensitive kinases allow for a reversible inhibition of their activity. Inhibition of IFNγ-stimulated Jak2 
activity over a defined time of 3 h in the initial stage of cytokine stimulation shows clear 
differences in the behaviour of IRF1, an immediate early gene induced by phospho-STAT1 (30), 
compared to the late phase response gene STAT1, which is regulated by IRF1 (31, 32). For this, 
cells were stimulated with IFNγ, 1NM-PP1 was added 5 min later and at 3 h the cells were 
washed and further cultivated in medium containing IFNγ but no inhibitor (Figure 6, supplemental 
figure 6). The initial phospho-STAT1 signal was rapidly suppressed by selective Jak2 inhibition, 
again showing the very short half-life of phosphorylated STAT1. Still, this level of STAT1 activity 
seems sufficient to lead to a modest but significant upregulation of IRF1 expression. Removal of 
the inhibitor after 3 h led to a strong peak in STAT1 phosphorylation, followed by a peak in IRF1 
expression 2 h later. Cells not treated with inhibitor (but with medium replaced after 3 h, upper 
panel of Figure 6) displayed essentially a pattern as observed in IFNγ-stimulated 2C4 cells (the 
parental cells to U4C- and γ2A-cells) (Supplemental figure 5A, supplementary figure 5B for 
comparison of IFNγ kinetics in 2C4 and γ2A-Jak2AS cells). This shows that the expression of 
IRF-1 closely follows phospho-STAT1 levels. In contrast, STAT1 expression seems rather 
independent from fluctuations in Jak2 activity during the early phase of IFNγ stimulation in which 
the initial phospho-STAT1 peak is observed.  
 
Discussion 
 
In this study we generated analogue-sensitive mutant kinases for Jak1 and Jak2 to analyze their 
respective contributions to signal transduction of IFNγ. We could demonstrate that inhibition of 
either Jak1 or Jak2 strongly reduces STAT1 tyrosine phosphorylation. Moreover, inhibition of 
either Jak1 or Jak2 activity similarly reduces expression of most target genes, pointing at an 
equally important role for both kinases in IFNγ signaling. Expression of STAT1 and IRF1, 
however, only depends on Jak2 activity.  
To generate analogue-sensitive kinases of Jak1 and Jak2, the gatekeeper residue in both 
kinases was mutated to a smaller residue to generate space for the accommodation of a “bulky” 
inhibitor, which cannot be used either by wild-type Jaks or ideally by any other kinase present in 
the cell (15, 33). The wild type or analogue-sensitive forms of Jak1 and Jak2 were introduced into 
U4C (Jak1-deficient) or γ2A (Jak2-deficient) cells, respectively, using the Flp-In system (13, 34). 
Importantly, both analogue-sensitive mutants of Jak1 and Jak2 performed similarly to the wild-
type Jak1 and Jak2 kinases in the context of IFNγ-mediated target gene expression (Figure 1). In 
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contrast to wild-type Jaks, the analogue-sensitive forms of Jak1 as well as Jak2 were selectively 
inhibited by 1NM-PP1 (Figure 2) what gave us the unique opportunity to study the outcome of 
specific pharmacologic inhibition of Jak1 and Jak2 in the context of the IFNγ response in Jak 
reconstituted U4C or γ2A cells.  
Inhibition of either Jak1AS or Jak2AS drastically reduced IFNγ-mediated STAT1 tyrosine 
phosphorylation (see Figures 2 and 3A/B). We consistently observed that the reduction in STAT1 
phosphorylation was somewhat stronger upon inhibition of Jak2AS compared to the inhibition of 
Jak1AS. Although both AS-kinases were fully dephosphorylated upon immunoprecipitation after 
1NM-PP1 treatment, we could initially not exclude that this “residual” STAT1 phosphorylation 
might be the result of a difference in the effectiveness of kinase inhibition within the cell where an 
inhibitor has to compete with ATP for binding to the catalytic cleft of the kinase in its active state. 
For reasons of comparison we therefore included kinase-inactive versions of Jak1 or Jak2 into 
the study, which carry an amino acid exchange precluding phosphotransferase activity. Jak1DN 
significantly affected the IFNγ-induced STAT1 phosphorylation although a partial STAT1 
phosphorylation was still observed (Figure 3B). On the other hand, STAT1 phosphorylation was 
completely abolished in cells expressing Jak2DN. Taken together our results indicate that STAT1 
tyrosine phosphorylation in response to IFNγ relies more on Jak2 than Jak1, but both kinases 
have to be active to observe a full activation. Importantly, the comparison of the kinase-inactive 
mutants and the pharmacologically inhibited analogue-sensitive mutants shows that the inhibition 
with 1NM-PP1 is efficient and reflects the kinase-inactive state. 
To assess the impact of specific Jak1AS or Jak2AS inhibition on the transcriptome, a microarray 
analysis was performed. The expression of the majority of genes induced by IFNγ was 
suppressed to some extent upon selective inhibition of either Jak1AS or Jak2AS (Figure 4, 
Supplemental figure 3, Supplemental table VI). These included genes encoding SOCS1 and 
genes associated with the antiviral response (Fig. 4). Former studies (12) using different kinase-
inactive Jak mutants and higher expression levels of reconstituted Jaks also find an important 
role for both kinases but attribute a much higher importance to Jak2 than we deduced from our 
system and the microarray data. Although in general STAT1 phosphorylation is reduced more 
efficiently by selectively inhibiting Jak2, many genes are influenced similarly by inhibition of Jak1 
and Jak2. Only a small subset of genes shows a regulation dependent on only one of the kinases 
(Supplemental tables II-V). Very interestingly, the IFNγ-induced expression of the genes encoding 
the transcription factors STAT1 and IRF1 seems to strongly depend on Jak2 activity; Jak1 activity 
was not necessary to induce STAT1 and IRF1 protein up-regulation (Figures 5A and B). These 
data are supported by the fact that STAT1 and IRF1 protein up-regulation was also seen in cells 
expressing the kinase-inactive mutant Jak1-DN (Figure 5B) and another variant of kinase-inactive 
mutant, Jak1-KE (12, 13). In contrast, Jak2 inhibition by a small molecule inhibitor (Jak2AS+1NM-
PP1) or by an inactivating mutation (Jak2DN) has a suppressive effect on STAT1 and IRF1 gene 
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expression (Figures 5A and B), as on the bulk of other genes (Supplemental figure 3). Thus, Jak1 
seems to play a less important role in IFNγ-mediated STAT1 and IRF1 gene expression. 
The availability of the specific and reversible inhibitors targeting only one Jak in our system gave 
us a possibility to specifically inhibit one Jak in a defined way over time and thus we addressed 
the temporal requirement of activated Jak2 for IFNγ-induced IRF1 and STAT1 expression in γ2A 
cells. The expression of IRF-1 closely followed phospho-STAT1 levels. It is well known that the 
gene encoding IRF1 contains GAS element(s) in its promoter and is upregulated shortly after 
IFNγ treatment. In contrast, STAT1 expression proved rather independent from fluctuations in 
Jak2 activity during the early phase of IFNγ stimulation. STAT1 gene regulation crucially depends 
on IRF1 (31, 32). Possibly the low levels of IRF1 induced upon IFNγ stimulation for only the first 5 
min may have been sufficient to allow for a similar time course of STAT1 expression as in cells 
not treated with the bulky inhibitor between 5 min and 3 h. Suppression of the early STAT1 
activation phase for different time lapses (30 min pre-stimulation to 1 to 3 h post-stimulation 
(Supplemental figure 7)) and experiments of inhibition of the late phase of signal transduction 
(Figure 5A) show that a sustained activation of phospho-STAT1 and a sustained IRF1 expression 
are essential for STAT1 protein expression through Jak2. 
Taken together, the analogue-sensitive Jak1 and Jak2 mutants are specifically inhibitable by 
1NM-PP1 and their inhibited state closely reflects the kinase-inactive state. In contrast to kinase-
inactive mutants, the analogue-sensitive mutants can be inhibited reversibly in a temporally 
defined way. It will be interesting to further investigate the requirements of the different phases of 
Jak activity and their repercussion on specific gene read-outs.  
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Jak1AS (Jak1M955G) and Jak2AS (Jak2M929A) are functional and promote IFNγ-
induced gene regulation 
A: U4C-Jak1WT and U4C-Jak1AS (-Jak1M955G) or γ2A-Jak2WT and γ2A-Jak2AS (-
Jak2M929A) were stimulated with IFNγ (10 ng/mL) for the indicated periods of time. Lysates were 
resolved by SDS-PAGE and subjected to quantitative Western blot analysis LI-COR® 
biosciences). IFNγ-mediated up-regulation of IRF1 and STAT1 was quantified using actin as 
reference. Bar diagrams represents the mean and SD values of three independent experiments. 
B: U4C-Jak1WT and U4C-Jak1AS or γ2A-Jak2WT and γ2A-Jak2AS were stimulated with IFNγ. 
Total RNA was prepared and TAP2 and LMP2 expression was analyzed by qPCR. The 
experiment was performed in triplicate and standard deviations are given.  
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Figure 2: The activity of Jak1AS and Jak2AS can be specifically suppressed by the 
inhibitor analogue 1NM-PP1  
U4C-Jak1WT and U4C-Jak1AS or γ2A-Jak2WT and γ2A-Jak2AS cells were pretreated or left 
untreated for 30 min with JI1 (1 µM) or 1NM-PP1 (40 µM) before IFNγ was added (10 ng/mL for 
30 min). After lysis, proteins were resolved by SDS-PAGE and analyzed by Western blot. 
Phosphorylation of STAT1 was detected and equal loading was verified by redetection of the blot 
with antibodies against STAT1 and FIN13.  
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Figure 3: Full IFNγ-induced STAT1 phosphorylation requires both active Jak1 and Jak2 
A: U4C-Jak1AS and γ2A-Jak2AS cells were left untreated or stimulated with IFNγ for 20 min and 
treated with 1NM-PP1 that was administrated 30 min prior to, simultaneously with or 10 min after 
cytokine stimulation. Western blots were prepared and phospho-STAT1 signals were quantified 
using actin as reference. The bar diagram represents the mean and SD values of three 
independent experiments. B: U4C-Jak1AS and γ2A-Jak2AS cells were left untreated or 
stimulated with IFNγ for 20 min and treated with 1NM-PP1 administrated 30 min prior to IFNγ. 
U4C-Jak1DN and γ2A-Jak2DN cells were stimulated with IFNγ for 20 min or left untreated. 
Phosphorylation of STAT1 was detected and equal loading was verified by redetection of the blot 
with antibodies against STAT1 and FIN13.  
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Figure 4: Both active Jak1 and Jak2 are required for full IFNγ-mediated gene expression 
U4C-Jak1AS and γ2A-Jak2AS cells were pretreated or left untreated for 30 min with JI1 (1 µM) or 
1NM-PP1 (40 µM) before IFNγ was added (10 ng/mL for 24 h). Total RNA was prepared and 
OAS3, OASL, PML and SOCS1 mRNA levels were analyzed by qPCR. The experiment was 
performed in triplicate and standard deviations are given.  
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Figure 5: IFNγ-mediated STAT1 and IRF1 protein expression strongly depends on active 
Jak2 
A: U4C-Jak1AS and γ2A-Jak2AS cells were left untreated or stimulated with IFNγ for 24 h and 
treated with 1NM-PP1 that was administrated 30 min prior to, simultaneously with or 1, 3 or 6 h 
after cytokine stimulation. Lysates were resolved by SDS-PAGE and subjected to Western blot 
analysis. Phospho-STAT1 and the expression of STAT1 and IRF1 were monitored and FIN13 
was used as loading control. B: U4C-Jak1AS, U4C-Jak1DN, γ2A-Jak2AS and γ2A-Jak2DN cells 
were left untreated or stimulated with IFNγ for 24 h and treated with 1NM-PP1 where indicated. 
Western blots were detected for the expression of IRF1 and STAT1. Equal loading was verified 
by detection with a FIN13 antibody. 
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Figure 6: In contrast to IRF1, IFNγ-induced STAT1 protein expression is insensitive to early 
fluctuations in Jak2 activity  
γ2A-Jak2AS cells were left untreated or stimulated with IFNγ (10 ng/mL). One part of IFNγ-
stimulated cells (lower panel) was additionally treated with the inhibitor analogue 1NM-PP1 (40 
µM) administrated 5 min after the cytokine stimulation. The time lapse of inhibitor treatment (5 
min to 3 h) is indicated in the lower panel by a bar subscribed 1NM-PP1. 3 h later cells were 
washed with PBS and new medium containing fresh IFNγ (10 ng/mL), but not supplemented with 
1NM-PP1 any more, was added. Lysates were resolved by SDS-PAGE and subjected to Western 
blot analysis. P-STAT1, IRF1, and STAT1 signals were quantified using α-Tubulin as reference 
(see Suppl. Fig. 6 for examples of original data). The scatter plot represents the mean of signal 
intensities obtained for each collected time point. The highest signal for P-STAT1, IRF1 and 
STAT1 was set to 100%. The experiment was performed three times and SD values are given.  
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Supplements: 
 
Supplementary Methods 
Cell culture and materials 
2C4, U4C and γ2A cells (human fibrosarcoma cells provided by Dr. I. M. Kerr, Cancer Research 
U.K., London, U.K.) were maintained in DMEM (Lonza). All media were supplemented with 10% 
FCS, 100 mg/L streptomycin, and 60 mg/L penicillin. U4C-Flp-In and γ2A-Flp-In cells (13, 34) 
stably expressing Jak1, Jak1-M955G (Jak1-AS), Jak1-D1002N (Jak1-DN) and Jak2, Jak2-M929A 
(Jak2-AS), Jak2-D976N (Jak2-DN), respectively, were generated using the Flp-In system from 
Invitrogen Life Technologies according to the manufacturer`s recommendations.   
U4C-Flp-In-Jak1, U4C-Flp-In-Jak1AS, U4C-Flp-In-Jak1DN, γ2A-Flp-In-Jak2, γ2A-Flp-In-Jak2AS, 
γ2A-Flp-In-Jak2DN cells were cultured with 250 µg/mL hygromycin. Cells were grown at 37°C in a 
water-saturated atmosphere at 5% CO2. IFNγ was obtained from Peprotech.  
 
Generation of Jak1 and Jak2 mutant constructs 
Standard cloning procedures were performed throughout this study. The mutations of Jak1 
(M955G, M955A, D1002N) and Jak2 (M929G, M929A, D976N) were introduced by PCR 
technique using a site-directed mutagenesis kit (Stratagene). All procedures were performed 
according to the manufacturer`s instructions. The mutations were introduced into 
pcDNA5/FRT/TO-Jak1 and pcDNA5/FRT/TO-Jak2 vectors containing the cDNA sequence of 
mJak1 or mJak2, respectively. The integrity of all constructs was verified by DNA sequencing at 
GATC Biotech, Constance, Germany.  
 
Quantitative PCR 
Total RNA was extracted using the NucleoSpin RNA II (Macherey-Nagel)) following the 
manufacturer`s instructions. The concentration of isolated RNA was measured using a NanoDrop 
spectrophotometer. Constant amounts of 1 µg of total RNA were reversely transcribed with the 
ThermoScript RT-PCR System (Invitrogen) in a volume of 20 µL, using 50 mM oligo(dT)20 
according to the manufacturer’s instructions. DNA contaminations were removed using the 
RNAse-free DNAse Set (Qiagen). The real-time PCR was carried out on a CFX96 Detection 
System (BioRad) using a total volume of 20 µL containing cDNA corresponding to 50 ng RNA 
template, 10 pmol of each forward and reverse primer and 10 µL of 2x Absolute QPCR SYBR 
Green Fluorescein Mix (ThermoScientific). Thermal cycling conditions for all assays were: 95ºC 
for 3 min, 40 cycles at 95ºC for 10 s and 60ºC for 30 s. Quantitative PCR results were normalized 
to TBP (TATA-binding protein). Relative fold changes were calculated by the comparative 
threshold cycles (CT) method, 2-∆∆CT. The specificity of qPCR products was documented by the 
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melting curve analysis with the following cycling conditions: 95ºC for 1 min, 60ºC for 1 min and 
60ºC for 30 sec followed by steps of increases of 0.5ºC for 30 sec until 95ºC is reached. Gene-
specific primers used in qPCR analysis were purchased from Eurogentec (Belgium), as follows:  
 
 
Microarray analysis 
Gene expression profiling experiments were performed using the Agilent 44K whole human 
genome microarrays (Agilent Biotechnologies, Diegem, Belgium) according to the two-color gene 
expression analysis (Quick Amp labeling) protocol (version 5.7) from the manufacturer. 
Hybridizations were performed by comparing cDNA derived from 300 ng of total RNA extracted 
from U4C-Jak1-M955G or γ2A-Jak2-M929A cells treated for 24h with IFNγ (10 ng/mL) and 40 µM 
of 1NM-PP1 or 1 µM of JI1 with that obtained from untreated cells. For each treatment, three 
biological replicates were analyzed in duplicate including one dye swap. Only high quality RNAs 
with a ribosomal RNA ratio greater than 1.9 and no evidence of degradation, as evaluated using 
the Agilent Bioanalyzer 2100 RNA 6000 nano assay, were used for analysis. Microarray images 
were quantified using the GenePix Pro 6.1 software (Molecular Devices, Sunnyvale, CA). The 
background level was detected using the morphological method “closing followed by openings”. 
GenePix flagging, able to filter out low-quality spots, was optimized to reduce the number of false 
negative and false positive spots in the analysis. The following GenePix script was used to 
determine the good quality spots. 
[Dia.] >= 45 and  
([F532 CV] + [F635 CV])/2 < 80 and  
TBP 
For: 5`- ACCCAGCAGCATCACTGTT -3`                                                                 
Rev:  5`- CGCTGGAACTCGTCTCACTA -3` 
SOCS1 
For: 5`- AGCTCCTTCCCCTTCCAG -3` 
Rev: 5`- CAAAATAACACGGCATCCC -3` 
LMP2 
For: 5`- CGTTGTGATGGGTTCTGATT -3` 
Rev: 5`- GCTTGTCAAACACTCGGTTC -3` 
TAP2 
For: 5`- GTAAGGAGGGTGCTGCACTT -3` 
Rev: 5`- CACGCTCTCCTGGTAGATCA -3` 
OASL 
For: 5`- GAGTGGAACGAAGAGGTGCT -3`                                                                                                   
Rev: 5`- ATGCTCCTGCCTCAGAAACT -3` 
OAS3 
For: 5`- GGAGAGGTTGTCATCTGGGT -3`                                                                                                          
Rev: 5`- CCTGGAATGAAATACACCCC -3` 
PML 
For: 5`- ACAGAGCACAGAGAGCCATC -3`                                                                                                   
Rev: 5`- GGGAGACCAAGTCCGAATAG -3` 
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([SNR 532] + [SNR 635])/2 > 4 and 
[F635 % Sat.] < 25 and  
[F532 % Sat.] < 25 and 
([% > B635+2SD] > 60 or [% > B532+2SD] > 60) and 
[Flags] <> [Bad] 
Information was imported from GPR files, processed and further analyzed by R/Bioconductor 
tools. First, various normalization methods were applied to remove experimental bias in the 
dataset. Spatial effects were removed using two-dimensional approximation of zero log-ratio level 
by radial basis functions. Dye-effects were removed by a Lowess normalization with the 
smoothing parameter f=0.67 (35). Finally, between-array normalization was performed by 
median-based centering and scaling of log-ratio distributions. The quality of microarrays was 
controlled by distributions of log-ratio values of the good-flagged spots, the total number of good-
flagged spots per array, the average correlation with other arrays and spatial homogeneity. 
Replicate spots were summarized and additionally filtered before the statistical analysis: only 
spots with intensities significantly higher than the background level were considered. To find 
genes with statistically significant regulation in each class (IFNγ, IFNγ+1NM-PP1, IFNγ+JI1) and 
between the three classes, the empirical Bayes method (36), implemented in Bioconductor’s 
limma package, was used. Genes with an adjusted p-value less then 0.05 are considered as 
significantly regulated. Microarray raw data were deposited in the ArrayExpress public repository 
with the reference number E-MEXP-2621 (Username: Reviewer_E-MEXP-2621; Password: 
1269281492172). 
 
PIQORTM Immunology microarray 
U4C-Flp-In-Jak1WT and U4C-Flp-In-Jak1AS were left untreated or stimulated with IFNγ for 24h. 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) and analyzed by the PIQORTM 
Immunology Microarray provided by Miltenyi Biotec. Bioinformatic analysis was performed by 
Miletnyi’s Biotec service.  
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Supplemental results 
Characterization of the gatekeeper mutations in Jak1 and Jak2 and the sensitivity of the mutants 
to the inhibitor analogues 1Na-PP1 and 1NM-PP1. 
To further test the functionality of the gatekeeper mutants of Jak1 and Jak2, U4C-Flp-In cells 
expressing either Jak1WT or Jak1 mutants and γ2A-Flp-In cells expressing either Jak2WT or 
Jak2 mutants were monitored for IFNγ-mediated STAT1 phosphorylation or target gene 
expression upon IFNγ stimulation. To verify if inhibitor analogues 1Na-PP1 and 1NM-PP1 inhibit 
these Jak1- and Jak2-gatekeeper-mutants, the tyrosine phosphorylation of STAT1 upon IFNγ and 
inhibitor treatment was analyzed.  
The naphtyl (1Na-PP1) and methylnaphtyl (1NM-PP1) groups (23) (Supplemental figure 1E) are 
the ones exploiting the extra space generated by the mutation of the gatekeeper residue, thereby 
ensuring that the wild type Jaks are not inhibited by these compounds. Jak-specific inhibitors with 
modifications exploiting this extra space would be optimal compounds to use in this kind of study. 
Such compounds are, however, not available commercially. WT Jaks are not inhibited by the PP1 
and PP2 inhibitors of the src family kinases since they harbor a bulkier gatekeeper residue, which 
clashes with the phenylmethyl group of PP1. The naphtyl- and methylnaphtyl-derivatives of PP1 
are still bulkier and the chance that these compounds would inhibit wild type Jaks was even 
lower.     
Supplemental Figure 1A shows that the Jak2M929G mutant does not sustain a robust STAT1 
phosphorylation which equals the one of Jak2WT. Concomitantly, SOCS1 gene transcription is 
not observed. Thus, this mutant is functionally impaired and cannot be further used to study IFNγ 
signal transduction events. Nevertheless, Jak2M929G was inhibitable by both 1Na-PP1 and 
1NM-PP1 (Supplemental Figure 1A) but this is of no further interest since functional integrity is a 
prerequisite. Jak2M929A, which is shown to sustain IFNγ signal transduction and target gene 
transcription (Figure 1) is also inhibited by 1Na-PP1 and is thus inhibitable by both bulky inhibitor 
analogues (Figure 1 and supplemental figure 1B). Both the Jak1M955G and Jak1M955A mutants 
showed a similar signal transduction compared to Jak1WT upon IFNγ (Figure 1; Supplemental 
figure 1C and D) and target gene upregulation comparable to Jak1WT (Figure 1; Supplemental 
figure 1D right panel). However, only Jak1M955G was inhibitable by 1NM-PP1 while Jak1M955A 
was not. Both, Jak1M955G and -M955A were not inhibitable by 1Na-PP1 (Supplemental figure 
1C and D).  
As a conclusion, the Jak1M955G (Jak1AS) and Jak2M929A (Jak2AS) mutants are functional and 
are both inhibited by the same inhibitor analog (1NM-PP1) so that they were chosen to conduct 
this study. The two mutations were therefore designated as Jak1AS and Jak2AS (AS = analog 
sensitive). 
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Supplemental figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental figure 1: Further characterization of the Jak1 and Jak2 analogue-sensitive 
mutants and their sensitivity to the inhibitor analogues 1Na-PP1 and 1NM-PP1. 
A: γ2A-Jak2WT and γ2A-Jak2M929G were treated with IFNγ and 1NM-PP1 or 1Na-PP1 as 
indicated. Western blots were detected for P-STAT1, STAT1, Jak2 and actin (left panel). SOCS1 
mRNA expression was investigated by qPCR upon IFNγ–treatment for the indicated times (right 
panel). B: γ2A-Jak2M929A cells were treated with IFNγ, JI1 and 1Na-PP1 as indicated. Western 
blots were detected for P-STAT1, STAT1, Jak2 and FIN13. C: U4C-Jak1M955G cells were 
stimulated with IFNγ, JI1 and 1Na-PP1 as indicated. Western blots were detected for P-STAT1, 
STAT1, Jak1 and actin. D: U4C-Jak1WT and U4C-Jak1M955A were treated with IFNγ, JI1, 1Na-
PP1 and 1NM-PP1 as indicated. Western blots were detected for P-STAT1, STAT1 (left panel) or 
for STAT1, IRF1 and FIN13 (right panel). E: The structures of PP1 and its derivatives 1Na-PP1 
and 1NM-PP1.  
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Supplemental figure 2: Jak1M955G induces a similar cellular response to IFNγ  compared 
to Jak1WT when expressed in U4C cells. 
Microarray analysis (PIQORTM Immunology Microarray, Miltenyi Biotec) of IFNγ (24 h)-stimulated 
U4C-Jak1WT and U4C-Jak1M955G cells. The 21 most regulated genes are shown as fold 
upregulated versus unstimulated cells.  
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Supplemental figure 3: Selective inhibition of Jak1 or Jak2 results in down-regulation of 
the expression of the majority of genes regulated by IFNγ . 
The scatter plots were generated by plotting normalized Log expression data obtained with U4C-
Jak1AS or γ2A-Jak2AS cells treated with IFNγ for 24 h against those found with cells pretreated 
with 1NM-PP1 for 30 min and then stimulated with IFNγ for 24 h. Each dot in the graph 
corresponds to the expression value of a particular gene found to be significantly differentially 
expressed upon IFNγ-treatment in both U4C-Jak1AS cells and γ2A-Jak2AS cells (FDR<0.05). 
The scatter plots were generated using BRB-ArrayTools developed by Dr. Richard Simon and 
BRB-ArrayTools Development Team (http://linus.nci.nih.gov/BRB-ArrayTools.html). 
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Supplemental figure 4: Jak1WT and Jak2WT are insensitive to the inhibitor analogue 1NM-
PP1.    
U4C-Jak1WT and γ2A-Jak2WT cells were left untreated or stimulated with IFNγ for 24 h and 
treated with 1NM-PP1 that was administrated 30 min prior to, simultaneously with or 1 h, 3 h, or 6 
h after cytokine stimulation. Lysates were resolved by SDS-PAGE and subjected to Western blot 
analysis. Expression of IRF1 and STAT1 was detected using specific antibodies. 
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Supplemental figure 5: IFNγ-mediated response in 2C4 and γ2A-Jak2AS cells. 
A: 2C4 cells were left untreated or stimulated with IFNγ (10 ng/mL) for the indicated periods of 
time. Western blots were detected with antibodies against P-STAT1, IRF1 and STAT1. Signals 
were quantified using α-Tubulin as reference. The scatter plot represents the mean of signal 
intensities obtained for each collected time point. The highest obtained signals for P-STAT1, IRF1 
and STAT1 were set to 100%. The experiment was performed three times and SD values are 
given. B: γ2A-Jak2AS were stimulated or not with IFNγ (10 ng/mL) for the time indicated. Western 
blots were detected with antibodies against P-STAT1, whose signal was quantified using actin as 
reference. The scatter plot represent the mean of signal intensities obtained for time points up to 
12 h collected in γ2A-Jak2AS cells and 2C4 cells (5A). The highest signal obtained for P-STAT1 
was set to 100%.  
 
 
 
RESULTS	   71	  
 
ANALOGUE-­‐SENSITIVE	  JAKS	   71	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental figure 6: IFNγ-mediated upregulation of IRF1 and STAT1 is differentially 
affected by fluctuations in Jak2 kinase activity during early time points of stimulation.  
Representative Western blots used for the quantitation in Figure 6 are represented (see also 
Figure 6 for treatment details). 
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Supplemental figure 7: The upregulation of STAT1 protein expression is not affected by 
the lack of Jak2 activity in the early phase of IFNγ response. 
γ2A-Jak2AS cells were left untreated or stimulated with IFNγ (10 ng/mL) as indicated. 
Additionally, cells were treated with the inhibitor analogue 1NM-PP1 administrated for limited 
intervals beginning 30 minutes prior interferon stimulation to 1or 3 hours post interferon 
stimulation.  Alternatively 1NM-PP1 was administered for the intervals beginning 5 minutes after 
cytokine stimulation to 1 or 3 hours post interferon stimulation. At the end of these intervals cells 
were washed with PBS and new medium containing fresh IFNγ (10 ng/mL) was added. Lysates 
were resolved by SDS-PAGE and subjected to quantitative Western blot analysis. STAT1 signals 
were quantified using STAT5 as reference. The bar diagram shows the mean of signal intensities 
where SD values of three independent experiments are given.  
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Supplemental table I 
 
Characteristics of the different gatekeeper mutations in Jak1 and Jak2. 
 
 
Supplemental table II 
 
The inhibitor analogue 1NM-PP1 reduces the IFNγ-mediated response only in Jak1AS cells. 
 
 
 
 
Supplemental table III 
 
The inhibitor analogue 1NM-PP1 enhances the IFNγ-mediated response only in Jak1AS cells. 
 
 
 
 PY-STAT1 
upon IFNγ  
Gene induction 
upon IFNγ  
1Na-PP1 
sensitive 
1NM-PP1 
sensitive 
Conclusion 
      
Jak1WT √ √ No No  
Jak1M955G √ √ No √ Functional and analogue-sensitive 
Jak1M955A √ √ No No Not suited 
      
Jak2WT √ √ No No  
Jak2M929G reduced reduced n.d. √ Not suited 
Jak2M929A √ √ √ √ Functional and analogue-sensitive 
  JAK1-AS (LogFC) JAK2-AS (LogFC) 
Systematic 
Name Gene IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 
A_23_P133133 ALPK1 6.22 4.49 #N/A 3.38 3.64 #N/A 
A_23_P32404 ISG20 5.62 4.68 0.81 4.22 3.81 1.46 
A_23_P381714 CA13 2.90 1.66 -0.38 2.44 2.08 0.96 
A_23_P27556 EMR1 2.12 0.94 #N/A 1.93 1.39 -0.34 
A_24_P44462 TPM1 -1.89 -1.06 1.34 -1.61 -2.36 -0.06 
A_24_P413126 TMEPAI -1.87 -0.76 -0.19 -2.90 -3.35 -0.76 
  JAK1-AS (LogFC) JAK2-AS (LogFC) 
Systematic 
Name Gene IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 
A_23_P4821 JUNB 3.00 4.27 1.97 2.08 1.65 1.28 
A_23_P86653 PRG1 1.88 2.58 0.39 2.14 2.01 0.70 
A_23_P93641 AKR1B10 -2.88 -3.61 -0.80 -2.80 -2.12 -1.28 
A_24_P940006 EFNB3 -1.47 -2.30 -1.48 -1.69 -1.78 -0.50 
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Supplemental table IV 
 
The inhibitor analogue 1NM-PP1 reduces the IFNγ-mediated response only in Jak2AS cells. 
 
 
 
Supplemental table V 
 
The inhibitor analogue 1NM-PP1 enhances the IFNγ-mediated response only in Jak2AS cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  JAK2-AS (LogFC) JAK1-AS (LogFC) 
Systematic 
Name Gene IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 
A_23_P56630 STAT1 10.55 5.86 2.26 9.07 8.75 2.69 
A_23_P207999 PMAIP1 3.95 2.43 1.94 4.57 4.54 2.44 
A_23_P34915 ATF3 5.13 2.66 1.49 4.06 3.63 2.62 
A_24_P167642 GCH1 3.61 2.60 1.07 3.28 2.90 0.53 
A_24_P319635 MCL1 2.93 1.35 1.19 3.16 3.60 1.36 
A_23_P121898 PARP8 3.95 0.39 0.69 2.89 2.35 0.84 
A_24_P394865 GOLPH2 3.18 2.16 1.04 2.66 2.40 1.18 
A_32_P38003 PKR 3.29 1.31 #N/A 2.29 1.93 1.10 
A_23_P63668 IFIT5 2.94 1.31 0.56 2.10 1.53 0.09 
A_23_P212475 SCOTIN 2.19 1.35 0.10 1.65 1.45 0.62 
A_24_P408772 PBEF1 2.64 1.05 1.29 1.64 1.70 1.50 
A_23_P321261 ME2 2.29 0.14 0.62 1.56 1.36 1.11 
A_23_P170058 PSMB2 2.34 0.31 0.09 1.53 0.95 -0.07 
A_23_P57658 HRASLS -2.19 -1.06 -0.73 -1.63 -1.39 -0.03 
  JAK2-AS (LogFC) JAK1-AS (LogFC) 
Systematic 
Name Gene IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 
A_24_P44462 TPM1 -1.61 -2.36 -0.06 -1.89 -1.06 1.34 
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Supplemental table VI 
 
The inhibitor analogue 1NM-PP1 reduces the IFNγ-mediated response in Jak1AS and Jak2AS 
cells. 
  JAK1-AS (LogFC) JAK2-AS (LogFC) 
Systematic 
Name Gene IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 
A_23_P74290 GBP5 23.31 11.18 #N/A 23.39 10.13 #N/A 
A_23_P166797 RTP4 19.44 10.56 #N/A 15.54 7.80 0.78 
A_32_P107372 GBP1 16.61 10.15 2.77 18.09 7.86 1.30 
A_23_P29237 APOL3 13.39 8.02 2.18 12.49 7.01 2.21 
A_23_P48513 IFI27 13.36 6.81 #N/A 13.73 7.70 1.24 
A_32_P44394 AIM2 13.08 7.32 #N/A 13.46 7.05 1.25 
A_23_P75786 SLC15A3 12.68 7.23 #N/A 12.32 5.63 #N/A 
A_32_P209960 CIITA 12.15 8.73 #N/A 11.94 8.58 #N/A 
A_23_P59005 TAP1 11.73 8.28 1.25 11.58 6.35 1.30 
A_23_P41765 IRF1 11.34 7.90 2.27 9.56 4.84 1.10 
A_23_P370682 BATF2 11.30 7.61 1.38 11.14 6.22 1.35 
A_23_P85693 GBP2 11.26 5.73 -2.18 12.90 5.94 -0.90 
A_23_P64173 COP1 11.11 8.59 #N/A 11.46 7.04 #N/A 
A_23_P30913 HLA-DPA1 10.96 6.16 #N/A 11.48 6.09 0.80 
A_23_P51487 GBP3 10.77 7.26 1.63 8.38 3.92 0.23 
A_23_P65651 WARS 10.73 9.04 4.01 9.67 5.49 2.29 
A_23_P153745 IFI30 10.52 4.79 -1.78 11.71 4.05 -0.28 
A_23_P14174 TNFSF13B 10.49 5.64 #N/A 11.41 5.20 #N/A 
A_23_P35412 IFIT3 10.30 5.72 #N/A 12.01 4.32 0.48 
A_23_P125107 HLA-B 9.50 6.21 0.91 9.42 5.45 0.60 
A_23_P202978 CASP1 9.34 6.31 1.77 9.21 5.92 1.91 
A_23_P111000 PSMB9 9.10 6.83 1.59 9.55 5.15 0.60 
A_23_P1962 RARRES3 9.04 5.16 #N/A 8.94 4.65 #N/A 
A_24_P161018 PARP14 8.79 4.12 -0.18 8.89 2.93 0.45 
A_23_P23074 IFI44 8.77 4.61 0.11 11.61 3.45 -0.40 
A_23_P75741 UBE2L6 8.51 5.35 1.52 8.32 4.61 0.95 
A_23_P145264 HLA-F 8.24 5.71 0.53 8.63 4.83 0.56 
A_23_P69383 PARP9 8.06 4.96 1.08 10.75 4.86 0.77 
A_24_P941167 APOL6 7.92 5.15 3.85 7.65 4.41 2.01 
A_24_P326082 HLA-E 7.89 5.43 0.36 8.86 4.53 0.34 
A_23_P314024 HLA-F 7.81 5.26 0.71 7.90 4.49 0.54 
A_24_P113674 HLA-B 7.75 5.27 0.64 8.12 4.66 0.52 
A_32_P351968 HLA-DMB 7.74 3.95 #N/A 11.85 6.03 #N/A 
A_23_P2492 C1S 7.65 4.83 2.10 11.19 6.77 1.68 
A_23_P65442 ISGF3G 7.58 4.50 3.66 10.74 6.05 3.29 
A_23_P140807 PSMB10 7.46 4.59 -0.72 8.07 4.03 -0.27 
A_23_P24004 IFIT2 7.44 5.56 1.04 8.25 4.50 1.46 
A_24_P298409 HLA-C 7.40 4.61 0.68 8.35 4.44 0.71 
A_32_P234459 HLA-H 7.39 4.73 0.39 7.04 4.22 0.49 
A_23_P138680 IL15RA 7.30 4.42 1.55 6.96 4.22 0.95 
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Supplemental table VI (continued) 
 
  JAK1-AS (LogFC) JAK2-AS (LogFC) 
Systematic 
Name Gene IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 
A_23_P126908 TNFRSF14 7.17 4.01 0.27 4.58 1.83 -0.17 
A_23_P819 ISG15 7.14 4.96 -0.97 9.21 4.57 0.62 
A_23_P18604 LAP3 7.13 3.74 0.11 6.76 0.98 0.00 
A_32_P460973 HLA-E 7.12 5.15 0.38 8.31 4.51 0.32 
A_23_P203498 TRIM22 7.01 3.77 0.68 7.27 3.07 1.25 
A_23_P152782 IFI35 6.98 4.71 0.04 7.73 3.97 0.55 
A_23_P47955 OAS3 6.87 3.45 0.92 7.76 2.28 0.13 
A_24_P87931 APOL1 6.84 4.22 0.17 6.18 2.69 -0.45 
A_23_P72737 IFITM1 6.83 3.25 -0.61 9.00 3.44 -0.42 
A_23_P139786 OASL 6.82 1.82 #N/A 7.72 1.15 -1.46 
A_23_P211488 APOL2 6.77 3.56 0.64 6.97 1.87 -0.21 
A_24_P376483 HLA-A 6.71 4.38 0.37 6.90 3.92 0.59 
A_24_P311926 HLA-G 6.59 4.26 0.53 7.35 4.04 0.54 
A_32_P132206 USP18 6.43 3.68 0.03 13.21 5.45 1.99 
A_23_P350295 HLA-H 6.41 4.37 0.42 6.37 3.59 0.59 
A_23_P68155 IFIH1 6.32 3.82 1.12 8.73 4.21 0.70 
A_23_P47691 TRIM21 6.29 3.02 0.30 3.84 1.05 -0.58 
A_23_P250629 PSMB8 6.17 3.59 0.53 6.32 2.62 -0.27 
A_23_P154235 NMI 6.06 4.02 1.87 5.88 2.77 0.75 
A_23_P368681 GIMAP2 5.93 3.91 #N/A 5.11 2.87 0.97 
A_23_P143713 APOBEC3G 5.91 3.35 0.67 5.16 1.47 0.00 
A_23_P201459 IFI6 5.86 2.71 -0.90 11.00 3.51 #N/A 
A_23_P36700 TAPBPL 5.72 3.61 #N/A 3.84 2.43 0.14 
A_23_P142849 RND3 5.68 3.43 0.75 7.83 4.33 2.09 
A_23_P29953 IL15RA 5.57 3.72 -0.19 5.26 2.73 -0.76 
A_23_P120002 SP110 5.55 2.04 -0.30 5.84 0.89 -0.62 
A_23_P167096 VEGFC 5.43 2.47 -1.19 4.09 2.07 0.61 
A_24_P311917 BTN3A3 5.29 2.76 #N/A 5.82 2.42 -0.47 
A_23_P39465 BST2 5.24 2.77 0.10 14.14 7.25 #N/A 
A_23_P61688 SLC12A7 5.20 2.70 1.59 5.24 2.45 0.74 
A_23_P156687 CFB 5.19 1.98 -0.23 7.85 2.37 -0.22 
A_24_P48898 APOL2 5.18 2.55 0.24 5.19 1.94 -0.30 
A_23_P1461 OPTN 5.07 2.92 1.11 4.77 2.48 0.99 
A_23_P37441 B2M 5.04 4.11 0.63 6.58 4.37 1.10 
A_23_P111804 PARP12 4.95 3.65 1.34 4.87 3.00 1.05 
A_24_P329065 BTN3A1 4.78 3.82 -0.01 5.60 3.29 0.68 
A_23_P217866 IFI16 4.76 2.47 1.61 4.64 2.07 1.15 
A_24_P207139 PML 4.71 1.62 -1.32 5.92 1.24 -0.78 
A_24_P16124 IFITM4P 4.68 1.43 -0.74 5.37 1.10 -0.52 
A_23_P21207 UBE1L 4.64 3.37 -0.36 6.03 2.95 0.34 
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Supplemental table VI (continued) 
 
  JAK1-AS (LogFC) JAK2-AS (LogFC) 
Systematic 
Name Gene IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 
A_23_P134176 SOD2 4.51 1.14 -0.92 3.52 -0.10 -0.33 
A_23_P47304 CASP5 4.47 2.80 1.05 4.33 3.04 1.71 
A_23_P30243 LRAP 4.46 2.88 -0.41 3.85 2.14 0.26 
A_23_P35912 CASP4 4.45 3.04 1.26 4.16 3.20 1.57 
A_23_P42306 HLA-DMA 4.45 1.97 -1.49 6.86 3.23 -0.18 
A_23_P69109 PLSCR1 4.43 2.21 0.43 4.51 1.21 0.12 
A_24_P385611 SP100 4.17 2.68 1.39 2.47 0.98 0.53 
A_24_P254933 IFITM3 4.12 1.12 -0.85 4.44 0.76 -0.70 
A_23_P319792 XRN1 4.00 1.92 0.34 2.93 0.96 -0.26 
A_24_P252078 BTN3A2 3.98 3.20 -0.83 4.83 3.19 0.01 
A_23_P6935 CD47 3.82 2.53 -0.60 3.83 1.90 0.47 
A_23_P136478 IRF2 3.81 1.62 #N/A 2.83 1.38 -0.68 
A_24_P49260 SPTLC3 3.79 1.19 #N/A 1.81 -0.05 -0.68 
A_23_P69310 CCRL2 3.72 2.29 0.14 3.70 1.79 1.13 
A_23_P151610 PSME1 3.71 3.05 0.78 4.63 2.49 0.77 
A_23_P142424 TMEM149 3.69 2.51 -1.69 4.51 3.04 -0.08 
A_23_P26815 RILP 3.66 1.91 -0.97 1.98 0.80 -0.54 
A_24_P116805 STAT3 3.66 2.00 #N/A 3.59 0.30 -0.31 
A_23_P350107 TRIM56 3.55 2.25 1.05 2.99 1.15 -0.12 
A_23_P142676 DNPEP 3.32 2.41 0.44 3.30 1.88 0.22 
A_24_P349117 GPR158 3.30 2.23 1.51 3.58 1.91 0.70 
A_23_P76145 CLIF 3.21 0.83 #N/A 2.95 0.51 -0.70 
A_23_P355244 SAMD9 3.18 1.89 0.29 3.60 1.63 -0.19 
A_23_P31810 CEBPD 3.14 0.57 -0.79 3.53 1.73 0.36 
A_23_P75220 SLC25A28 3.14 1.33 -0.07 3.11 0.67 0.18 
A_32_P167592 1-8U 3.13 0.49 -1.07 4.20 0.84 -0.50 
A_23_P52266 IFIT1 3.05 0.30 -3.28 8.35 1.43 -2.08 
A_23_P92073 PARP3 3.03 1.36 0.92 2.70 1.07 0.75 
A_23_P12572 CASP7 3.02 1.77 0.24 2.31 1.15 -0.07 
A_23_P201097 GUK1 2.91 1.34 -0.75 3.06 1.01 -0.18 
A_24_P23034 ZNFX1 2.88 1.66 1.34 3.13 1.10 0.64 
A_24_P287043 1-8D 2.81 0.40 -0.91 3.60 0.73 -0.47 
A_23_P97064 FBXO6 2.77 1.13 0.16 2.88 1.12 -0.82 
A_23_P365719 TAPBP 2.76 1.76 0.35 3.03 1.88 0.36 
A_23_P66017 PRRT2 2.75 0.22 -2.65 2.40 -0.65 -2.02 
A_23_P62642 CCDC19 2.75 -0.43 -1.06 3.14 -1.69 -1.79 
A_23_P129486 SEPX1 2.72 1.19 -1.52 2.00 0.61 -0.81 
A_24_P343233 HLA-DRB1 2.70 0.44 #N/A 5.90 3.27 -0.30 
A_23_P216655 TRIM14 2.70 1.11 0.33 2.67 0.75 0.45 
A_24_P362317 ADAR 2.53 1.74 0.66 3.15 0.93 0.08 
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Supplemental table VI (continued) 
 
 
 
 
 
 
 
 
 
 
  JAK1-AS (LogFC) JAK2-AS (LogFC) 
Systematic 
Name Gene IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 
A_24_P263623 PTGES3 2.45 1.12 0.86 3.68 0.88 0.78 
A_23_P212089 NFKBIZ 2.39 1.77 #N/A 3.15 -0.09 0.27 
A_23_P88819 MVP 2.39 1.74 -0.40 2.33 1.62 0.13 
A_24_P30194 IFIT5 2.37 1.57 0.10 2.97 1.22 0.13 
A_23_P135548 DPYD 2.34 0.84 0.13 3.40 1.00 1.20 
A_23_P142750 EIF2AK2 2.32 1.21 -0.32 3.19 1.25 -0.16 
A_23_P60479 DNAJA1 2.17 1.40 0.09 2.50 0.39 -0.44 
A_23_P123343 NUDCD1 2.13 1.19 0.87 1.75 0.58 0.82 
A_23_P123672 TDRD7 2.08 0.97 -0.21 2.47 0.84 -0.15 
A_23_P140301 PSMA3 2.08 0.77 -0.70 1.96 -0.14 -0.75 
A_32_P184916 GNB4 1.92 0.84 0.18 3.01 0.30 0.09 
A_23_P12044 TMEM51 1.90 0.98 -0.25 1.95 0.63 0.03 
A_23_P212397 LARS2 1.83 1.09 -0.02 1.60 0.30 0.19 
A_23_P359245 MET 1.81 0.46 0.84 1.81 0.37 0.27 
A_23_P251480 NBN 1.77 0.68 0.41 2.10 0.20 -0.10 
A_23_P104046 BPNT1 1.76 -0.10 -2.25 3.03 0.15 -0.73 
A_23_P86216 PSMA5 1.63 0.93 0.22 2.04 -0.22 0.30 
A_23_P53345 ARNTL2 1.60 0.94 0.36 1.92 0.71 0.63 
A_23_P31143 TPD52L1 -3.98 -1.42 0.91 -5.88 -0.12 0.19 
A_23_P422212 SLC35F3 -3.80 -0.27 0.53 -4.24 0.82 1.51 
A_23_P14083 AMIGO2 -3.00 -1.25 4.01 -2.99 -1.93 1.07 
A_23_P30275 PCYOX1L -2.64 0.14 -0.12 -2.25 0.79 0.87 
A_23_P35456 SH3PXD2A -2.44 0.39 0.17 -1.65 0.20 -0.17 
A_23_P388168 RAB3B -2.23 -1.55 -1.54 -2.17 -0.40 -0.04 
A_23_P111995 LOXL2 -2.13 -0.42 -0.13 -1.63 -0.43 0.36 
A_23_P97990 HTRA1 -1.96 -0.60 -1.01 -1.74 0.24 -0.03 
A_23_P251841 NRXN3 -1.95 -0.30 -1.40 -3.26 0.31 -0.35 
A_23_P422911 HS6ST3 -1.87 0.70 -0.79 -2.33 1.88 0.73 
A_23_P165840 ODC1 -1.85 0.70 0.52 -3.43 -0.62 0.96 
A_23_P120883 HMOX1 -1.45 0.24 3.17 -3.26 0.26 1.55 
A_23_P24433 CTSF -1.45 0.30 0.49 -1.74 1.23 0.87 
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Supplemental table VII 
 
The inhibitor analogue 1NM-PP1 enhances the IFNγ-mediated response in both Jak1AS and 
Jak2AS cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  JAK1-AS (LogFC) JAK2-AS (LogFC) 
Systematic 
Name Gene IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 IFNγ 
IFNγ + 
1NM-
PP1 
IFNγ +  
JI1 
A_23_P214080 EGR1 4.14 8.35 2.17 2.60 6.01 2.84 
A_23_P60933 MT1G 3.13 5.40 -0.19 2.96 4.95 2.10 
A_23_P303242 MT1X 2.96 5.51 0.29 2.70 4.61 2.28 
A_23_P414343 MT1H 2.83 5.14 0.19 2.83 4.41 2.28 
A_23_P54840 MT1A 2.78 5.36 0.40 2.66 4.52 2.15 
A_23_P37983 MT1B 2.76 5.33 -0.15 2.84 4.68 1.91 
A_23_P206724 MT1E 2.50 4.94 0.01 2.73 4.64 2.07 
A_24_P937405 PRSS23 -3.43 -6.05 -1.68 -2.91 -4.23 -1.55 
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4.2    “ERLOTINIB SUPPRESSES GROWTH OF LEUKEMIC CELLS 
EXPRESSING JAK2-V617F OR JAK3-A572V BY A MECHANISM 
INVOLVING EIF2α” 
 
4.2.1 Preamble 
 
Since several gain-of-function mutants of Jaks have been discovered in various 
hematological malignancies, the interest in developing specific Jak kinase inhibitors has 
increased. Since almost all kinase inhibitors are ATP-competitive compounds targeting 
the catalytic cleft of the kinase domain, many inhibitors available on the market show a 
certain unspecificity. Erlotinib, which was designed to inhibit epidermal growth factor 
receptor (EGFR) activity, was reported to possibly suppress many other kinases, 
including the Janus kinases (Fig. 15). 
 
 
 
Figure 15 
The kinase dendrogram represents possible targets of Erlotinib. Kinases found to bind Erlotinib 
are marked with red circles, where larger circles represent higher affinity. The interaction protein 
kinases of Erlotinib were determined by performing an in-vitro competition binding assay with a 
panel of 317 protein kinases. Adapted from (26). 
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Hovewer, a relatively high concentration of Erlotinib had to be used in an in-vitro kinase 
assay to obtain an inhibitory effect on Jak2 (192). In contrast to that, Erlotinib effectively 
suppressed growth of leukemic HEL cells expressing the Jak2-V617F mutant at much 
lower concentrations. This discrepancy was suggestive of other targets of Erlotinib than 
Jak2-V617F. Molecular modeling approaches also suggested that Erlotinib binding to 
Jak2 is rather unlikely, since Jaks have a more spacious gatekeeper residue than the 
EGFR kinase domain (see Supplementary figure 4 of Kaczor et al., submitted; page 
114).  
In the present study the activity of Erlotinib was investigated on a panel of leukemic cell 
lines expressing constitutively active Jak2-V617F or Jak3 mutants (A572V or A573V). 
Erlotinib-mediated effects on cellular signaling, gene expression, proliferation and 
apoptosis were compared with those mediated by known Jak inhibitors (TG101348, CP-
690550 and JI1). We could show that the Jak inhibitors but not Erlotinib were able to 
suppress constitutive activity of STAT5 and Erk1/2 phosphorylation. Regardless of that, 
growth of leukemic cells driven by the constitutively active Jak2 or Jak3 mutants was 
effectively inhibited by Erlotinib. Since the EGF receptor is not expressed on leukemic 
cells we tested if Erlotinib treatment had an effect on related kinase targets but failed to 
identify a possible target. By microarray analysis we determined gene expression 
profiles, which were quite different for cells treated either with Erlotinib or Jak Inhibitor 1. 
Interestingly, Erlotinib induced a number of genes involved in the ER stress response. 
Moreover, all leukemic cell lines and also polycythemia vera patient cells treated with 
Erlotinib displayed enhanced phosphorylation of eIF2α. Transformed cells are known to 
react to ER stress and the activation of the eIF2α-ATF4 pathway with growth arrest or 
apoptosis (193, 194). Since Erlotinib targets a pathway independent of Jak2 we 
investigated whether the combination of Jak inhibitors with Erlotinib has beneficial 
effects on growth suppression of leukemic cells. Interestingly, we found that combined 
treatment of Jak-specific inhibitors together with Erlotinib was much more efficient in 
suppressing the growth of leukemic cells than either agent alone. 
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Abstract 
 
Several hyperactive Janus kinase mutants were recently discovered in myeloproliferative 
neoplasms and leukemia, which lead to an aberrant signal transduction and growth. These 
constitutively active kinases are interesting targets for ATP-competitive kinase inhibitors, some of 
which we set out to further characterize. We analyzed the suppressive effects of Erlotinib and 
three Jak inhibitors on constitutive activity of Jak2 and Jak3 mutants in leukemic cell lines and 
cells from patients with polycythemia vera. The properties of these kinase inhibitors were 
analyzed by monitoring cell growth, apoptosis, protein phosphorylation, and gene expression 
profiling experiments. Growth of Jak2-V617F-(HEL, UKE-1, SET-2) and Jak3-A572V-positive 
(CMK) leukemic cells was efficiently inhibited by Janus kinase inhibitors (Jak Inhibitor 1, 
TG101348 and CP690550) as well as by Erlotinib. However, only Jak inhibitors but not Erlotinib 
dose-dependently abrogated constitutive STAT5 and Erk1/2 phosphorylation and inhibited STAT- 
and AP-1-dependent target gene expression. Microarray analysis revealed that Jak Inhibitor 1 
and Erlotinib affected the expression of strikingly different sets of genes in HEL cells with only a 
marginal overlap. Erlotinib was found to affect the eIF2α/ATF4 pathway. By targeting different 
growth inhibitory mechanisms the combination of a Jak inhibitor and Erlotinib showed an 
enhanced effect on cell growth suppression and apoptosis induction of leukemic cells.   
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Introduction 
 
Janus kinases are involved in a variety of biological processes including hematopoiesis and the 
regulation of the immune system. Upon cytokine-induced receptor aggregation, the cytokine 
receptor-associated Janus kinases (Jaks) auto-activate and phosphorylate the receptor and 
various signaling proteins leading to the activation of STATs (signal transducers and activators of 
transcription), MAPK (mitogen activated protein kinase) and other signaling pathways (1). Since 
cytokines and Jaks regulate processes like cell growth and survival, it is not surprising that a 
deregulation of cytokine signaling pathways is often found in cancer.  
Mutations in the Janus kinase 2 gene were found with high incidence in patients with 
myeloproliferative neoplasms (MPNs) (Jak2-V617F and a number of point mutations and 
deletions in exon 12) (2), in myeloid leukemia (Jak2-T875N) (3), in acute lymphoblastic leukemia 
(ALL) (Jak2-L611S) (4), and in acute megakaryoblastic leukemia (AMKL) (Jak2-V617F and Jak2-
M535I) (5). These constitutively active Jak2 mutants have been described to activate STAT5 and 
STAT3, MAP kinases and PI3K/AKT. Gain of function mutations of Jak3 (A572V, A573V) were 
found in ALL and AMKL patients (6, 7) while activating mutations in Jak1 have also been reported 
for ALL (8, 9).  
More and more genetic alterations within Jak genes are discovered in MPN and leukemia. 
Moreover, Jaks are interesting targets as they are involved in graft rejection and autoimmune 
disease. Thus, the interest in developing small molecule inhibitors has risen and some 
compounds are presently tested in clinical trials (10). Compounds like Jak Inhibitor 1, TG101348 
and CP690550 were identified to suppress Janus kinase activity (11). Very recently, an epidermal 
growth factor receptor inhibitor, Erlotinib (Tarceva) approved for the treatment of advanced non–
small cell lung cancer (NSCLC) (12) and advanced or metastatic pancreatic cancer (13), was 
described to potently inhibit growth of Jak2-V617F harbouring cells (14). By in-vitro kinase and 
binding competition assays, Erlotinib was shown to interact with Jak2 and Jak3, respectively (14, 
15). The number of compounds that are reported to inhibit growth of cells harbouring Jak mutants 
is increasing but some of these compounds, including Erlotinib, were not biochemically 
characterized in depth. Thus we set out to investigate the effects of this inhibitor in greater detail. 
In the present study, we explored the inhibitory effects of Erlotinib and several Jak inhibitors, Jak 
Inhibitor 1, TG101348 and CP690550, on constitutive activity of Jak2 mutants (V617F, K539L, 
T875N) and Jak3 mutants (A572V, A573V) in leukemic cell lines as well as in cells from 
polycythemia vera patients. We present evidence that Erlotinib does not directly inhibit Jak-
dependent signal transduction although it potently inhibits growth of leukemic cell lines. In 
contrast to Jak inhibitors, Erlotinib induced phosphorylation of eukaryotic initiation factor 2-alpha 
(eIF2α). Interestingly, combined treatment of Jak-specific inhibitors together with Erlotinib was 
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much more efficient in suppressing growth of Jak mutant-positive leukemic cells than either agent 
alone. 
 
Materials and methods 
Information on materials, cell culture, constructs, cell lysis and Western blot as well as microarray 
analysis is provided as Supplementary Information. 
 
Quantitative PCR 
Total RNA from HEL cells was extracted using the NucleoSpin RNA II (Macherey-Nagel) 
following the manufacturer’s instructions. DNA contaminations were removed from RNA 
preparations using the RNAse-free DNAse Set (Qiagen, Valencia, CA). The concentration of 
isolated RNA was measured using a NanoDrop ND1000 spectrophotometer. Constant amounts 
of 1 µg of total RNA were reversely transcribed with the ThermoScript RT-PCR System 
(Invitrogen) in a volume of 20 µL, using random hexamer primers according to the manufacturer’s 
instructions.  The real-time PCR was carried out on a CFX96 Detection System (Bio-Rad) using a 
total volume of 20 µL containing cDNA corresponding 50 ng RNA template, 10 pmol of each 
forward and reverse primer and 10 µL of 2x Absolute qPCR SYBR Fluorescein Mix 
(ThermoScientific). For further information please see the Supplemental information section. 
 
XBP1 mRNA RT-PCR 
Total RNA from HEL cells was extracted using the NucleoSpin RNA II (Macherey-Nagel, Düren, 
Germany) following the manufacturer`s instructions. The concentration of isolated RNA was 
measured using a NanoDrop ND1000 spectrophotometer. Constant amounts of 1 µg of total RNA 
were reversely transcribed with the ThermoScript RT-PCR System (Invitrogen) following the 
manufacturer`s instructions. The PCR was performed using Platinum Taq polymerase under the 
following conditions: 95°C for 5 min, followed by 35 cycles of 50 sec 95°C, 50 sec 50°C and 30 
sec at 72°C. The last step was incubation at 72°C for 10 min. The XBP1 primers (forward: 
CCTTGTAGTTGAGAACCAGG; reverse: GGGGCTTGGTATATATGTGG) amplify the unspliced 
XBP1 mRNA resulting in a 442 bp band and the spliced form with a band at 416 bp. 
 
Cell proliferation assay   
All experiments were done in triplicate and the results normalized to growth of untreated cells. For 
the WST-1 assay, 5x103 cells were plated into microtiterplate wells in 100 µL growth medium with 
the indicated concentrations of inhibitor. The relative growth of cells was quantified after 72 h 
using the WST-1 Cell Proliferation Kit (Invitrogen) according to the manufacturer’s instructions.  
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Apoptosis assay 
For the apoptosis assay, 5x105 cells were grown in 6-well plates with addition of the indicated 
concentration of inhibitors for 48 h. Cells were harvested and processed as described in the 
Annexin V-FITC Apoptosis kit (Miltenyi Biotec). FITC and propidiumiodide fluorescences were 
measured using a BD FACS Canto II (Becton Dickinson). As positive control for apoptosis, 
Etoposide (50 µM) was used. All experiments were done in triplicate and standard deviations are 
given. 
 
Isolation of primary cells 
For the isolation of primary CD14+ monocytes, primary PBMC were isolated by a 
Ficoll-Paque PLUS (GE Healthcare) gradient centrifugation according to the provider’s protocol. 
CD14+ cells were purified using CD14 MicroBeads on LS columns and a QuadroMACS 
Separator (all from Miltenyi Biotec) according to the manufacturer’s instructions.  
CD14+ cells were then cultured for further experiments in IMDM (Lonza) supplemented with 10% 
human serum, 100 mg/mL streptomycin, 60 mg/mL penicillin, and 0.05 % L-Gln. 
 
Functional classification of microarray regulated genes 
Lists of significantly differentially expressed genes containing gene identifiers and associated Log 
expression values were submitted to Ingenuity Pathway Analysis (Ingenuity Systems®, 
www.ingenuity.com) for functional analysis. Each identifier was mapped to its corresponding gene 
object in the Ingenuity knowledge base. A Fisher’s exact test was used to calculate a p-value 
determining the probability that each biological function is assigned just by chance. Functions 
with a p-value lower than 0.05 were considered as significantly enriched. 
 
Results 
 
Erlotinib exerts anti-proliferative and slight pro-apoptotic effects on Jak2-V617F- or Jak3-A572V-
expressing leukemic cells.  
A panel of leukemic cell lines carrying either the Jak2-V617F mutation (UKE-1, SET-2, HEL) or 
the Jak3-A572V mutation (CMK) were used to evaluate the effect of Erlotinib and known Jak 
inhibitors such as Jak Inhibitor 1, TG101348 and CP690550 on cell growth and apoptosis. Cells 
were grown in the presence of increasing concentrations of inhibitors and cell proliferation as well 
as apoptosis was assessed by WST-1 or Annexin V assays, respectively. The Jak2-V617F-driven 
growth of the leukemic cell lines (HEL, UKE-1, SET-2) was effectively suppressed by Jak Inhibitor 
1 and TG101348, while the Jak3-A572V-positive cell line CMK was potently inhibited by 
CP690550 (Figure 1A, Supplemental figure 1). The EGFR inhibitor Erlotinib was very effective in 
inhibiting proliferation of all tested cell lines, however, at slightly higher concentrations than the 
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Jak inhibitors. Of note, the primary target of Erlotinib, i. e. the EGFR, is not expressed in leukemic 
cells lines (16). Specific inhibition of Jak2-V617F in HEL cells or Jak3-A572V in CMK by 
TG101348 or CP690550, respectively, induced modest up-regulation of apoptosis (Figure 1B). In 
contrast, Erlotinib treatment had almost no effect on cell death induction. 
Taken together, the three Jak-specific inhibitors and Erlotinib potently suppress growth of Jak2-
V617F- or Jak3-A572V-positive leukemic cells although the concentrations of Erlotinib need to be 
slightly higher than those of the Jak inhibitors to have similar potency. In comparison, Erlotinib 
induces less apoptosis than the three Jak inhibitors. 
 
The constitutive signaling mediated by Jak mutants is effectively inhibited by Jak inhibitors but not 
by Erlotinib. 
The constitutively active Jak mutants lead to cytokine-independent activation of various signaling 
proteins including STATs and Erk1/2 kinases (6, 7, 18). We used leukemic cell lines carrying the 
Jak2-V617F mutant or one of the Jak3 mutants (A572V or A573V) as well as Jak2-V617F-
positive cells from polycythemia vera (PV) patients to monitor the activation of Jak downstream 
targets. Treatment of HEL cells with Jak Inhibitor 1 led to a dose-dependent reduction of STAT5 
and Erk1/2 phosphorylation (Figure 2A). Interestingly, even the highest concentration of Erlotinib 
(15 µM) had no effect on constitutive phosphorylation of STAT5 and Erk1/2 (Figure 2A), although 
it suppresses growth of HEL, SET-2 and UKE-1 cells at even lower concentrations. Also in SET-2 
and UKE-1 cells, phosphorylation of STAT5 and Erk1/2 was not affected by Erlotinib treatment 
(Supplemental figure 2A), but was readily abrogated by Jak Inhibitor 1 treatment. It is known that 
the highest achievable concentration of Erlotinib in blood of treated patients is around 5 µM (17). 
Thus for most of the following experiments 5 µM of Erlotinib was used. To validate these results 
on the level of readout genes, we performed quantitative real-time PCR to monitor the expression 
of known STAT5 target genes (PIM1 or CIS) (19, 20) or the Erk/AP1 target gene MCP1 (21). 
PIM1, CIS and MCP1 are expressed in all Jak2-V617F-expressing leukemic cell lines (HEL, UKE-
1, SET-2) due to the constitutive signaling. Treatment with Jak Inhibitor 1 suppressed the 
expression of PIM1, CIS and MCP1 mRNA (Figure 2B) while Erlotinib treatment had little effect. 
Moreover, Erlotinib had no effect on STAT5 activation in polycythemia vera patient-derived cells 
(Supplemental figure 2B) or in CMK (Jak3-A572V) and CMY (Jak3-A573V) leukemic cells (Figure 
2C) while Jak Inhibitor 1 or CP690550 were effectively inhibiting STAT5 phosphorylation.  
In line with the results obtained for leukemic cells, Erlotinib was also ineffective in suppressing 
STAT5 phosphorylation mediated by Jak2WT, Jak2-V617F, Jak2-T875N and Jak2-K539L 
(Supplemental figure 2C) in the previously described inducible Hek-EPOR cell system (22). 
Treatment with Jak Inhibitor 1 again led to an inhibition of STAT5 phosphorylation in HEK cells 
expressing Jak2-WT or the different constitutively active mutants found in myeloid leukemia or 
MPN. The same was observed for Gö6976, an additional inhibitor with Jak inhibitory activity (29). 
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Since Erlotinib was described to have inhibitory activity against Jak2WT and Jak2-V617F (14, 16) 
we also tested it against its primary target, EGFR, to assure that our compound was functional. In 
A431 human epidermoid carcinoma cells the EGF-dependent activation of EGFR was totally 
abrogated by 1 µM of Erlotinib (Supplemental figure 2D) showing that our compound had good 
activity. To furthermore assess the potency of Erlotinib in Jak inhibition we tested it in in-vitro 
kinase assays in comparison to Jak Inhibitor 1. Erlotinib had an IC50 concentration of 3600 nM 
compared to 1.6 nM for Jak Inhibitor 1 in in vitro kinase assays at 13 µM ATP (data not shown). 
This explains why Erlotinib does not inhibit Jak2 at millimolar ATP concentrations in cells. 
Taken together, Erlotinib fails to inhibit Jak2- and Jak3-dependent STAT5 and Erk1/2 
phosphorylation while known Jak inhibitors readily do. 
 
Erlotinib affects cellular phosphorylation events in a way distinct from specific Jak inhibitors. 
Erlotinib was not able to interfere with Jak-mediated signaling but still inhibited growth of cells 
driven by the constitutively active Jak2 or Jak3 mutants. Therefore, we further investigated the 
underlying mechanism. We first compared the phosphorylation pattern of lysates from Jak 
Inhibitor 1- and Erlotinib-treated HEL cells. Western blots of these lysates were detected using a 
general phosphotyrosine antibody or a specific phosphotyrosine antibody for the activation loop 
tyrosines of Jak2. The band patterns of these detections showed that Jak Inhibitor 1 and Erlotinib 
affected different phosphorylation targets in HEL cells (Figure 3A). Even detection with the Jak2-
phosphotyrosine-specific antibody leads to an “unspecific” detection of further tyrosine 
phosphorylated bands, which might represent targets of Jaks since their epitope may well be 
sequentially related to the autophosphorylation epitope in the Jak2 activation loop. We then 
tested Western blots of these lysates with a panel of well characterized phosphospecific 
antibodies against proteins known to be involved in Jak/STAT signaling and against other targets 
known to be involved in leukemia. The phosphorylation of the receptor tyrosine kinases PDGFR, 
cKIT, FLT3 as well as EGFR (which was not expressed) was not regulated by either of the 
inhibitors (data not shown). Src also was not involved (data not shown). However, we found that 
Jak Inhibitor 1 also suppresses the phosphorylation of p38 and SHP2 (in addition to the one of 
STAT5 and Erk1/2) while Erlotinib did not affect the phosphorylation of these proteins (Figure 
3B). SHP2 is a phosphatase that can downregulate Jak/STAT signaling and is also known to 
mediate MAPK activation by adopting an adapter function in Jak/STAT signaling. P38 is also 
known to be activated cytokine-dependently. This again argues against an involvement of 
Erlotinib in the inhibition of the oncogenic Jak2-V617F. 
Interestingly, a hyperphosphorylation of Jak2 could be observed upon treatment with Jak Inhibitor 
1 in Western blots detected with the phospho-Jak2-specific antibody (directed against the 
activation loop tyrosines) although Jak-dependent signaling was abrogated (Figure 3A, right 
panel). This was not seen in blots detected with a general phosphotyrosine antibody. The 
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observation was reproducible in SET-2 cells and macrophages derived from PV patients (Figure 
3C). We corroborated the results seen from the lysates by performing immunoprecipitations (IP) 
and detecting Western blots of those IPs with the Jak-specific phosphotyrosine antibody. 
Consistent with the previous observations, phosphorylation increased upon Jak inhibitor 
treatment (Figure 3C, lower panel).  
Although we identified proteins involved in mediating Jak2-V617F-dependent signal transduction 
and further provide evidence for a hyperphosphorylation “priming” of Jak2-V617F by Jak-specific 
inhibitors, we failed to identify a possible target of Erlotinib with the approaches described above. 
 
Erlotinib induces phosphorylation of eIF2α in cells expressing constitutively active Jak mutants. 
To further characterize the differences of Jak Inhibitor 1 (JI1) and Erlotinib treatment, we 
subjected HEL cells to a whole human genome DNA microarray analysis. In total 128 genes were 
found to be significantly differentially expressed upon treatment with JI1, expression of 77 genes 
being downregulated while 51 genes were upregulated (Figure 4A). Erlotinib treatment resulted in 
the differential expression of 57 genes of which 15 were down-regulated and 42 were up-
regulated compared to the untreated control (Figure 4A, Supplemental table 1). Expression of 
only three genes was affected by both inhibitors. Hierarchical clustering of induced or repressed 
genes involved in cell growth showed that there was no overlap in the gene expression 
signatures associated with Jak Inhibitor 1 and Erlotinib (Figure 4B). Altogether, and in line with all 
previous results, the data suggest that growth inhibition triggered by Jak Inhibitor 1 and Erlotinib 
occurs through distinct pathways. 
Further analysis of the microarray data revealed that a number of the Erlotinib-regulated genes 
were related to the ER-stress response (23, 24), more precisely to genes associated with the 
phospho-eIF2α/ATF4 pathway (Table 1). The ER stress response has been described to activate 
several signaling pathways, i.e. the PERK/eIF2α/ATF4, the IRE1/XBP1, and ATF6 pathways 
(25). Phosphorylation of eIF2α leads to a general attenuation of protein translation and to 
enhanced transcription and translation specifically of ATF4-dependent targets. These involve 
genes regulating cell growth and apoptosis. Since ATF4-dependent genes seemed to be 
regulated in the array, we investigated whether Erlotinib induced eIF2α phosphorylation in the 
HEL cells, an initial event leading to activation of this pathway. Erlotinib induced eIF2α 
phosphorylation dose-dependently, while Jak Inhibitor 1 and the src kinase inhibitor PP2 (used as 
another unrelated control compound) did not do so (Figure 5A). Again, Jak Inhibitor 1 was the 
only compound able to suppress STAT5 phosphorylation. ATF4, the crucial transcription factor, 
regulated transcriptionally (26) and translationally (27) upon eIF2α phosphorylation, was also up-
regulated upon Erlotinib treatment as investigated by qPCR (Figure 5B). As positive controls, 
HEL cells were treated with tunicamycin and thapsigargin, known inducers of ER stress and 
ATF4. A target gene downstream of eIF2α phosphorylation and ATF4 is CHOP/DDIT3, which has 
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been shown to contribute to cell growth inhibition upon ER stress induction (28). CHOP mRNA 
was up-regulated in HEL cells upon Erlotinib treatment but not upon Jak Inhibitor 1 treatment, and 
up-regulation was evident from 3 hours to 24 hours of treatment (Figure 5C). 
We also investigated whether the IRE1/XBP1, another ER stress-regulated pathway, was 
activated upon Erlotinib treatment. XBP1 mRNA is spliced (XBP1s) upon ER stress induction, to 
yield the active transcription factor involved in the ER stress response. Only the ER stress 
inducers tunicamycin and thapsigargin could induce the splicing of XBP1 mRNA, whereas 
Erlotinib did not (Figure 5D). Thus, Erlotinib does not seem to induce a classical ER stress 
response, but rather selectively induces the eIF2α/ATF4 pathway by a yet unknown mechanism. 
The other Jak2-V617F positive leukemic cells UKE-1 and SET-2 (Supplemental figure 3A), cells 
derived from PV patients (Supplemental figure 3B) and leukemic CMK cells carrying the Jak3-
A572V mutation (Supplemental figure 3C) also responded to Erlotinib treatment by increased 
eIF2α phosphorylation. In fact, the induction of eIF2α phosphorylation upon Erlotinib could be a 
general phenomenon in myeloid leukemia cells as we could observe it also in leukemia cells not 
harbouring constitutively active Jak mutations (data not shown). 
Taken together, Erlotinib induces phosphorylation of eIF2α by a mechanism independent of Jak2 
activity since the gene induction profile and the phosphoprotein regulation pattern of Erlotinib and 
Jak Inhibitor 1 are drastically different. 
 
The combination of a Jak inhibitor and Erlotinib leads to greater antiproliferative effects and 
stronger apoptosis induction than either agent alone. 
Since the specific Jak inhibitors (Jak Inhibitor 1, TG101348, and CP690550) and Erlotinib 
suppress leukemic cell growth while having different targets we hypothesized that the 
combination of a Jak inhibitor and Erlotinib could have an enhanced effect on leukemic cell 
growth by targeting different growth inhibitory mechanisms. Jak2-V617F- or Jak3-A572V-positive 
leukemic cells were treated with Jak inhibitors (JI1, TG101348, and CP690550) or Erlotinib alone 
or a combination of them (Figure 6). Indeed, when the Jak inhibitor and Erlotinib treatments were 
combined, greater antiproliferative effects were achieved in HEL, UKE-1, SET-2 and CMK cells 
(Figure 6A). Importantly, very low doses of each inhibitor could be used to achieve good 
antiproliferative effects. Interestingly, Erlotinib, which alone does not have a strong potential to 
stimulate apoptosis in HEL or CMK cells (Figure 1B), enhanced the Jak inhibitor-mediated cell 
death induction. Combination of Erlotinib and TG101348 or CP690550 in HEL and CMK cells, 
respectively, was more effective in inducing apoptosis (Figure 6B) than each compound alone.  
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Discussion 
 
We used the patient-derived Jak2-V617F or Jak3-A572V expressing leukemic cell lines HEL, 
SET-2, UKE-1 and CMK, respectively, to evaluate the capacity of Jak inhibitors (Jak Inhibitor 1, 
TG101348, and CP690550) and Erlotinib to influence Jak-dependent signaling and cell growth. 
The three known Jak inhibitors and Erlotinib effectively suppressed cell growth at low micromolar 
concentrations. We set out to investigate the effects of Erlotinib, compared to the Jak-specific 
inhibitors, in detail in the context of constitutively active Janus kinase signaling. 
Cells expressing Jak2-V617F or the Jak3 mutants (Jak3-A572V or Jak3-A573V) show 
constitutive activation of signaling pathways, e.g. constitutive STAT5 and Erk1/2 phosphorylation, 
which was effectively abrogated by the Jak inhibitor treatment. In contrast, however, Erlotinib did 
not reduce STAT5 or Erk1/2 phosphorylation up to concentrations of 5 µM (maximal 
concentration achievable in patients: 6 µM (17)) in any of the Jak2-V617F- or Jak3-mutant 
expressing cells (Figure 2, Supplemental figure 2A). Erlotinib also failed to inhibit Epo-dependent 
Jak2-WT signaling or cytokine-independent signaling through other constitutively active Jak2 
mutants (Jak2-T875N and Jak2-K539L, Supplemental figure 2C). Consistently, STAT5 signaling 
was also not affected by Erlotinib in PV patient cells (Supplemental figure 2B). This compound 
was previously reported to target Jak2-V617F and to inhibit growth of V617F-positive cells (see 
also Figure 1A and Supplemental figure 1) and PV hematopoietic progenitor cells at low 
micromolar concentrations (14). However, Erlotinib effects were not characterized in depth in the 
cellular context. Indeed, the reported IC50 concentrations of Erlotinib determined in in vitro-kinase 
assays (4000 nM) and in cell growth assays (2000 nM) rather suggest that the primary target of 
Erlotinib is not Jak2-V617F (14), as the IC50 concentration of an ATP-competitive kinase inhibitor 
determined in in vitro-kinase assays is lower than the concentration determined in assays with 
intact cells, mainly due to higher intracellular ATP levels (29-31). These observations are also 
supported by a molecular modeling approach. Using structural data on the Jak2 kinase domain 
we tried to fit Erlotinib into the binding pocket of Jak2 (32, 33). As shown in Supplemental figure 
4, Erlotinib cannot be accommodated into the Jak2 ATP binding pocket due to the bulkier 
“gatekeeper” residue in Jak2 (Methionine in Jak2; threonine in EGFR). Interestingly, it has been 
reported that mutation of the EGFR threonine to methionine renders the EGFR insensitive to 
Erlotinib inhibition (34). In the same line of evidence some formerly described micromolar 
inhibitors of Jaks which are structurally related to Erlotinib (WHI-P131 (also called Janex1 or 
Jak3-inhibitor-I) and WHI-P154 (also called Jak3-inhibitor-II) have been recognized to be in fact 
low nanomolar inhibitors of EGFR (35).  
Erlotinib also did not inhibit Jak2-V617F-dependent target gene expression. CIS and PIM1, two 
genes controlled at the transcriptional level downstream of Jak2-V617F/STAT5, and MCP1, 
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which is transcriptionally regulated by Jak2-V617F/Erk/AP1, were strongly down-regulated by Jak 
Inhibitor 1, but not by Erlotinib (Figure 2B).  
Surprisingly, and regardless of its inability to inhibit Jak2-dependent signaling, Erlotinib potently 
inhibited growth of Jak2-V617F-harbouring HEL, SET-2, and UKE-1 cells as well as of Jak3-
A572V-carrying CMK cells (Figure 1A, Supplemental figure 1). So far, several reports showed 
that Erlotinib and another EGFR inhibitor, Gefitinib, induce differentiation and inhibit proliferation 
of AML and MDS cells (16). It is noteworthy that those cells do not express EGFR, thereby 
indicating that Erlotinib and Gefitinib function through a previously unrecognized, EGFR-
independent mechanism. 
Moreover, overall tyrosine phosphorylation of HEL cells was differentially affected by Jak Inhibitor 
1 and Erlotinib (Figure 3A) what strongly suggested that the two inhibitors do not have the same 
target. We tested a number of potential target kinases using phosphospecific antibodies for 
kinases involved in hematologic disease and for signaling molecules often regulated by these 
kinases. We failed to find an evidence for the Erlotinib target by this approach but could show that 
SHP2 and p38 are activated by Jak2-V617F in HEL cells. We also further characterized the 
hyperphosphorylation observed upon inhibition of Jak2 and showed that it appears in several cell 
lines. This phenomenon of inhibitor priming of kinases has been described before (36-38) and is 
thought to occur when the inhibitor binds the kinase in the active conformation. This is the case 
for the Jaks since solved structures with the inhibitor compounds Jak Inhibitor 1 and CP690550 
have shown that Jaks bind these inhibitors in their active conformation (33, 39). 
cDNA microarray analysis of HEL cells again suggested that Erlotinib seems to be very different 
from Jak Inhibitor 1 with regard to its molecular targets. Of the total genes significantly and 
differentially expressed by JI1 (128 genes) and Erlotinib (57 genes), only 3 genes were common 
(Figure 4A), and various genes associated with the ER-stress response were regulated by 
Erlotinib. Erlotinib, in contrast to Jak Inhibitor 1 and CP690550, can induce activation of the 
eIF2α/ATF4 pathway by induction of eIF2α phosphorylation in Jak2-V617F- or Jak3-A572V-
positive leukemic cells as well as in cells from PV patients (Figure 5A, Supplemental figure 3). 
ATF4 and the ATF4-dependent gene CHOP were up-regulated as shown by qPCR (Figure 5B, 
5C). Moreover 7 of the 10 ER stress-related genes found to be up-regulated in the microarray 
analysis are known ATF4 target genes (Table 1). eIF2α phosphorylation leads to a general 
transcriptional block and ATF4 induction followed by transcription of ATF4-regulated genes (40-
42). ATF4-dependent genes, e. g. CHOP/DDIT3, have been shown to contribute to cell growth 
inhibition upon ER stress induction (28). To further investigate if ER stress was induced by 
Erlotinib we checked whether XBP1 mRNA was spliced as described under ER stress conditions 
in particular as it has been reported that the RNAse activity of IRE-1, the enzyme catalyzing the 
splicing event of XBP1 mRNA, can be activated by conformational changes by kinase inhibitor 
binding to the kinase domain directly adjacent to the RNAse catalytic domain (43). However, no 
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splicing of XBP1 mRNA could be detected (Figure 5D), so that we conclude that Erlotinib does 
not induce a classical ER stress response, but rather selectively the eIF2α/ATF4 pathway.  
We tested whether Erlotinib, a known kinase inhibitor, activates kinases which target eIF2a, 
notably PERK and PKR. It cannot be excluded that a kinase inhibitor can have an allosteric 
activating effect on another kinase, different from its primary target. However, investigation of the 
phosphorylation status of the PERK and PRK kinases upon Erlotinib does not suggest an 
involvement of these kinases in the phosphorylation of eIF2α (data not shown).   
The PERK/eIF2α/ATF4 pathway of ER stress was recently shown to lead to impaired cell 
proliferation or apoptosis (44). Thus, it is likely that Erlotinib induces growth inhibition of the 
leukemic cell lines with involvement of the eIF2α phosphorylation-dependent pathway through yet 
unknown upstream regulators. Since Erlotinib and Jak-specific inhibitors affect cell growth by 
distinct pathways we set out to investigate whether a combined treatment of these compounds 
was more efficiently inhibiting growth than either compound alone. Salubrinal, a compound 
selectively activating the eIF2α/ATF4 pathway (45) was shown to enhance the action of 
proteasome inhibitors in leukemia cells and multiple myeloma (46, 47). Interestingly, 
simultaneous administration of a Jak inhibitor (JI1, TG101348, CP690550) and Erlotinib achieved 
greater anti-proliferative effects in HEL, UKE-1, SET-2 and CMK cells than one agent alone 
(Figure 6A). It has been shown that the reduced cell growth of HEL cells treated with Jak Inhibitor 
1 is mainly due to G1 cell cycle arrest and only marginal to apoptosis induction (48). Two other 
Jak inhibitors TG101348 and CP690550 also only moderately induced apoptosis of HEL and 
CMK cells, respectively, which was further enhanced by co-treatment with Erlotinib (Figure 6B). 
Erlotinib, used at this low concentration on its own, does not exert strong growth-suppressive or 
pro-apoptotic effects but it remarkably enhances those mediated by JI1, TG101348 or CP690550. 
It should be noted that both inhibitors TG101348 and CP690550 are currently in the clinical trials 
(clinicaltrials.gov). These Erlotinib concentrations are in the range of the achievable steady state 
plasma concentration (between 1 and 6 µM) in patients (17). Taken together, our study suggests 
that the combination of a Jak-targeting inhibitor together with Erlotinib, both inhibitors used at 
relatively low concentrations, might be an interesting approach for further clinical studies in the 
development of more efficient treatment strategies for MPNs or leukemias involving constitutively 
active Jak mutants. 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Erlotinib suppresses proliferation of Jak2-V617F-expressing leukemic cells but it 
does not exert strong pro-apoptotic effects. 
(A) WST-1 proliferation assay of HEL and CMK cells incubated for 72 h with the indicated 
concentrations of Jak Inhibitor 1 (JI1), TG101348 (TG), CP690550 (CP), or Erlotinib (ERL). 
Experiments were done in triplicate and the results were normalized to the growth of untreated 
cells, which was set 100%. Standard deviations are indicated. (B) Annexin-V apoptosis assay of 
HEL and CMK cells incubated for 48 h with the indicated concentrations of TG101348, CP690550 
or Erlotinib. Etoposide (50 µM, 48 h) treatment served as positive control for apoptosis induction. 
The bar diagrams represent the percentages of apoptotic and necrotic cells measured for each 
condition. The standard deviations of three experiments are given.  
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Figure 2: Signaling through the Jak2-V617F and Jak3-A572V mutants is effectively 
inhibited by Jak inhibitors but not by Erlotinib. 
A: Leukemic HEL cells were treated for 3 h with the indicated concentrations of Jak Inhibitor 1 
(JI1), or Erlotinib (ERL) or were left untreated. After lysis of the cells, the proteins were resolved 
by SDS-PAGE and subjected to Western blot analysis. Phosphorylation of STAT5 and Erk1/2 
was detected using phospho-specific antibodies. Equal loading was verified by stripping the blot 
and reprobing it with antibodies directed against the STAT5 and Erk1/2. B: HEL, UKE-1 and 
SET2 cells were treated for 3 h with Jak Inhibitor 1 (1 µM) or Erlotinib (5 µM) or were left 
untreated. Total RNA was prepared and CIS, PIM1 and MCP1 expression was analyzed by 
qPCR. The experiment was performed in triplicate and standard deviations are given. C: CMK 
and CMY cells left untreated or treated with CP690550 or Erlotinib for 3h were lysed and 
analyzed as described in A. 
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Figure 3: Erlotinib affects overall protein phosphorylation differentially from Jak Inhibitor 
1.  
A: HEL cells were left untreated or were treated with Jak Inhibitor 1 (1 µM) or Erlotinib (5 µM) for 
3 h. After lysis and SDS-PAGE, Western blot was performed and protein phosphorylation was 
detected using the general phospho-tyrosine specific antibody (PY99) or an antibody recognizing 
the double tyrosine motif (Y1007/8) in the activation loop of Jak2. The black and white arrows 
indicate proteins whose phosphorylation was affected by Jak Inhibitor 1 or Erlotinib, respectively. 
B: HEL cells untreated or treated with JI1 (1 µM) or Erlotinib (5 µM) for 3 h were lysed and 
subjected to Western blot analysis with the indicated antibodies. C: (Upper panel) Macrophages 
isolated from PV patient blood and SET-2 cells were treated with JI1 or Erlotinib, lysed and 
Western blots were detected using phospho-specific antibodies against STAT5 (Y694) or Jak2 
(Y1007/8). (Lower panel) HEL cells treated with Jak Inhibitor 1 for the indicated periods of time 
were lysed and Jak2 was immunoprecipitated using a Jak2-specific antibody. Immunoprecipitates 
were resolved on SDS-PAGE and the Western blot was detected with a P-Jak2 antibody. Equal 
loading was verified by stripping the blot and reprobing it with an antibody directed against Jak2. 
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Figure 4: Microarray analysis reveals a minimal overlap of genes regulated after treatment 
of HEL cells with Jak Inhibitor 1 or Erlotinib. 
A: Venn diagram showing the number of genes found significantly differentially expressed upon 
Jak Inhibitor 1 (JI1) or Erlotinib treatment. HEL cells were treated for 9 hours with JI1 or Erlotinib 
and the samples were processed as described in materials and methods. B: Hierarchical 
clustering of induced and repressed genes involved in cell growth. Genes, whose expression was 
enhanced or suppressed by the inhibitor, are indicated by the red or green color, respectively.  
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Figure 5: Erlotinib selectively induces activation of the eIF2α /ATF4 pathway  
A: HEL cells were incubated for 3 h with the indicated inhibitors: Erlotinib (10 µM left panel, 0.5-5 
µM right panel), JI1 (1 µM), PP2 (10 µM). Cells were lysed, resolved by SDS-PAGE and analysed 
by Western blot. Phosphorylation of eIF2α and STAT5 was detected using phospho-specific 
antibodies. Equal loading was verified by stripping the blot and reprobing it with antibodies 
directed against eIF2α and STAT5. B: HEL cells were treated with tunicamycin (Tun, 10 µM), 
thapsigargin (Tha, 1 µM) or Erlotinib (ERL, 5 µM) for the indicated times, RNA was extracted and 
processed as described in materials and methods. ATF4 and CHOP mRNA levels were 
investigated by qPCR. C: HEL cells were treated with Jak Inhibitor 1 (JI1, 1 µM) or Erlotinib (ERL, 
5 µM) for the indicated times, RNA was extracted and CHOP expression was determined by 
qPCR. D: HEL cells were left untreated or treated with tunicamycin (Tun, 10 µM), thapsigargin 
(Tha, 1 µM), or Erlotinib (ERL, 10 µM) for the indicated periods of time before RNA was isolated. 
After RT-PCR, the samples were separated on an agarose gel to identify the spliced XBP1 
mRNA. 
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Figure 6: Erlotinib enhances growth-suppressive and pro-apoptotic effects mediated by 
Jak inhibitors. 
A: WST-1 proliferation assay of HEL, UKE-1, SET-2 and CMK cells treated for 72 h with the 
indicated inhibitors, alone or in combinations: Jak Inhibitor 1 (JI1, 0.6 µM), TG101348 (TG, 0.5 
µM), CP690550 (CP, 0.5 µM), Erlotinib (ERL, 3 µM). B: Flow cytometric Annexin-V apoptosis 
assay of HEL and CMK cells treated with TG101348, CP690550 or Erlotinib as indicated. 
Experiments were performed in triplicates and standard deviations are given. 
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Table 1: Analysis of the microarray data revealed that a number of the Erlotinib-regulated 
genes were related to the ER-stress response. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENE logFC INFORMATION LIT. 
CHOP/DDIT3 4.141 ATF4-dependent, growth inhibition or apoptosis induction upon ER stress. (49) (26) 
RGS16 3.969 Induced upon UPR. (50) 
TRIB3 3.041 ATF4-dependent, negative feedback regulation of ATF4 pathway. (49) (26) 
DDIT4 2.986 ATF4-dependent, modulator of the mTOR pathway. (49) (51) 
WARS 2.293 Tryptophanyl-tRNA synthetase, regulated by ER-stress. (49) 
CEBPγ 2.183 ATF4-dependent, transcriptional regulation upon ER stress response (49) (26) 
S100P 2.032 ATF4-dependent. (52) 
SEC31B 2.01 Component of the COPII compex, essential for ER-Golgi transport. (53) (54) 
CEBPβ 1.954 ATF4-dependent,  transcriptional regulation upon ER stress response (49) (26) (51) 
PPP1R15A 1.733 ATF4-dependent, regulation of PP1.   (49) (26) 
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Supplements: 
 
Supplemental material and methods 
Cell culture and materials 
HEL cells, SET-2, CMK, A431 cells (all from DSMZ, Braunschweig, Germany), and CMY cells 
(provided by Dr. Miura and Dr. Sato, Chiba University, Japan) were grown in RPMI 1640 medium. 
HEK293-Flp-In cells (Invitrogen, Carlsbad, CA) expressing EpoR were grown in Dulbecco´s 
modified Eagle´s medium supplemented with 1 µg/mL puromycin. UKE-1 cells (a kind gift of Dr. 
Fiedler, UKE Hamburg, Germany) were grown in IMDM medium. All media were supplemented 
with 10% or 20% fetal calf serum, 100 mg/L streptomycin, and 60 mg/L penicillin. Additionally, the 
medium for SET-2 and UKE-1 was supplemented with cytokine cocktails containing IL-3/IL-6/GM-
CSF/SCF or IL-3/GM-CSF, respectively. Cells were grown at 37°C in a water-saturated 
atmosphere at 5% CO2. The HEK293-Flp-In-EpoR stable transfectants expressing Jak2 and 
mutants thereof were described before (1). Epo (erythropoietin) and EGF (epidermal growth 
factor) were obtained from Peprotech (Rocky Hill, NJ). Jak Inhibitor 1, Tunicamycin and 
Thapsigargin were obtained from Calbiochem (Gibbstown, NJ), CP690550 was from Selleck 
Chemicals LLC (Houston, TX), Erlotinib and TG101348 were from Symansis (Washdyke, New 
Zealand) and Gö6976 was from Sigma (St. Louis, MO). Doxycycline (Sigma) was used at a 
concentration of 1 ng/mL.  
 
Constructs  
The EpoR expression construct was a kind gift of Dr. Stefan N. Constantinescu (Brussels, 
Belgium). Standard cloning procedures were performed throughout this study. The mutations of 
Jak2 resulting in amino acid substitutions K539L, V617F and T875N were described before (1).  
 
Cell lysis, immunoprecipitation and Western blot analysis 
Cell lysis, immunoprecipitation and Western blotting were performed as described previously (2). 
The anti-STAT5 and anti-SH-PTP2 (SHP-2) antibodies were from Santa Cruz Biotech (Santa 
Cruz, CA). Antibodies directed against phospho-Jak2, Jak2, phospho-SHP2, phospho-p38, p38, 
phospho-Erk1/2, Erk1/2, phospho-eIF2α, eIF2α and phospho-EGFR were purchased from Cell 
Signalling (Danvers, MA). Anti-FIN13 and anti-phospho-STAT5 antibodies were from 
Transduction Laboratories (Franklin Lakes, NJ). The horseradish peroxidase-conjugated 
secondary antibodies were purchased from Cell Signalling. Signals were detected using a self-
made ECL solution described previously (3).  
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Quantitative PCR 
The following experimental protocol was used: denaturation program (95ºC for 3 min), 
amplification and quantification program (95ºC for 10 sec, 60ºC for 30 sec), repeated 40 times. 
Quantitative PCR results were normalized to TBP (TATA-binding protein). Relative -fold changes 
were calculated by the comparative threshold cycles (CT) method, 2-∆∆CT. The specificity of qPCR 
products was documented by melting curve analysis which resulted in single product-specific 
melting temperatures. The melting curve analysis was carried out as follows: 95ºC for 1 min, 60ºC 
for 1 min and 60ºC for 30 sec followed by steps of increases of 0.5ºC for 30 sec until 95ºC was 
reached. DNA contaminations were removed from RNA preparations using the RNAse-free 
DNAse Set (Qiagen). All investigated samples were transcribed in parallel. The plate was 
covered by microseal film (BioRad), centrifuged and placed into the real-time PCR detection 
system.  
 
Microarray analysis  
Gene expression profiling experiments were performed using Agilent 44K whole human genome 
microarrays (Agilent Biotechnologies, Diegem, Belgium) according to the two-color gene 
expression analysis (Quick Amp labeling) protocol (version 5.7) from the manufacturer. 
Hybridizations were performed by comparing 300 ng of total RNA extracted from HEL cells 
treated with either 5 µM of JI1 or 10 µM of Erlotinib with that obtained from untreated cells. For 
each treatment, three biological replicates were analyzed in duplicate including a dye swap. Only 
high quality RNAs with a ribosomal RNA ratio greater than 1.9 and no evidence of degradation, 
as evaluated using the Agilent Bioanalyzer 2100 RNA 6000 nano assay, were used in this study. 
Microarray images were quantified using the GenePix Pro 6.1 software (Molecular Devices, 
Sunnyvale, CA). Background level was detected using the morphological method “closing 
followed by openings”. GenePix flagging, able to filter out low-quality spots, was optimized to 
reduce the number of false negative and false positive spots in the analysis. The following 
GenePix script was used to determine the good quality spots. 
[Dia.] >= 45 and  
([F532 CV] + [F635 CV])/2 < 80 and  
([SNR 532] + [SNR 635])/2 > 4 and 
[F635 % Sat.] < 25 and  
[F532 % Sat.] < 25 and 
([% > B635+2SD] > 60 or [% > B532+2SD] > 60) and 
[Flags] <> [Bad] 
Information was imported from GPR files, processed and further analyzed by R/Bioconductor 
tools. First, various normalization methods were applied to remove experimental bias in the 
dataset. Spatial effects were removed using two-dimensional approximation of zero log-ratio level 
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by radial basis functions. The dye-effect was removed by a Lowess normalization with the 
smoothing parameter f=0.67 (4). Finally, between-array normalization was performed by median-
based centering and scaling of log-ratio distributions. The quality of microarray was controlled by 
distributions of log-ratio values of the good-flagged spots, total number of good-flagged spots per 
array, average correlation with other arrays and spatial homogeneity. Replicate spots were 
summarized and additionally filtered before the statistical analysis: only spots with an intensity 
significantly higher than the background level were considered. To find genes with statistically 
significant regulation in each class (ERL, JI1) and between the two classes, the empirical Bayes 
method (5), implemented in Bioconductor’s limma package was used. Genes with adjusted p-
values less than 0.05 are considered as significantly regulated. Microarray raw data were 
deposited in the ArrayExpress public repository with the reference number E-MEXP-2244 
(Username: Reviewer_E-MEXP-2244; Password: 1247176897450). 
 
 
Supplemental results 
Erlotinib does not inhibit signaling elicited by Jak2-WT or by the constitutively active mutants 
Jak2-V617F, -T875N, and -K539L.  
To investigate the effect of Erlotinib on other constitutively active Jak2 mutants (-T875N and -
K539L) and on Jak2-WT, we generated stable transfectants inducibly expressing Jak2-WT, -
V617F, -T875N and -K539L using the HEK Flp-In-EpoR cell line (1). In these cells the gene of 
interest can be inserted into a Flp recombinase target (FRT) site so that the different mutants are 
isogenically expressed from the same site in the genome. Induction by doxycycline (Dox) enables 
the expression of controlled levels of Jaks. Expression of Jak2-WT, -V617F, -T875N, or -K539L 
was induced with doxycycline for 12 hours (Supplemental figure 2C). The expression of the Jak2 
mutants elicited constitutive signaling as demonstrated by the phosphorylation of STAT5. In 
contrast, expression of Jak2-WT did not lead to constitutive signaling events but the cells 
responded to Epo stimulation with STAT5 phosphorylation. In line with the results obtained for 
leukemic cells and PV patient cells (Figure 2, Supplemental figures 2A and 2B), treatment with 
Jak Inhibitor 1 and Gö6976 (6) led to an inhibition of STAT5 phosphorylation in HEK cells 
expressing Jak2-WT or the three constitutively active mutants while Erlotinib was ineffective. 
 
The gatekeeper residue M929 may preclude binding of Erlotinib to the catalytic cleft of Jak2. 
Analysis of the EGFR residues involved in Erlotinib binding reveals a very high conservation of 
these residues in Jak2 (Supplemental table 2). This strongly suggests that the binding mode of 
the quinazoline group of the inhibitor would be identical in Jak2 (Supplemental figure 4). 
However, the presence of a methionine residue in Jak2 (instead of the smaller threonine T790 in 
the EGFR) at the “gatekeeper” position of the kinase leads to a sterical clash with the 
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ethynylphenyl group of the inhibitor. Most interestingly, a cancer-associated mutation in the 
EGFR, T790 to methionine, was reported to cause resistance to both Erlotinib and Gefitinib (7). A 
solved crystal structure of this EGFR mutant T790M with a quinazoline-based inhibitor shows that 
the methionine can adopt an alternative conformation and still allows the binding of the inhibitor 
(8). It was proposed that resistance of the EGFR-T790M mutant to Erlotinib and Gefitinib is rather 
due to increased affinity for ATP than a sterical clash with the inhibitor. In the crystal structure of 
Jak2, however, the methionine residue M929 cannot adopt a conformation similar to M790 in the 
mutated EGFR and thereby evade a clash with the inhibitor. The comparison of the solved crystal 
structures thus suggests that the larger methionine residue M929 may not allow the 
accommodation of Erlotinib in the catalytic cleft and supports our biochemical data. 
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Supplemental figures 
 
 
 
 
 
 
 
 
Supplemental figure 1: Erlotinib suppresses growth of Jak2-V617F-driven leukemic cells 
UKE-1 and SET-2. 
WST-1 proliferation assay of UKE-1 and SET-2 treated for 72 h with the indicated concentrations 
of Jak Inhibitor 1 and Erlotinib. The results were normalized to the growth of untreated cells and 
standard deviations of three experiments are indicated. 
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Supplemental figure 2: In contrast to Jak2 signaling, Erlotinib potently inhibits EGF-
mediated activation of EGFR and its downstream target Erk1/2. 
A: UKE-1 and SET-2 cells were left untreated or were incubated with the indicated concentrations 
of Jak Inhibitor 1 (JI1) or Erlotinib (ERL). Cells were lysed and subjected to Western blot analysis. 
Phosphorylation of STAT5 and Erk1/2 was detected using phospho-specific antibodies. Equal 
loading was verified by stripping the blot and reprobing it with antibodies directed against STAT5 
and Erk1/2. B: Macrophages isolated from PV patient blood were left untreated or treated with 5 
µM of Erlotinib or 1 µM of Jak Inhibitor 1 for 3 h. Cells were lysed and analyzed as in A. C: 
Stable, inducible HEK-Jak2-WT, -V617F, -T875N, and K539L cells were treated with 1 ng/mL 
doxycycline for 12 hours or were left untreated (-). The cells were treated with 10 ng/mL Epo, with 
Jak Inhibitor 1 (J, 1 µM), Gö6976 (G, 5 µM) or Erlotinib (E, 15 µM) as indicated. The cells were 
lysed, lysates were resolved by SDS-PAGE and subjected to Western blot analysis with the 
indicated antibodies. D: A431 epidermoid cancer cells were pretreated for 30 min with the 
indicated concentrations of Erlotinib before EGF was added (50 ng/mL). Western blots of lysates 
were detected with antibodies directed against P-EGFR, P-Erk1/2, Erk1/2, and FIN13. 
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Supplemental figure 3: Erlotinib induces eIF2α phosphorylation. 
A: SET-2 and UKE-1 cells were left untreated or were incubated for 3 h with 5µM of Erlotinib. 
Cells were lysed, resolved by SDS-PAGE and analyzed by Western blot. Phosphorylation of 
eIF2α was detected using phospho-specific antibodies. Equal loading was verified by stripping 
the blot and reprobing it with antibodies directed against eIF2α and STAT5 B: Macrophages 
isolated from PV patient blood were left untreated or treated with 5µM of Erlotinib for 3 h. Cells 
were lysed and analyzed as in A. C: CMK cells were incubated with the indicated concentrations 
of Erlotinib (ERL) or CP690550 (CP) for 3 h. Cells were lysed and analyzed by Western blot 
analysis. Phosphorylation of STAT5 and eIF2α was detected using phospho-specific antibodies.   
 
 
 
 
 
 
 
 
RESULTS	   113	  
 
ERLOTINIB	  affects	  eIF2α 	   113	  
 
 
 
 
 
 
 
 
 
Supplemental figure 4: Structural aspects of Erlotinib binding to the EGFR and to Jak2.  
The figure shows an overlay of the solved crystal structures of the EGFR/Erlotinib complex 
(highlighted in grey) ((9), PDB entry code 2ITY) and the solved structure of the Jak2 kinase 
domain (highlighted in green) ((10), PDB entry code 2B7A). The gatekeeper residues T790 of the 
EGFR and M929 of Jak2 are represented as rod models. The inhibitor Erlotinib is represented as 
rod model and van der Waals radii are shown. 
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Supplemental tables 
Supplemental table 1: Erlotinib treatment resulted in the differential expression of 57 
genes of which 42 were upregulated and 15 were downregulated compared to the 
untreated control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
SystematicName Gene logFC 
NM_002928 RGS16 4.686 
NM_004083 DDIT3 4.141 
NM_002928 RGS16 3.969 
NM_001017535 VDR 3.595 
NM_172374 IL4I1 3.195 
NM_004864 GDF15 3.166 
NM_021158 TRIB3 3.041 
NM_019058 DDIT4 2.986 
AF011794 CPR8 2.389 
NM_004184 WARS 2.293 
NM_018420 SLC22A15 2.266 
NM_001806 CEBPG 2.183 
NM_018440 PAG1 2.154 
NM_052966 FAM129A 2.139 
NM_006509 RELB 2.043 
NM_005980 S100P 2.032 
NM_003204 NFE2L1 2.008 
NM_015490 SEC31B 2.004 
NM_173528 C15orf26 1.992 
NM_005194 CEBPB 1.954 
NM_178120 DLX1 1.949 
NM_002079 GOT1 1.941 
NM_145032 FBXL13 1.919 
NM_145056 DACT3 1.861 
NM_021642 FCGR2A 1.816 
NM_080593 HIST1H2BK 1.776 
NM_024523 GCC1 1.774 
NM_017622 C17orf59 1.766 
AL833530 AL833530 1.745 
NM_014330 PPP1R15A 1.733 
NM_004626 WNT11 1.722 
NM_058172 ANTXR2 1.625 
CR625561 CR625561 1.607 
L13689 BMI1 1.590 
ENST00000360896 CR614522 1.480 
NM_004793 LONP1 1.439 
NM_003877 SOCS2 1.401 
NM_032048 EMILIN2 1.392 
NM_018370 DRAM 1.367 
NM_032947 MST150 1.360 
CR609843 CR609843 1.343 
NM_007240 DUSP12 1.320 
SystematicName Gene logFC 
XM_931256 CR1L -2.197 
NM_001034 RRM2 -2.091 
NM_006047 RBM12; CPNE1 -2.081 
NM_006597 HSPA8 -1.931 
NM_006597 HSPA8 -1.839 
NM_031942 CDCA7 -1.837 
NM_006597 HSPA8 -1.786 
ENST00000284676 C2orf77 -1.777 
CR595668 CR595668 -1.761 
NM_024094 DSCC1 -1.691 
NM_031844 HNRNPU -1.657 
A_23_P21907 PGDS -1.509 
ENST00000338146 SPRYD4 -1.414 
NM_018048 MAGOHB -1.308 
NM_006998 SCGN -1.307 
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Supplemental table 2: EGFR residues that contact the 4-anilinoquinazoline-based 
inhibitors Erlotinib and Gefitinib and corresponding residues in Jak2. 
 
 
*based on the crystal structures by Yun et al. (9), Stamos et al. (11), and Lucet et al. (10) (Pdb 
entry codes 1m17, 2ITY and 2B7A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibitor region EGFR residue* Contact Jak2 residue 
ethynylphenyl-group L788 hydrophobic L927 
 T790 hydrophobic M929 
 K745 hydrophobic K882 
 V726 hydrophobic V863 
 L844 hydrophobic L983 
 M766 hydrophobic L902 
quinazoline group A743 hydrophobic A880 
 M793 hydrogen bond with 
mainchain amide group 
L932 
 L844 hydrophobic L983 
 L718 hydrophobic L855 
 V726 hydrophobic V863 
 L792 hydrophobic Y931 
 G796 hydrophobic G935 
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4.3  “SOCS-MEDIATED DOWN-REGULATION OF MUTANT JAK2 
(V617F, T875N AND K539L) COUNTERACTS CYTOKINE-
INDEPENDENT SIGNALING” 
4.3.1 Preamble 
 
In 2005, an aquired gain-of-function mutation, V617F, has been found in the gene 
encoding Jak2. This activating mutation is believed to be a major event contributing to 
the pathogenesis of myeloproliferative neoplasms such as polycythemia vera, essential 
thrombocythemia and chronic idiopathic myelofibrosis. Shortly after the discovery of the 
Jak2-V617F mutants in MPNs, other gain-of-function mutations in Jak2 were found in 
patients suffering from different kind of leukemias. Due to that, the interest in 
understanding the molecular mechanism of action of the constitutively active Jak 
mutants and their inhibition has risen.  
 
SOCS proteins are known to be strong negative regulators of Jak-mediated signaling. To 
date, no clear picture exists concerning the negative regulation of Jak mutants by the 
SOCS family proteins. It has been reported that Jak2-V617F cannot be regulated by 
SOCS1, SOCS2, or SOCS3. Moreover, SOCS3 was found to potentiate and modulate 
the activity of the Jak2-V617F mutant (195). On the other hand, elevated levels of 
SOCS1 and SOCS3 mRNA have been reported in patient cells expressing Jak2-V617F 
(196, 197) and these proteins are well known to down-regulate Jak activity and mediate 
their degradation (135, 198, 199). Interestingly, epigenetic silencing of SOCS1 and 
SOCS3 was found in around 40% of patients with Ph-negative chronic myeloid disorders 
(200). 
 
To study different constitutively active Jak mutants in the same system; we generated 
the Hek Flp-In-293 cell line stably expressing either Jak2-WT, Jak2-V617F, Jak2-T875N 
or Jak2-K539L. Each Jak protein was inserted into a FRT (FLP recombinase target) site 
and its expression was not constitutive but stayed under the control of the Tet repressor 
(tetR) protein (Fig. 16). The tetR protein, upon binding to doxycycline (Dox), dissociates 
from the DNA what enables the expression of the inserted Jak gene. Importantly, levels 
of Jaks can be controlled depending on the Dox concentration used. We reveal that due 
to their constitutive activity the Jak2 mutant proteins (K539L, V617F, T875N) have a 
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decreased stability and their levels gradually decrease over time. Furthermore, they 
show increased ubiquitination and are efficiently targeted for degradation in the 
proteasome. We could show that SOCS1 and SOCS3 proteins are strongly induced in 
cells expressing the Jak2 mutants. Moreover, the SOCS3 mRNA level shows kinetics 
that parallels Jak2-V617F protein expression and the SOCS3 protein was found to bind 
Jak2-V617F. Importantly, treatment of cells expressing Jak2-V617F with SOCS3 or 
SOCS1 siRNA increased the Jak2 mutant protein level. We show that there is a certain 
threshold of the expression level of Jak2-V617F at which full cytokine-independent 
activation can occur despite a functioning SOCS-dependent negative feedback. 
Furthermore, increasing levels of the constitutively active Jak2 mutant lead to 
enhancement of STAT5 activation. This is in line with the observation, that the level of 
the Jak2-V617F protein seems to correlate with the disease severity (201).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 
The figure illustrates the mechanism of doxycycline-regulated repression and derepression of the 
Jak2-V617F gene stably inserted into the Hek-Flp-In-293 cell line previously transfected with an 
expression vector encoding the erythropoietin receptor. The constitutively expressed tetR protein 
(blue) binds to Tet operator 2 (TetO2) sequences in the pcDNA5/FRT/TO vector thereby 
repressing transcription of Jak2-V617F (red). Upon addition, doxycycline (Dox) binds to the tetR 
protein and that causes a conformational change in tetR and its release from TetO2 sequences. 
The expression level of the Jak2-V617F mutant can be controlled by the concentration of Dox 
used. A low concentration of Dox ensures subendogenous levels of Jak2-V617F or other Jak 
proteins expressed from the pcDNA5 vector.    
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My contributions to this work published in the Oncogene journal were the following: 
- establishment of cell lines employing the HEK-FRT/TO system 
- assessment of the mRNA levels of SOCS1 and SOCS3 by quantitative PCR (Fig. 
2A, 2B) 
- monitoring the Jak2-V617F protein expression by Western blot (Fig. 2B) 
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Supplementary Information 
 
Supplemental materials and methods 
Materials, cell culture and transfection 
Epo was obtained from Peprotech. Janus Kinase Inhibitor 1 and the proteasome inhibitor MG132 
(all from Calbiochem) were dissolved in DMSO. Doxycycline (Sigma) was usually used at 
concentrations of 1 ng/mL unless stated differently in the Figure legends. HEL (DSMZ) SET2 
(DSMZ) and HEK Flp-In-293 cells (Invitrogen) were maintained in RPMI and Dulbecco´s modified 
Eagle´s medium, respectively with 10 to 20% fetal calf serum, 100 mg/L streptomycin and 60 
mg/L penicillin. The HEK Flp-In stable transfectants were generated using the Flp-InTM System 
from Invitrogen and cultured with 50 µg/mL hygromycin. Cells were transfected using the Fugene 
reagent (Roche) or Dharmafect (Dharmacon) according to the manufacturer’s protocol.  
 
Constructs and siRNA 
The HA-tagged EpoR expression construct was a kind gift of Dr. Stefan N. Constantinescu 
(Brussels, Belgium). Flag-tagged pCMV-SOCS3 constructs and Flag-tagged pEF-SOCS1 and 
pEF-SOCS3 constructs were generously provided by Dr. Akihiko Yoshimura (Fukuoka, Japan) 
and Dr. Douglas Hilton (Victoria, Australia), respectively. 
Standard cloning procedures were performed throughout this study. Mutations were introduced 
using the Quick Change Kit from Stratagene into pcDNA5/FRT/TO-Jak2 (Haan et al, 2008). For 
the generation of pcDNA5/FRT/TO-YFP-Jak2, YFP-Jak2 was subcloned from pEF-YFP-Jak2 
(Behrmann et al, 2004) using AgeI and NheI sites introduced between AflII and ApaI of 
pcDNA5/FRT/TO (Invitrogen). pcDNA5/FRT/TO-YFP-Jak2-V617F and -T875N were generated 
by exchanging HindIII/NheI-digested sequences between correspondingly mutated 
pcDNA5/FRT/TO-Jak2 derivatives and pcDNA5/FRT/TO-YFP-Jak2.  
For siRNA-experiments, the SOCS1, SOCS3 and scrambled control siRNA SMART-pools® from 
Dharmacon were used at a concentration of 50 to 100 nM. 
 
Cell lysis, immunoprecipitation and Western blot analysis 
All steps of cell lysis and immunoprecipitation were performed at 4°C using ice cold buffers. Cells 
were lysed on the dish with lysis buffer containing 0.5% IGEPAL-CA630 or 1% Triton-X-100, 20 
mM Tris/HCl, pH 7.5, 150 mM NaCl, 10 mM NaF, 1 mM sodium vanadate, 10 mM PMSF, 1 mM 
benzamidine, 5 µg/mL aprotinin, 3 µg/mL pepstatin, 5 µg/mL leupeptin and 1 mM EDTA. After 
incubation of the cleared lysates with antibodies, the immunoprecipitates were collected with 
protein A-sepharose for 1 hour, washed several times and analyzed further by SDS-PAGE. The 
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proteins were transferred to a polyvinylidene difluoride membrane (Amersham Pharmacia 
Biotech) and probed with the respective antibodies. Anti-Jak2 (Cell Signaling or Upstate) and 
anti-SOCS3 (IBL) were used for immunoprecipitation. Anti-phosphotyrosine and anti-SOCS3 
were from Santa Cruz Biotech. The anti-Jak2, anti-phospho-Jak2, anti-phospho-STAT3, anti-
Erk1/2, anti-phospho-Erk1/2, anti-Calnexin and anti-HA antibodies were purchased from Cell 
Signaling. Anti-STAT3 and anti-Fin13 were from Transduction Laboratories while anti-GFP was 
from Rockland. The horseradish peroxidase-conjugated secondary antibodies were purchased 
from Dako. Signals were detected using an ECL solution containing 2.5 mM luminol, 2.6 mM 
hydrogenperoxide, 100 mM Tris/HCl pH 8.8 and 0.2 mM para-coumaric acid. 
 
Quantitative PCR 
Total RNA from HEK Flp-In-293 cells expressing Jak2-WT or Jak2-V617F was extracted using 
the RNeasy Mini Kit (Qiagen) following the tissue protocol of the manufacturer`s instructions. The 
concentration of isolated RNA was measured using a NanoDrop ND1000 spectrophotometer. 
Constant amounts of 1 µg of total RNA were reversely transcribed with the ThermoScript RT-
PCR System (Invitrogen) in a volume of 20 µL, using random hexamer primers according to the 
manufacturer`s instructions. DNA contaminations were removed using the RNAse-free DNAse 
Set (Qiagen). All investigated samples were transcribed in parallel. The real-time PCR mastermix 
contained: 10.5 µL of water, 12.5 µL of SYBR Green, 1 µL (12.5 ng) of template and 0.5 µL (10 
µM) forward primer and 0.5 µL (10 µM) reverse primer. 25 µl of master-mix was filled into the 
wells of a 96-well qPCR plate (BioRad). The plate was covered by microseal film (BioRad 
Laboratories), centrifuged and placed into the I-Cycler. The following I-Cycler experimental 
protocol was used: denaturation program (95ºC for 3 min), amplification and quantification 
program (95ºC for 10 sec., 60ºC for 30 sec.), repeated 40 times. Quantitative PCR results were 
normalized to TBP (TATA-binding protein). Relative -fold changes were calculated by the 
comparative threshold cycles (CT) method, 2-∆∆CT. Gene-specific primers for qPCR analysis were 
purchased from Eurogenetc: SOCS1 forward: 5`-AGCTCCTTCCCCTTCCAG-3`; reverse: 5`-
CAAAATAACACGGCATCCC-3`; SOCS3 forward: 5`- ATGAGAACTGC-CGGGAATC-3`; reverse: 
5`-CCCAGGCTCCACAACCA-3`; TBP forward: 5`-ACCCA-GCAGCATCACTGTT-3`; reverse: 5`- 
CGCTGGAACTCGTCTCACTA-3`. The specificity of qPCR products was documented by I-Cycler 
melting curve analysis (denaturation program: 95ºC for 1 min, amplification program: 55ºC for 90 
s, repeated 81 times), which resulted in single product-specific melting temperatures (SOCS1: 
84.5ºC, SOCS3: 81ºC).  
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Supplementary figures 
 
 
 
 
Supplemental figure 1: The constitutively active mutant Jak2-K539L behaves similarly to 
Jak2-V617F and Jak2-T875N.   
A: Jak2-K539L is constitutively active and shows reduced protein expression. HEK-EpoR cells 
stably and inducibly expressing Jak2-WT, -V617F, -T875N or -K539L were treated with 1 ng/mL 
doxycycline for the times indicated or were left untreated (-). After lysis of the cells, the proteins 
were resolved by SDS-PAGE and subjected to Western blot analysis. Phosphorylation of proteins 
was detected using phospho-specific antibodies directed against the different phospho-proteins. 
Equal loading and expression was checked by stripping the blot and reprobing it with antibodies 
directed against the various proteins. B: Treatment of HEK-EpoR-Jak2-K539L cells with Jak 
Inhibitor I increases the steady state expression levels of the mutant protein (as observed for 
Jak2-V617F and -T875N) Inducible HEK-EpoR-Jak2-WT, -V617F, -T875N and -K539L cells were 
treated with 1 ng/mL doxycycline for several passages to induce steady state Jak2 levels. The 
cells were then treated with Jak Inhibitor I (0.5 µM) for 48 h or were left untreated. Western blots 
were prepared from cell lysates, Jak2 levels were determined using a Jak2 antibody and STAT5 
staining is given as loading control. C: Cytokine-dependent signaling is lost at higher steady state 
expression levels of Jak2-K539L. Inducible HEK-EpoR-Jak2-K539L cells were treated with 0.5, 1 
and 5 ng/mL doxycycline for several passages to induce steady state Jak2 levels. The cells were 
then stimulated with Epo (10 ng/ml for 30 min), were treated with with Jak Inhibitor I (JII) for 3 h or 
were left untreated.  Western blots were analyzed as described in A. D: Mutant Jak2 can be 
coprecipitated with SOCS3. HEK-Jak2-WT, -V617F, -T875N or -K539L cells were treated with 
1ng/mL doxycycline for 12 h and MG132 was added 3 h prior to cell lysis. SOCS3 was then 
precipitated with a SOCS3 antibody. Co-precipitated Jak2 as well as SOCS3 was detected by 
Western blot analysis. Phosphorylation and expression of Jak2 proteins as well as Fin13 
expression was detected from the lysates.  
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Supplemental figure 2: Constitutively active Jak2 mutants activate multiple signaling 
components and show reduced expression levels in HEK cells.  
HEK- cells stably and inducibly expressing Jak2-WT, -V617F and -T875N were treated with 1 
ng/mL doxycycline for the times indicated or were left untreated (-). After lysis of the cells, the 
proteins were resolved by SDS-PAGE and subjected to Western blot analysis. Phosphorylation of 
proteins was detected using phospho-specific antibodies directed against the different phospho-
proteins. Equal loading and expression was checked by stripping the blot and reprobing it with 
antibodies directed against the various proteins.  
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Supplemental figure 3: SOCS1 and SOCS3 inhibit Jak2-V617F activity. 
A: 293T cells were transfected with 0.5 µg Jak2-WT or Jak2-V617F plasmid together with 0.5 µg 
HA-tagged EpoR construct and 0.5 µg of the different FLAG-tagged pCMV-SOCS3-constructs 
(SOCS3-WT, SOCS3-F25A, SOCS3-R71K and SOCS3-ΔBox). 48 h post-transfection, the cells 
were lysed and the lysates were subjected to Western blot analysis. The detections were 
performed using antibodies directed against phosphotyrosine, Jak2 as well as FLAG- and HA-
tags. For clarity, two exposures of the phosphotyrosine-Jak2 detection are shown (separated by a 
dashed line). Different exposures of the same detection are separated by a dotted line. A 
quantification of the Jak2 expression is provided below the Jak2 blot with Jak2-WT or –V617F 
levels in non-SOCS3 expressing cells set to 1.0. B: 293T cells were transfected with 0.25 µg 
Jak2-V617F plasmid together with 0.5 µg HA-tagged EpoR construct and 0.5 µg of FLAG-tagged 
pCMV-SOCS3-WT or –Δbox constructs. A non-transfected control is given (nt). 48 h post-
transfection, the cells were lysed and the lysates were subjected to Western blot analysis. The 
detections were performed using antibodies directed against Jak2 and FLAG- tag. Fin13 levels 
are given as loading control. The bar diagram represents a quantification of Western blot 
analyses from four experiments. Jak2-V617F expression was normalized using the Fin13 levels 
and the standard deviation for four experiments are given. C: SOCS1 and SOCS3 dose-
dependently inhibit Jak2-V617F. 293T cells were transfected with 0.5 µg HA-EpoR, 0.5 µg Jak2-
V617F and increasing amounts pEF-FLAG-SOCS1 or pEF-FLAG-SOCS3 and analyzed by 
Western blot analysis. 
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Most signal transduction pathways rely on protein kinase activity, which is therefore an 
attractive target for small molecule inhibition. Many protein kinase inhibitors have been 
developed to study specific functions of kinases in signaling pathways and as potential 
therapeutic agents (202). The human kinome contains more than 500 proteins and all 
kinases share the common fold of the kinase domain. The design of a specific inhibitor 
for a kinase of interest has been proven difficult because most inhibitors target the 
common ATP-binding site and today only a small percentage of kinases can be inhibited 
with high specificity.  
The enzymatic activity of a kinase can be pharmacologically inhibited in two different 
ways: by competing with ATP for binding to the catalytic cleft of the kinase or by 
allosteric inhibition. In the non-ATP competitive (allosteric) inhibition, the inhibitor binds 
to a loop or a pocket outside the ATP-binding cleft of the kinase, preferably blocking the 
binding and/or phosphorylation of the substrate or directly inhibiting the kinase 
activation. It is assumed that this approach would result in high selectivity and potency, 
mainly because such inhibitors would compete with only nM of protein substrates, rather 
than µM or mM levels of ATP. The design of allosteric kinase inhibitors is particularly 
challenging because the exact binding mode of the targeted interaction has to be known, 
which is seldom the case. In contrast to the enormous variety in potential allosteric 
binding sites, the active sites are highly conserved in kinases. The majority of kinase 
inhibitors are based on ATP-competitive inhibition interfering with the substrate binding. 
The ATP-binding pocket is highly conserved among kinases, thus most ATP-competitive 
kinase inhibitors target more than one kinase and off-target effects are common. The 
activity of kinase inhibitors may be significantly influenced by multiple factors, such as 
cell permeability, drug efflux, their stability, toxicity and solubility. However, the 
remarkable success and the relative high selectivity of Gleevec (imatinib mesylate) in the 
treatment of chronic myelogenous leukemia has proven the concept of ATP-competitive 
inhibitors to be very useful. Currently there are eight small molecule inhibitors targeting 
protein kinases approved by the FDA for clinical use in humans. Importantly, protein 
kinase inhibitors are valuable not just for the treatment of diseases, but also as reagents 
to help us to understand more about the physiological roles of protein kinases. The 
specificity of inhibitors was thought to be of critical importance for its clinical utility. 
However, the approval of Sunitinib, a multi-kinase inhibitor targeting many kinases at low 
nanomolar range for the treatment of renal cell carcinoma and Gleevec-resistant 
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gastrointestinal stromal tumor, has obviously changed this view. The required specificity 
of kinase inhibitors depends on the type of diseases they are used to treat. In case of 
cancers, where treatment time is limited and the danger to life is iminent, specificity may 
not be the major concern as long as the disease is driven into remission. However, 
strong side effects usually accompany low specificity, which is an important issue in 
case of diseases that require constant treatment over prolonged time. Many inhibitors 
that cannot be used as drugs for reasons of e.g. toxicity represent extremely useful tools 
for research purposes. In research, specificity is one of the most important parameter 
that the kinase inhibitor should fulfil.  
 
TARGETING JAKs WITH KINASE INHIBITORS 
 
Protein kinase inhibitors have been used to better understand the role of Janus kinases 
in many signal transduction pathways. Noteworthy, most inhibitors targeting the catalytic 
cleft of Janus kinases showed only micromolar activity. AG490 and WHI-P131 represent 
good examples of small molecule inhibitors initially reported to specifically inhibit Jak2 
and Jak3, respectively, and they have been extensively used to study Jak-mediated 
signaling responses. However, both of these compounds were also shown to suppress 
other kinases, e.g. EGFR, in much lower concentrations, what consequently makes the 
direct attribution of the biochemical and physiological effects of these inhibitors to the 
Jaks not possible. Recently inhibitors of Jaks have been reported, which possess 
nanomolar activity in cellular assays (14). However, most of the potent Jak inhibitors 
show activity against several Jak members and also target other kinases. The sequential 
similarity of the Jak kinase domains is quite high, which increases the challenge to 
generate specific compounds that do not inhibit other Jaks.  
Alternative approaches are available to examine the involvement of a given kinase in 
signal transduction. Genetic techniques, such as “knockouts”, have provided important 
insights into the roles of specific proteins. However, it is known that possible 
compensatory mechanisms can occur, what masks the real function of the targeted 
kinase. Moreover, knockout mice may not be viable at all, e.g. Jak2 knockout mouse die 
during embryogenesis due to the lack of erythropoiesis. The siRNA-based approach 
represents a potential solution by offering a temporal or stable suppression of the 
expression of the gene of interest. However, this approach may be incomplete in terms 
of the efficiency of inhibition, and moreover it could evoke double-stranded RNA-
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mediated side effects. Furthermore, targeting the kinase of interest by genetic or siRNA 
approaches might have effects, which cannot be attributed to the enzymatic activity of 
the kinase but e.g. to its potential structural role. To overcome this problem, kinase-
inactive mutants can be introduced into kinase-deficient cells. 
However, a way to combine mutational and pharmacological approaches is to use a 
mutation to confer selectivity for a small molecule, i.e. the chemical genetics approach. A 
genetically modified kinase and a chemically modified small molecule inhibitor are the 
key components of this approach. The kinase of interest has to be mutated in a way so 
that it can accommodate the modified inhibitor. The so-called “gatekeeper” residue, 
which limits the size of the ATP-binding pocket in PTKs, is conserved as a large- to 
medium-sized residue. It shows variation between kinases and by this also controls the 
sensitivity towards different ATP-competitive inhibitors. Mutation of this residue to a 
smaller one like glycine or alanine creates a space, which is not found in any other 
kinase. This novel pocket can then be uniquely accessed by the modified inhibitor 
analogue, which is a known kinase inhibitor with a bulky modification that occupies the 
extra space generated by the mutation of the gatekeeper.   
We have generated analogue-sensitive mutants of Jak1 and Jak2, whose activity could 
be specifically suppressed by an inhibitor analogue. All Janus kinases, but especially 
Jak1, are involved in many cytokine signaling pathways. We investigated how specific 
inhibition of either Jak1 or Jak2 by a small molecule inhibitor would affect the IFNγ-
mediated response and we could demonstrate that inhibition of either Jak1 or Jak2 
strongly reduces STAT1 phosphorylation, which in turn has a significant repercussion on 
IFNγ-mediated target gene expression. The vast majority of genes induced by IFNγ 
including those involved in the antiviral response were strongly down-regulated if Jak1 or 
Jak2 enzymatic activity was inhibited. Surprisingly, expression of two major players in 
IFN signalling, IRF1 and STAT1, was dependent on Jak2 but not Jak1. How relevant this 
finding is in terms of late IFNγ–mediated effects has to be further determined. It has 
been shown that STAT1 in its unphosphorylated state is transcriptionally active and 
initiates or sustains IFNγ-induced gene transcription at the late phase of the response 
(118, 203, 204), which would most likely be affected by specific Jak2 inhibitors. Our data 
further suggest that the selective inhibition of either Jak1 or Jak2 would impair the 
antiviral responses as well as the immune system, since the IFNγ-induced expression of 
many genes involved in these responses was strongly downregulated.  
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This study was based on the inhibitor analogue 1NM-PP1 that suppresses activity of 
analogue-sensitive kinases bearing small residues at the “gatekeeper” position. Ideally, 
only the analogue-sensitive kinases should be sensitive to this inhibitor. However, there 
are several naturally occurring kinases, such as Src family members, which possess a 
threonine residue at the “gatekeeper” site, which is also relatively small. It is known that 
these kinases are also sensitive to some inhibitor analogues (214, 215), thus, caution is 
needed in interpreting experiments performed using cells expressing the analogue-
sensitive mutants instead of the wild-type kinases. Although we have performed 
experiments showing that the wild-type Jak1 and Jak2 were not suppressed by the 
inhibitor analogue 1NM-PP1 it cannot be excluded that other kinases i.e. Src were not 
affected. It has to be taken into account that kinase inhibitors may also bind to non-
kinase proteins. 1NM-PP1 had to be used at relatively high concentration what increases 
the probability of non-kinase off-target effects (Fig. 17).    
 
 
 
Figure 17 
Estimated likelihood of non-kinase off-target effects at different concentration of inhibitor applied 
to cells. The fraction of small molecules that bind to a protein in vitro is usually low at nanomolar 
concentrations but it increases if used at µM range. Compounds used at concentrations above 
100 µM are rather unlikely to have any significant selectivity. Adapted from (205). Concentration 
range at which the analogue inhibitor 1NM-PP1 was used to inhibit the analogue-sensitive Jak1 
and Jak2 mutants is indicated.  
 
By performing DNA microarray analysis we aimed at identification of genes, whose IFNγ-
induced expression is either Jak1- or Jak2-dependent. Since we could not exclude the 
possibility that by treating the cells with the 1NM-PP1 inhibitor we target not only the 
analogue-sensitive Jak1 or Jak2 variant, we focused specifically on genes known to be 
IFNγ- and Jak-dependent. Experiments performed with cells expressing wild-type Jak1 
or Jak2 served as controls confirming that the effects seen in cells expressing the 
analogue-sensitive Jaks upon 1NM-PP1 treatment are really due to suppression of AS-
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Jaks and not to off-target effects of the inhibitor. Certainly, it would be of great interest to 
develop a bulky analogue of a Jak-specific inhibitor. Such Jak inhibitor-analogue could 
be used at lower concentration without compromising the efficiency of inhibition of the 
analogue-sensitive kinase what was an issue in case of 1NM-PP1.  
The fact that a whole variety of cytokine receptors uses only four Jaks means that even 
a specific Jak inhibitor targets multiple cytokine pathways. Specific inhibitors for Jak1 or 
Jak2 to target e.g. leukemic cells expressing Jak1 or Jak2 gain-of-function mutants, 
respectively, will not confine their effects to the oncogenic pathways but would also have 
repercussion on receptors activating e.g. mainly Jak1 (IL-6-type cytokines) or only Jak2 
(EpoR, TpoR). The question is, however, how a specific Jak1 inhibitor would affect other 
signaling pathways, which in addition to Jak1 require Jak2, Tyk2 or Jak3. We could 
demonstrate that the overall response to IFNγ is significantly decreased if either Jak1 or 
Jak2 was specifically inhibited. It would be of interest to apply an analogous approach to 
other signaling pathways, e.g. to IFNα/β- or IL-2-mediated responses, which signal via 
the combination of Jak1/Tyk2 and Jak1/Jak3, respectively.  
 
KINASE INHIBITORS IN THE CLINIC 
 
Regardless of the above-mentioned unspecificity presented by most inhibitors, several of 
them have successfully been approved for patient treatment (i.g. Sunitinib or Sorafenib 
target multiple kinases (Table 1)). Moreover, the case of Imatinib (Gleevec), an inhibitor 
of Abl kinase (206), shows that sometimes inhibiting more than one protein target 
increases the efficacy of treatment with great benefit for patients suffering from chronic 
myeloid leukemia (CML). In addition to Abl kinase, Imatinib has been identified as 
inhibitor of RTKs PDGFR (platelet derived growth factor receptor) and KIT (the receptor 
for SCF) (207). By applying a chemical genetics approach an analogue-sensitive allele 
of Bcr-Abl has been generated (35). Wong et al. have shown that specific inhibition of 
that mutant by the inhibitor analogue was sufficient to suppress cell proliferation in 
murine CML lacking the RTK KIT. Very surprisingly, in cells expressing KIT, single 
inhibition of Bcr-Abl had no physiologic effect. Combinatorial inhibition by Imatinib of 
both Bcr-Abl and KIT was necessary for a comparable obstruction of cell proliferation. 
These results argue that the efficacy of Imatinib in CML is not exclusively owing to its 
ability to block Bcr-Abl but, additionally, to some unspecificity towards KIT.  
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Moreover, suppression of Abl kinase activity by Imatinib was shown to induce ER stress 
(208), a mechanism that shuts down general protein translation and up-regulates the 
expression of specific protective stress response genes as well as apoptotic genes. 
Depending on the severity of the different responsive pathways, the cell is either 
protected or undergoes apoptosis, which is the case if ER stress is prolonged.  
ER stress is induced by several drugs, e.g. the proteasome inhibitor Bortezomib used in 
cancer therapy (193). ER stress is associated with several signal transduction events, 
which play roles in different physiological effects. Global reduction of mRNA translation 
is achieved by phosphorylation and inactivation of eIF2α what leads to reduced protein 
synthesis. Interestingly, certain mRNAs gain a selective advantage for translation under 
these conditions, including the mRNA encoding transcription factor ATF4, which 
regulates the promotors of several genes implicated in the unfolded protein response. 
Depending on the activation intensity and the cellular context, eIF2α phosphorylation by 
upstream kinases, like PERK, can induce survival, growth arrest and/or apoptosis in 
response to ER stress. Our studies show for the first time that the protein kinase inhibitor 
Erlotinib induces activation of the phospho-eIF2α–ATF4 pathway. We showed that 
phosphorylation of eIF2α was linked to the induction of cell growth arrest in leukemic 
cells expressing Jak2 or Jak3 gain-of-function mutants. Noteworthy, none of these cells 
express EGFR, which represents the main target of Erlotinib, thus unravelling an 
interesting off-target effect of a compound that was believed to specifically target EGFR. 
Previously, other research groups have shown that Erlotinib inhibits the growth of 
leukemic cell lines and myeloblasts of patients with myelodysplastic syndrome (MDS) 
and acute myeloid leukemia (AML). However, this off-target effect was explained by the 
inhibitory action on Jak2 (192, 209-211). In our hands Erlotinib was not able to suppress 
the activity of Jaks, neither of the wild-type nor of mutants, and in in-vitro kinase assays 
it showed only micromolar potency (data not shown), which excludes it from being a “Jak 
inhibitor”. Molecular modelling indicated that the methionine gatekeeper of Jak2 
precludes its binding to Erlotinib.  
The rationale for combination treatment is to use drugs that work by different 
mechanisms of action, thereby decreasing the likelihood that resistant cancer cells will 
develop. Resistance to Imatinib treatment has been reported in patients with CML due to 
Bcr-Abl gene amplification or acquired point mutations of Bcr-Abl. Since there is no 
specific Jak inhibitor used right now in the clinic to treat patients suffering from any 
haematological neoplasm, it is difficult to predict what would be the influence of 
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prolonged administration of a drug targeting an oncogene, such as Jak2-V617F. 
Currently, a Jak2 inhibitor TG101348 is expected to enter phase II of clinical trails for 
treatment of myelofibrosis (www.targegen.com), which belongs to the group of 
myeloproliferative neoplasms where the Jak2-V617F mutation is found with high 
incidence. Because of its clinical relevance, TG101348 was included into our studies, 
showing strong inhibitory effect on the growth of leukemic cells. If used in combination 
with Erlotinib, the concentration of both inhibitors, TG101348 and Erlotinib, could be 
reduced without compromising the efficacy of growth suppression.     
 
JAK2-V617F AND ITS REGULATION 
 
Any therapy with the goal to treat cancer must show a differential toxicity towards tumour 
cells relative to healthy cells. Cancer cells usually show some unique properties not 
shared by normal cells, e.g. oncogene addiction and/or an altered metabolism. Cells 
expressing Jak gain-of-function mutants are “addicted” to their constitutive activity. On 
the other hand the tumorigenic properties of Jak mutants depend on the normal cellular 
functions of certain genes that are themselves not oncogenic. It has been shown that 
STAT5 together with the homodimeric type I receptors EpoR, TpoR, or G-CSFR are 
critical for Jak2-V617F-mediated transformation (172, 178). By this rationale, cancer 
cells are addicted to oncogenes, such as Jak2-V617F, and non-oncogenes like STAT5 
or EpoR. 
The level of activation of signaling proteins like STAT5 strongly depends on the level of 
Jak2-V617F mutant and on the overall induction of feedback regulators like SOCS 
proteins. We found that the Jak2-V617F protein, if catalytically active, is targeted to 
degradation in the proteasome. When we increase Jak2-V617F levels in cells, the level 
of phosphorylated STAT5 increases concomitantly, ultimately reaching a point at which 
cytokine stimulation does not further enhance signaling. Interestingly, 25-30% of patients 
with PV are characterized by Jak2-V617F homozygosity and display a significantly 
higher haemoglobin level as well as a higher rate of fibrotic transformation (212, 213). 
Using an animal model where expression of Jak2-V617F could be regulated it has been 
hypothesized that the ratio of mutant to wild-type Jak2 is critical for the phenotypic 
manifestation (201). If expression of Jak2-V617F was lower than the endogenous wild-
type Jak2, mice developed a phenotype resembling ET (essential thrombocythemia). 
Conversely, higher levels of Jak2-V617F resulted in a PV-like phenotype.  
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Moreover, in addition to the V617F mutation in Jak2, several other alterations in the Jak 
genes have been identified leading to constitutively activated kinases. What is really 
interesting is the fact, that different mutational hotspots could be identified in Jak2 
mutants that were found in patients suffering from different disease i.e. different types of 
leukemia (T-ALL, B-ALL, AML) and MPNs (PV, ET or IMF) (79). As mentioned-above, 
the MPN phenotype strongly depends on the level of Jak2-V617F, which regulates 
activation of STAT5. However, little is still known about the pathogenesis of leukemia 
with the exception of chronic myeloid leukemia, which in majority is caused by the BCR-
ABL fusion protein. Why are some of the Jak mutants found in leukemia and others in 
MPNs? One could speculate that these Jak mutants might have different substrate 
specificities possibly due to binding to different cytokine receptor chains or cross-
activating different Jaks bound to the second chain of the receptor complexes. 
Proteomic analysis would certainly be of use to generate protein expression and more 
importantly protein phosphorylation profiles for each Jak mutant. Substrate identification 
could employ the chemical genetics approach, as analogue-sensitive mutants allow for 
specific labeling of the direct substrates of the investigated kinases. Moreover, it would 
certainly be of interest to compare different Jak mutants with respect to their 
phosphorylation sites that in the end could determine direct interacting proteins of the 
Jak mutants. Identified substrates if involved directly in the tumorigenic cell transforming 
potency could be considered as potential targets for inhibitors. 
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ABL  Abelson proto-oncogene  
ALL  Acute Lymphoblastic Leukemia 
AMKL  Acute Megakaryoblastic Leukemia 
AML  Acute Myeloid Leukemia 
AS  Analogue-Sensitive 
ATF  Activating Transcription Factor  
ATP  Adenosine Triphosphate  
BCR  Break-point Cluster Region 
CIS  Cytokine-inducible SH2 containing protein  
CML  Chronic Myeloid Leukemia 
CREB  cAMP Responsive Element Binding Protein 
EGF  Epithelial Growth Factor 
EPO  Erythropoietin 
ER  Endoplasmic Reticulum  
ERK  Extracellular Signal-regulated Kinase 
ET  Essential Thrombocythemia 
FACS  Fluorescence-Activated Cell Sorting 
FDA  Food and Drug Administration 
FERM  4.1, ezrin, radixin, moesin 
FRT  Flipase Recognition Target   
GAS  Gamma-Activated Sequence  
GIST  Gastrointestinal Stromal Tumor   
gp130  Glycoprotein 130 
GH  Growth Hormone 
GRB-2  Growth Receptor Binding Protein 2 
HAT  Histone Acetyltransferase 
IFN  Interferon 
IGF-1  Insulin-like Growth Factor 1 
IL  Interleukin 
IRE1  Inositol-requiring Enzyme 1 
IRF  Interferon Regulated Factor 
IRK  Insulin Receptor Kinase 
JAK  Janus Kinase  
JH  Jak Homology  
JNK  Jun N-terminal Kinase 
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KIR  Kinase Inhibitory Region 
MAPK  Mitogen-activated Protein Kinase 
MPN  Myeloproliferative Neoplasm 
NCBI  National Center for Biotechnology Information 
NK  Natural Killer  
NSCLC Non-small Cell Lung Cancer  
OSM  Oncostatin M 
PIAS  Protein Inhibitor of Activated STAT 
PDB  Protein Data Base 
PH  Pleckstrin Homology  
PI3-K  Phosphoinositide 3-kinase 
PKA  Protein Kinase A 
PKC  Protein Kinase C  
PKI  Protein Kinase Inhibitor 
PMF  Primary Myelofibrosis 
PTP  Protein Tyrosine Phosphatase 
PV  Polycythemia Vera 
qPCR  Quantitative Polymerase Chain Reaction 
RCC  Renal Cell Carcinoma 
RTK  Receptor Tyrosine Kinase  
SCID  Severe Combined Immunodeficiency  
SH  Src Homology   
SHP  SH2 domain-containing Phosphatase 
STAT  Signal Transducer and Activator of Transcription 
SOCS  Suppressor of Cytokine Signaling 
TCPTP T-Cell Protein Tyrosine Phosphatase 
TPO  Thrombopoietin  
TR  Tet Repressor 
UPR  Unfolded Protein Response 
XBP-1  X-box Binding Protein 1 
YFP  Yellow Fluorescent Protein 
ZAP-70 Zeta-chain-associated Kinase 70 
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Supplemental information: 
 
Supplemental experimental procedures 
Reporter gene constructs 
The pGL3-EPO-HRE-Luc containing three HRE elements preceding the firefly luciferase gene 
was described before (1). The pGL3-VEGF-Luc contains the KpnI-NheI fragment of the human 
VEGF promoter region from -2.28 kb to +55 bp relative to the transcriptional start site (2) 
upstream of the firefly luciferase gene. Mutations were introduced into the published binding 
sequences for HIF1 at -978 (ACG  CGA) (3), for STAT3 at -848 (TTCCGCGT) (4), or for AP1 
at -1129 (TCAGCT) (5). The pGL-hPAI-796 plasmid containing the human PAI1 promoter 5’-
flanking region from -796 bp to +13 bp and the pGL3-hPAI-796-M2 construct with a mutation in 
the HRE were described (6). The constructs for pG5E1B-LUC (7), pSG424 (8) and for Gal4-
HIF1α-TADN, Gal4-HIF1α-TADNM (9), Gal4-HIF1α-TADC and Gal4-HIF1α-TADCM (9) were 
already described. In Gal4-HIF1α-TADNM and Gal4-HIF1α-TADCM proline P564 or asparagine 
N803 were mutated to alanine, respectively.  
 
Detailed description of the quantitative PCR procedure 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s 
instructions. The concentration of isolated RNA was measured using a NanoDrop 
spectrophotometer. 1 µg of total RNA was reverse-transcribed with the ThermoScript RT-PCR 
System (Invitrogen) in a volume of 20 µL, using 50 mM oligo(dT)20 according to the 
manufacturer’s instructions. The cDNA was additionally treated with 2 units RNase H at 37°C for 
20 min.  
Quantitative real time PCR (qPCR) was carried out on an iQ5 Real-Time PCR detection system 
(Bio-Rad Laboratories). The reaction was performed in a total volume of 20 µL containing cDNA 
corresponding to 12.5 ng RNA template, 10 pmol of each forward and reverse primer and 10 µL 
of 2x Absolute QPCR SYBR Green Fluorescein Mix (ThermoScientific). Thermal cycling 
conditions for all qPCR assays consisted of an initial enzyme activation step at 95°C for 15 min, 
followed by 40 cycles of denaturation at 95°C and annealing and elongation at 60°C for 30 sec. 
The housekeeping gene TBP (TATA-binding protein) and the target genes were assayed in 
parallel for each sample. All samples were run in triplicates.  
Standard curves using four 10-fold dilutions (1x, 0.1x, 0.01x, 0.001x) were produced to ensure 
that the amplification efficiencies were similar and in the range of 95-105%. The exact efficiencies 
were 103.9% for TBP, 98% for HIF1a, 102.4 % for VEGF and 98.5% for PAI1. The specificity of 
real-time PCR was verified by single product-specific melting curves. The melting curve analysis 
was carried out as follows: 95ºC for 1 min, 60ºC for 1 min and 60ºC for 30 sec followed by steps 
of increases of 0.5ºC for 30 sec until 95ºC is reached. Gene-specific primers used in qPCR 
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analysis were purchased from Eurogentec (Belgium), as follows: TBP forward 5`-
ACCCAGCAGCATCACTGTT-3`, reverse 5`- CGCTGGAACTCGTCTCACTA-3`; HIF1α forward 
5`-CGTTCCTTCGATCAGTTGTC-3`, reverse 5`-TCAGTGGTGGCAGTGGTAGT-3`; VEGF 
forward 5`-TTCTCACACCATTGAAACCA-3`, reverse 5`-GATCCTGCCCTGTCTCTCTG-3`; PAI1 
forward 5`-TTCAGAGGTGGAGAGAGCC-3`, reverse 5`-TTGTCCACGGCTCCTTTC-3`. 
 
siRNA transfections 
2.5 x 105 HepG2 cells were transfected with either STAT3 or HIF1 validated Stealth Duo Pak 
siRNA or Stealth RNAi negative control using 3 ml Lipofectamine RNAiMAX  per well (all from 
Invitrogen) following the reverse transfection protocol. The final concentration of each duplex was 
30 nM. 48 h after transfection the cells were used for qPCR or Western blot analysis. 
For cotransfection of siRNAs and reporter gene constructs, transfection mixtures included 30 nM 
siRNA and additionally 500 ng of the β-galactosidase control plasmid and 500 ng of the reporter 
gene construct. 5 ml Lipofectamine RNAiMAX were used per well according to the reverse 
transfection protocol.  
 
ELISA 
5 x 105 HepG2 cells per well were seeded in 1.5 mL FCS-free DMEM/F-12. Cells were treated 
with 10 ng/mL OSM for 12h before the supernatants were harvested. ELISA for VEGF and PAI1 
(both R&D Systems) were used according the manufacturer’s protocol to analyze these proteins 
in the supernatants.  
 
Other reagents 
pCAGGS or pCAGGS-STAT3DN (gifts from Koichi Nakajima and Toshio Hirano, Osaka, Japan). 
Jak inhibitor I, U0126, PD98059, SB202190, SB203590, Wortmannin, LY294002 and MG132 
were from Calbiochem. Stattic was from Sigma. Antibodies against IκB and phospho-IκB used for 
Western blot detections were from New England Biolabs. The g-fibrinogen antibody was from 
Upstate. Human recombinant IFNg, IL-6, TNFα and IL1β were from Peprotec. The VEGF and 
PAI1 ELISA kits were from R&D. 
APPENDIX	   177	  
 
OSM	  UP-­‐REGULATES	  HIF1α 	   177	  
 
Supplemental results 
OSM induces HIF1α more efficiently than other cytokines. 
As IL1β and TNFα, both activating the NFκB pathway, have previously been described to lead to 
an increased HIF1a expression (10), we compared the effect of OSM versus the effects of these 
inflammatory cytokines in HepG2 cells. Whereas IL1β clearly leads to a transient increase of 
HIF1α expression after 4 and 6 hours, TNFa-induced expression was only marginal, although the 
cells were responsive to TNFα and IL1β, as phosphorylation of IkB could readily be observed 
(Suppl. Fig. 1A). The increase of HIF1α by OSM was stronger than for the two other stimuli. 
Costimulation of OSM and IL1b enhanced the HIF1α levels even more (data not shown).  
IL6, which induces STAT3 as does OSM, also led to an upregulation of HIF1α but OSM had a 
much stronger effect than IL6 (Suppl. Fig. 1B). However, IFNγ, which induces a strong STAT1 but 
not a STAT3 signal, did not affect HIF1α expression significantly. Thus, compared to other 
cytokines, OSM seems to be a particularly potent inducer of HIF1α. 
 
OSM and hypoxia differentially affect HIF1α expression and activity. 
Under normoxic conditions the HIF1α subunit is hydroxylated, polyubiquitinated and quickly 
degraded via the proteasome. Under hypoxic conditions the activity of the hydroxylases is 
reduced, HIF1α protein is stabilized and can bind to hypoxia-responsive elements (HREs) within 
the regulatory areas of HIF target genes and efficiently recruit cofactors.  
To compare the ubiquitination status of HIF1α, we incubated cells treated with OSM, hypoxia and 
OSM plus hypoxia with the proteasome inhibitor MG132. We observed that upon addition of 
MG132 a broad HIF1α band pattern of weaker intensity appeared at higher molecular masses on 
the Western blot as observed by others (11, 12). This band pattern represents the 
polyubiquitinated HIF1α. Two exposures of the HIF1α detection are shown since the intensity of 
the HIF1α and ubiquitinated- HIF1α bands was different. In the lower exposure one can see the 
similar induction of HIF1α by OSM and hypoxia and the even higher induction by the combined 
treatment (see also printed text). Upon OSM treatment the polyubiquitinated HIF1α band 
increases, thus showing that a polyubiquitination readily occurs upon OSM-treatment (compare 
lanes 3 and 4 in Suppl. Fig. 2A). This observation is in line with the observed quick degradation of 
OSM-induced HIF1α (Fig. 3A)). Upon stimulation by hypoxia alone or OSM and hypoxia 
combined the polyubiquitinated HIF1α band decreases in intenstiy compared to the control (lane 
3)(compare lanes 3, 7 and 8 in Suppl. Fig. 2A), although the HIF1α levels are much elevated. 
This corresponds to a reduction of ubiquitination compared to the relative HIF1α expression. 
Thus, our results show that OSM-stimulated HIF1α is clearly ubiquitinated while hypoxic 
conditions interfere with the ubiquitination as described previously (13). 
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In addition, we performed an ubiquitination assay based on transfection of both HIF1α and 
ubiquitin. HepG2 cells, transfected with vectors for V5-tagged HIF1α and HA-ubiquitin, were 
treated with OSM or incubated under hypoxia for 6 h. Western blots of the immunoprecipitates 
(with the V5-tag antibody) were detected with a ubiquitin antibody. We found that HIF1a was 
strongly ubiquitinated under normoxia while ubiquitination occurred to a lesser extend under 
hypoxia. Treatment of cells with OSM did not affect ubiquitination when compared to the 
normoxic control. Thus, these data indicate that OSM does not inhibit ubiquitination of HIF1α. 
We next compared the ability of OSM and hypoxia to interfere with the hydroxylation of the 
proline and asparagine residues involved in protein stabilization and transactivation. These 
residues are hydroxylated by corresponding hydroxylases under normoxia but not under hypoxia. 
They are located in two transactivation domains (TADs) present in HIF1α and referred to as 
amino-terminal (TADN) (contains proline) and carboxy-terminal (TADC) (contains asparagine) 
TAD. HepG2 cells were cotransfected with the luciferase reporter construct pG5-E1B-Luc that 
contains 5 copies of a Gal4 response element and vectors allowing expression of fusion proteins 
consisting of the Gal4-DNA binding domain (Gal4) and either HIF1a TADN or TADC. If these 
TADs are not hydroxylated the reporter gene activity increases and an increase in luciferase 
activity is measured. As shown in Suppl. Fig. 2C, HIF1α TADN and TADC transactivity were 
induced by hypoxia in line with previous studies whereas treatment with OSM had no effect. It 
has been well demonstrated that the key amino acid proline 564 in the TADN plays a crucial role 
in HIF1α stabilization. The mutation of the critical amino acid proline (P 564) in the construct 
Gal4-HIF1aTADNM led to a hydroxylation-resistant fusion protein and caused an increase in 
transactivity; but OSM did not acuse any effect. Furthermore, asparagine (N 803) in HIF1a TADC 
can also be hydroxylated by another hydroxylase named FIH and thus block the interaction of 
HIF1α and p300/CBP. While this mutation of asparagine 803 to alanine enhanced transactivation 
it also abolished hypoxic induction and again OSM had no effect. Thus, OSM does not affect 
protein stability by influencing hydroxylases, which is in line with our cycloheximide data on the 
protein stability of OSM-induced HIF1α.  
Together these data indicate that OSM does not affect hydroxylation and ubiquitination of HIF1α 
and support the data indicating that OSM induces HIF1α via a transcriptional mechanism. 
 
Involvement of Jaks, Erks, and STAT3 in OSM-mediated upregulation of HIF1α protein and 
mRNA levels. 
To identify signaling components involved in OSM-mediated HIF1α expression, inhibitor 
experiments were performed. As shown in Suppl. Fig. 3A, inhibition of Jaks by Jak inhibitor I 
almost completely abrogated OSM-mediated STAT3 and Erk phosphorylation and HIF1α 
expression. Inhibition of the Erk pathway with U0126 and PD98059 also partly diminished OSM-
mediated HIF1α induction. Comparable observations as in HepG2 hepatoma cells were made for 
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the hepatocyte cell line PH5CH8 (Suppl. Fig. 3C). Again, the Jak inhibitor abrogated the OSM-
induced HIF1α upregulation while treatment with U0126 showed a partial downregulation of 
HIF1α protein. 
To investigate the influence of STAT3 in the OSM-mediated HIF1a expression HepG2 cells were 
pretreated with the STAT3 inhibitor Stattic (14) before OSM stimulation. STAT3 inhibition by 
Stattic also led to a loss of HIF1α expression (Suppl. Fig. 3B). Expression of the STAT3-
dependent acute phase protein γ-fibrinogen, monitored as a positive control, was also lost upon 
treatment with Stattic. Taken together, these data show that STAT3 and the MEK/Erk pathway 
are involved in OSM-mediated HIF1α protein expression.  
To clarify the role of the MEK/Erk and the Jak/STAT pathway in the OSM-mediated expression of 
HIF1a mRNA, HepG2 cells were pretreated with Jak Inhibitor I, U0126 or Stattic before 
stimulation with OSM. After 4 h the RNA was isolated und analyzed by qPCR. Upon OSM 
stimulation the HIF1a mRNA level was induced 2.5-fold whereas the Jak inhibitor I abrogated this 
effect (Suppl. Fig. 3D). The inhibition of the MEK/Erk cascade resulted in a 1.5-fold induction of 
the HIF1α mRNA level. Stattic totally inhibits the HIF1a mRNA induction by OSM. These data 
indicate that the Jak/STAT and to a lesser extent the MEK/Erk pathway are both important for the 
OSM-mediated HIF1α induction on the mRNA level. 
Although OSM leads to p38 phosphorylation, treatment with two different p38 inhibitors, 
SB202190 and SB203590, had no effect on OSM-mediated HIF1α expression (data not shown). 
We did not observe activation of the PI3 kinase pathway by OSM, and application of the PI3 
kinase inhibitors Wortmannin and LY294002 did not affect HIF1α expression (data not shown). 
 
Jaks, Erks, and STAT3 are involved in the OSM-mediated upregulation of the HIF1α-dependent 
3xHRE promotor gene construct. 
To investigate the effects of the different inhibitors on HRE promoter activity, HepG2 cells were 
transfected with the luciferase reporter gene plasmids pGL3-EPO-HRE-Luc and the b-
galactosidase expression vector pCH110 and 3xHRE-dependent luciferase activity was 
measured in the presence or absence of the different inhibitors (Suppl. Fig. 4A). Jak inhibitor I 
and the MEK inhibitor led to a down-regulation of the OSM-induced reporter gene activity. 
Although these results correlate well with the observed reduction of HIF1a mRNA and protein 
levels (Suppl. Fig. 3), we cannot exclude that MEK/Erk inhibition by U0126 additionally affected, 
directly or indirectly, HIF1α transactivational activity (15-17).  
As an alternative to Stattic (which is toxic upon prolonged treatment) in studying the function of 
STAT3 in OSM-mediated HIF1α induction, reporter gene assays with the HIF-responsive 
luciferase construct were performed upon co-expression of dominant negative STAT3. As shown 
in Suppl. Fig. 4B, induction of luciferase activity was reduced when an expression construct for 
dominant negative STAT3 was cotransfected. Dominant negative STAT3 did not, however, affect 
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increased luciferase activity observed upon treatment with CoCl2 (data not shown). Thus, STAT3 
plays an important role for the increase of HIF1α activity upon OSM-treatment. Taken together, 
these data show again that STAT3 and the MEK/Erk pathway are involved in OSM-mediated 
induction of HIF1α activity.  
 
Inhibitors of Jaks, Erks, and STAT3 abrogate the OSM-mediated upregulation of VEGF and PAI1 
mRNA levels. 
The VEGF and the PAI1 are both known targets of HIF1α and OSM. By inhibition of the 
MEK1/Erk cascade and the Jak/STAT signaling with specific inhibitors we could show that both 
pathways are important for the OSM-mediated upregulation of the VEGF and PAI1 mRNA (Suppl. 
Fig. 5): Jak inhibitor I, the MEK1 inhibitor U0126, and the STAT3 inhibitor Stattic abrogated the 
induction of the respective mRNAs upon OSM treatment. 
 
OSM-induced HIF1α is crucially involved in the transcriptional regulation of the genes for VEGF 
and PAI1.  
Hypoxia-induced HIF1α and OSM are described to induce the expression of VEGF and PAI1. To 
investigate the relevance of HIF1α expression in the OSM signal transduction, we examined the 
effects of HIF1α suppression by siRNA on the target genes PAI1 and VEGF upon OSM 
stimulation. VEGF and PAI1 mRNA levels were downregulated by HIF1α siRNA compared to 
control siRNA (Suppl. Fig. 6). 
 
OSM-induced VEGF and PAI1 at the protein level.  
To investigate the effects of OSM on VEGF and PAI1 protein level expression, HepG2 cells were 
stimulated with OSM for 12 h to induce the expression of VEGF and PAI1. The protein 
concentrations in the supernatant were determined by ELISA. As shown in Suppl. Fig. 7, we 
found that OSM upregulates VEGF and PAI1 also at the protein level.  
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Supplemental Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental figure 1: OSM induces HIF1α  protein levels more efficiently than other 
cytokines. 
(A) HepG2 cells were treated for the indicated periods of time with OSM, IL1b or TNFα (10 
ng/mL). Lysates of the cells were separated by SDS-PAGE, and Western blots of the membranes 
were detected with antibodies directed against HIF1α, phospho-IkB, phospho-STAT3, IkB, 
STAT3, and Fin13. (B) HepG2 cells were treated for the indicated periods of time with OSM, IL6 
or IFNg (10 ng/mL). Lysates of the cells were separated by SDS-PAGE, and Western blots of the 
membranes were detected with antibodies directed against HIF1α, phospho-STAT3, phospho-
STAT1, STAT3, and STAT1. 
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Supplemental figure 2: The regulation of HIF1α  by OSM is independent of the 
hydroxylation sites and does not affect ubiquitination of HIF1α  
(A) Where indicated, HepG2 cells were pre-incubated for 3h with MG132 (10 mM) before 
treatment with hypoxia and/or OSM (10 ng/mL) for additional 4h. Lysates and Western blots were 
prepared and the membranes were detected with an HIF1α, phosphospecific STAT3- and 
STAT3-antibody (B) HepG2 cells transfected with expression vectors for V5-tagged HIF1a and 
HA-tagged ubiquitin were cultured under normoxia (16% O2), hypoxia (5% O2) and under 
normoxia in the presence of OSM for 6 h were immunoprecipitated (IP) with anti-V5 antibodies 
and analyzed with ubiquitin antibodies. Whole-cell extracts (WCE) of HepG2 cells were probed 
with V5 antibodies. (C) HepG2 cells were cotransfected with a luciferase reporter construct pG5-
E1B-LUC and different fusion gene constructs in which the Gal4 DNA-binding domain was fused 
to either the HIF1α region from amino acid 532-585 containing TADN or 727-826 containing 
TADC, respectively, as shown on the left. The mutations in the constructs are indicated. After 24 
h the transfected cells were treated with OSM or hypoxia for 6 h. Values are means ± SEM of 
three independent culture experiments. *: P ≤ 0.05 vs. control in the same group. 
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Supplemental figure 3: Jaks, STAT3, and Erks mediate OSM-induced HIF1α  upregulation.  
(A) HepG2 cells were pretreated for 30 min with DMSO alone, U0126 (2.5 mM), PD98059 (10 
mM) or Jak inhibitor I (200 nM). Cells were then stimulated for the indicated periods of time with 
OSM (10 ng/mL). The lysates were used to prepare Western blots, which were detected with 
antibodies directed against HIF1α, phospho-Erk1/2, phospho-STAT3, STAT3, and Erk1/2. (B) 
HepG2 cells were pretreated for 30 min with DMSO alone or Stattic (10 and 20 mM) and then 
processed as described in (A). C) PH5CH8 cells were pretreated for 30 min with DMSO alone, 
U0126 or Jak inhibitor I as described in (A). D) HepG2 cells were pretreated for 0.5 h with Jak 
Inhibitor 1 (1 mM), U0126 (5 mM) or Stattic (20 mM). After 4 h stimulation with OSM, RNA was 
extracted and HIF1α mRNA level was measured by quantitative PCR. **: P < 0.01, ##: 
statistically significant difference with respect to OSM-treated cells (P < 0.01).  
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Supplemental figure 4: Jaks, Erks, and STAT3 are involved in the OSM-mediated 
upregulation of the HIF1α-dependent 3xHRE promotor gene construct. 
A) HepG2 cells were transfected with the luciferase reporter gene plasmids pGL3-EPO-HRE-Luc 
and the b-galactosidase expression vector pCH110 and the cells were processed as described in 
Fig. 1C. The different inhibitors were added together with OSM. **: P < 0.01, # #: statistically 
significant difference with respect to OSM-treated cells (P < 0.01). B) HepG2 cells were 
transfected with the luciferase reporter gene plasmids pGL3-EPO-HRE-Luc and the b-
galactosidase expression vector pCH110 in the absence or presence of an expression vector for 
dominant negative STAT3 and the cells were processed as described in Fig. 1C. **: P< 0.01.  
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Supplemental figure 5: Inhibitors of Jaks, Erks, and STAT3 abrogate the OSM-mediated 
upregulation of VEGF and PAI1 mRNA levels. 
HepG2 cells were pretreated for 0.5 h with Jak Inhibitor 1 (1 mM), U0126 (5 mM) or Stattic (20 
mM). Afterwards the cells were stimulated with OSM for 4 h followed by the extraction of the 
RNA. The VEGF and PAI1 mRNA level was measured by quantitative PCR. **: P < 0.01, ##: 
statistically significant difference with respect to OSM-treated cells (P < 0.01).  
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Supplemental figure 6: HIF1a knockdown by siRNA reduces OSM-induced mRNA levels of 
VEGF and PAI1.  
HepG2 cells were transfected with siRNA against HIF1α or scrambled negative control siRNA. 
48h after transfection the cells were stimulated with OSM for 4 h followed by the extraction of the 
RNA. The VEGF and PAI1 mRNA levels were measured by quantitative PCR. ***: P < 0.001, **: 
P < 0.01, *: P < 0.05. 
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Supplemental figure 7: OSM upregulates VEGF and PAI1 at the protein level. 
HepG2 cells were treated with OSM (10 ng/mL) for 12h. The supernatants were harvested and 
protein concentrations of VEGF and PAI1 were analyzed by ELISA. ***: P<0.001  
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